DDI-DrugBank.d779.s0	When WRB 0	methyldopa NN B-noun.person	is VBZ 0	used VBN B-verb.consumption	with IN 0	other JJ B-adj.all	antihypertensive_drugs NNS B-noun.object	, , 0	potentiation NN B-noun.person	of IN 0	antihypertensive JJ B-adj.all	effect NN B-noun.phenomenon	may MD 0	occur VB B-verb.stative	. . 0	. . 0
DDI-DrugBank.d575.s2	Therefore RB 0	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	used VBN B-verb.consumption	in IN 0	administering VBG B-verb.communication	VUMON NNP B-noun.person	( ( 0	teniposide JJ 0	injection NN B-noun.event	) ) 0	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	these DT 0	other JJ 0	agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d737.s6	Other JJ 0	drugs NNS B-noun.person	eliminated VBN B-verb.emotion	via IN 0	renal JJ B-adj.all	secretion NN B-noun.act	, , 0	Population NNP B-noun.other	pharmacokinetic JJ B-adj.all	analysis NN B-noun.communication	suggests VBZ B-verb.communication	that DT 0	coadministration NN B-noun.person	of IN 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	secreted VBN B-verb.possession	by IN 0	the DT 0	cationic JJ B-adj.pert	transport NN B-noun.act	system NN B-noun.cognition	( ( 0	e.g. UH 0	, , 0	cimetidine NN B-noun.person	, , 0	ranitidine NN B-noun.person	, , 0	diltiazem NN B-noun.person	, , 0	triamterene NN B-noun.person	, , 0	verapamil RB B-adv.all	, , 0	quinidine NN B-noun.location	, , 0	and CC 0	quinine NN B-noun.location	) ) 0	decreases VBZ B-verb.change	the DT 0	oral JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	pramipexole NN B-noun.shape	by IN 0	about IN 0	20 CD B-adj.all	% NN 0	, , 0	while IN 0	those DT 0	secreted VBN B-verb.creation	by IN 0	the DT 0	anionic JJ B-adj.all	transport NN B-noun.act	system NN B-noun.cognition	( ( 0	e.g. UH 0	, , 0	cephalosporins NNS B-noun.person	, , 0	penicillins NNS B-noun.person	, , 0	indomethacin NN B-noun.person	, , 0	hydrochlorothiazide NN 0	, , 0	and CC 0	chlorpropamide NN 0	) ) 0	are VBP B-verb.stative	likely JJ B-adj.all	to TO 0	have VB B-verb.change	little JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	oral JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	pramipexole NN B-noun.communication	. . 0	. . 0
DDI-MedLine.d161.s3	In IN 0	the DT 0	present JJ B-adj.all	study NN B-noun.artifact	, , 0	we PRP 0	tested VBD B-verb.social	whether IN 0	the DT 0	highly RB B-adv.all	specific JJ B-adj.all	metabotropic NN B-noun.attribute	glutamate NN I-noun.attribute	receptor NN B-noun.communication	5 CD B-adj.all	antagonist NN B-noun.person	, , 0	3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine JJ 0	, , 0	reduces VBZ B-verb.creation	dopaminergic JJ I-verb.creation	and CC 0	noradrenergic JJ B-adj.all	neuronal JJ B-adj.all	loss NN B-noun.process	in IN 0	monkeys NNS B-noun.person	rendered VBD B-verb.communication	parkinsonian JJ I-verb.communication	by IN 0	chronic JJ B-adj.all	treatment NN B-noun.plant	with IN 0	low JJ B-adj.all	doses NNS B-noun.event	of IN 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine CD 0	. . 0	. . 0
DDI-MedLine.d221.s2	Quantitative JJ B-adj.all	toxicological JJ B-adj.all	analysis NN B-noun.person	showed VBD B-verb.communication	that IN 0	the DT 0	concentrations NNS B-noun.cognition	of IN 0	etizolam NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	promethazine NN B-noun.person	and CC 0	chlorpromazine NN B-noun.act	in IN 0	the DT 0	femoral JJ B-adj.all	blood NN B-noun.act	were VBD B-verb.stative	86 CD 0	ng FW 0	/ FW 0	ml FW 0	, , 0	5082 CD B-adj.all	microg NNS B-noun.quantity	/ : 0	ml PRP 0	, , 0	0.107 CD 0	microg NN B-noun.quantity	/ : 0	ml NN B-noun.quantity	and CC 0	0.144 CD 0	microg NNS B-noun.quantity	/ : 0	ml PRP 0	, , 0	respectively RB B-adv.all	, , 0	and CC 0	large JJ B-adj.all	amounts NNS B-noun.quantity	of IN 0	drugs NNS B-noun.artifact	were VBD B-verb.stative	also RB B-adv.all	detected VBN B-verb.perception	in IN 0	the DT 0	stomach NN B-noun.body	contents NNS B-noun.group	. . 0	. . 0
DDI-DrugBank.d776.s16	Rifampin NNP B-noun.person	, , 0	Rifampin NNP B-noun.person	enhances VBZ B-verb.motion	the DT 0	metabolism NN B-noun.attribute	of IN 0	concurrently RB B-adv.all	administered VBN B-verb.emotion	DIFLUCAN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d597.s17	Furosemide RB 0	, , 0	single JJ B-adj.all	and CC 0	multiple JJ B-adj.all	dose NN B-noun.person	pharmacodynamics NNS B-noun.person	and CC 0	pharmacokinetics NNS B-noun.person	are VBP B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	meloxicam NN B-noun.person	. . 0	. . 0
DDI-MedLine.d182.s21	The DT 0	zinc NN B-noun.communication	/ : 0	o SYM 0	- : 0	cymen-5-ol JJ 0	system NN B-noun.cognition	has VBZ 0	direct JJ B-verb.competition	antimicrobial JJ B-adj.all	effects NNS B-noun.phenomenon	and CC 0	inhibits VBZ B-verb.stative	oral JJ B-adj.all	disease NN B-noun.feeling	- : 0	related JJ B-adj.all	processes NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d183.s6	Furthermore RB B-adv.all	, , 0	it PRP 0	is VBZ B-verb.stative	well RB 0	known VBN B-verb.cognition	that IN 0	acute JJ B-adj.all	treatment NN B-noun.plant	with IN 0	MPTP NNP B-noun.group	can MD 0	cause VB B-verb.creation	a DT 0	severe JJ 0	loss NN B-noun.process	of IN 0	tyrosine JJ B-adj.all	hydroxylase NN B-noun.person	and CC 0	dopamine NN 0	transporter NN 0	protein NN B-noun.communication	levels NNS B-noun.attribute	and CC 0	dopamine NN B-noun.act	contents NNS B-noun.group	in IN 0	the DT 0	striatum NN B-noun.attribute	of IN 0	mice NNS B-noun.animal	, , 0	as IN 0	compared VBN 0	to TO 0	continuous JJ B-adj.all	MPTP NNP B-noun.group	treatment NN B-noun.communication	. . 0	. . 0
DDI-MedLine.d143.s5	The DT 0	influence NN B-noun.cognition	of IN 0	the DT 0	other JJ B-adj.all	proton_pump_inhibitors NNS B-noun.person	when WRB 0	used VBN B-verb.consumption	simultaneously RB B-adv.all	with IN 0	clopidogrel NN B-noun.group	has VBZ 0	not RB B-adv.all	yet RB 0	been VBN 0	investigated VBN B-verb.communication	in IN 0	adequately RB B-adv.all	randomized VBN B-verb.consumption	studies NNS I-verb.consumption	. . 0	. . 0
DDI-DrugBank.d615.s1	The DT 0	effects NNS B-noun.phenomenon	of IN 0	anticholinergic_drugs NNS B-noun.object	, , 0	such JJ 0	as IN 0	atropine JJ B-adj.all	and CC 0	tricyclic_antidepressants NNS B-noun.act	may MD 0	be VB 0	enhanced VBN B-verb.change	by IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	triprolidine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d739.s15	It PRP 0	is VBZ B-verb.stative	reasonable JJ B-adj.all	to TO 0	employ VB B-verb.consumption	appropriate JJ B-adj.all	clinical JJ B-adj.all	monitoring NN B-verb.perception	when WRB 0	potent JJ B-adj.all	cytochrome NN B-noun.person	P450 NN I-noun.person	enzyme NN I-noun.person	inducers NNS I-noun.person	, , 0	such JJ 0	as IN 0	phenobarbital JJ B-adj.all	or CC 0	rifampin NN B-noun.communication	, , 0	are VBP B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	montelukast NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d775.s8	A DT 0	greater JJR B-adj.all	potentiation NN B-noun.person	of IN 0	the DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	effects NNS B-noun.phenomenon	of IN 0	MIVACRON NNP B-noun.group	may MD 0	be VB 0	expected VBN B-verb.cognition	with IN 0	higher JJR B-adj.all	concentrations NNS B-noun.attribute	of IN 0	enflurane NN B-noun.person	or CC 0	isoflurane NN B-noun.substance	. . 0	. . 0
DDI-MedLine.d202.s1	Conventional JJ B-adj.all	therapeutic JJ B-adj.all	drug NN B-noun.artifact	monitoring NN B-noun.person	based VBN B-verb.cognition	on IN 0	measuring VBG B-verb.cognition	immunosupressive_drug JJ 0	concentrations NNS B-noun.attribute	in IN 0	blood NN B-noun.act	is VBZ B-verb.stative	important JJ B-adj.all	in IN 0	the DT 0	clinical JJ B-adj.all	management NN B-noun.process	of IN 0	immunosuppressive JJ B-adj.all	therapy NN B-noun.person	in IN 0	transplantation NN 0	medicine NN 0	. . 0	. . 0
DDI-DrugBank.d781.s8	Lithium NNP B-noun.person	, , 0	Increased VBD B-verb.change	serum NN B-noun.artifact	lithium NN B-noun.artifact	and CC 0	symptoms NNS B-noun.communication	of IN 0	lithium NN B-noun.substance	toxicity NN B-noun.phenomenon	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	concomitant JJ B-adj.all	lithium NN B-noun.substance	and CC 0	ACE NNP 0	inhibitor NN 0	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d619.s5	One CD 0	case NN 0	of IN 0	hypertensive JJ B-adj.all	crisis NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	a DT 0	patient NN B-noun.person	taking VBG B-verb.social	the DT 0	recommended VBN B-verb.communication	doses NNS B-noun.person	of IN 0	selegiline NN B-noun.person	and CC 0	a DT 0	sympathomimetic_medication NN B-noun.other	( ( 0	ephedrine NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d572.s27	When WRB 0	ZETIA NNP B-noun.group	is VBZ 0	administered VBN B-verb.possession	with IN 0	an DT 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitor NN B-noun.person	in IN 0	a DT 0	woman NN B-noun.person	of IN 0	childbearing VBG B-verb.communication	potential JJ I-verb.communication	, , 0	refer VBP B-verb.cognition	to TO 0	the DT 0	pregnancy NN B-noun.person	category NN B-noun.person	and CC 0	package NN B-noun.artifact	labeling VBG B-verb.contact	for IN 0	the DT 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitor NN B-noun.person	. . 0	. . 0
DDI-MedLine.d169.s0	Calcium NN B-noun.person	does VBZ 0	not RB B-adv.all	inhibit VB B-verb.change	the DT 0	absorption NN B-noun.artifact	of IN 0	5 CD B-adj.all	milligrams NNS B-noun.quantity	of IN 0	nonheme JJ B-adj.all	or CC 0	heme_iron NNP B-noun.person	at IN 0	doses NNS B-noun.location	less JJR 0	than IN 0	800 CD 0	milligrams NNS B-noun.quantity	in IN 0	nonpregnant JJ B-adj.all	women NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d671.s2	Decreased VBN B-verb.change	seizure NN 0	threshold NN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	CYLERT NNP B-noun.group	concomitantly RB B-adv.all	with IN 0	antiepileptic_medications NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d775.s10	Other JJ 0	drugs NNS B-noun.artifact	which WDT 0	may MD 0	enhance VB B-verb.change	the DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	action NN B-noun.process	of IN 0	nondepolarizing_agents NNS 0	such JJ 0	as IN 0	MIVACRON NNP B-noun.person	include VBP B-verb.change	certain JJ B-adj.all	antibiotics NNS B-noun.attribute	( ( 0	e.g. UH 0	, , 0	aminoglycosides NNS B-noun.person	, , 0	tetracyclines NNS B-noun.artifact	, , 0	bacitracin NN B-noun.person	, , 0	polymyxins NNS B-noun.person	, , 0	lincomycin NN B-noun.communication	, , 0	clindamycin NN B-noun.person	, , 0	colistin NN B-noun.person	, , 0	and CC 0	sodium_colistimethate NNP B-noun.location	) ) 0	, , 0	magnesium NN B-noun.person	salts NNS B-noun.substance	, , 0	lithium NN B-noun.person	, , 0	local JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	procainamide NN B-noun.person	, , 0	and CC 0	quinidine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d640.s0	Diuretics NNS B-noun.person	, , 0	Excessive JJ 0	reductions NNS B-noun.group	in IN 0	blood NN B-adj.all	pressure NN B-noun.act	may MD 0	occur VB B-verb.stative	in IN 0	patients NNS B-noun.person	on IN 0	diuretic JJ B-adj.all	therapy NN B-noun.artifact	when WRB 0	ACE_inhibitors NNS B-noun.person	are VBP 0	started VBN B-verb.creation	. . 0	. . 0
DDI-MedLine.d149.s0	[ : 0	Protective JJ 0	effects NNS B-noun.phenomenon	of IN 0	ginseng NN B-noun.person	- : 0	ginko NN B-noun.person	extracts VBZ B-verb.stative	combination NN B-noun.event	on IN 0	rat NN 0	primary NN B-noun.person	cultured VBD B-verb.communication	neurons NNS B-noun.person	induced VBN B-verb.creation	by IN 0	Abeta(1 SYM 0	- : 0	40 LS 0	) ) 0	] : 0	. . 0	_ PRP 0	. . 0
DDI-MedLine.d184.s6	Male NN B-noun.person	rats NNS B-noun.person	demonstrated VBD B-verb.cognition	sensitization NN B-noun.person	to TO 0	amphetamine VB B-verb.social	, , 0	although IN 0	this DT 0	was VBD 0	muted VBN B-verb.communication	compared VBN B-verb.emotion	with IN 0	female JJ B-adj.all	rats NNS B-noun.location	, , 0	and CC 0	were VBD B-verb.stative	unaffected JJ B-adj.all	by IN 0	neonatal JJ B-adj.all	quinpirole NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d636.s3	Mephenytoin NNP B-noun.person	may MD 0	also RB 0	affect VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	other JJ 0	drugs NNS B-noun.artifact	, , 0	which WDT 0	include VBP B-verb.stative	some DT 0	steroid_medications NNS B-noun.artifact	, , 0	warfarin NN B-noun.location	, , 0	certain JJ B-adj.all	heart NN B-noun.body	medicines NNS I-noun.body	, , 0	birth NN 0	control NN B-noun.act	pills NNS B-noun.artifact	, , 0	anti NNS B-noun.person	- : 0	infective_medicines NNS B-noun.communication	, , 0	furosemide RB 0	and CC 0	theophylline PRP 0	Please VB 0	note VB B-verb.perception	that IN 0	Mephenytoin NNP B-noun.person	may MD 0	interact VB B-verb.change	with IN 0	other JJ 0	drugs NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	not RB B-adv.all	listed VBN B-verb.social	here RB 0	. . 0	. . 0
DDI-DrugBank.d689.s1	MAO_Inhibitors NNS B-noun.person	; : 0	The DT 0	pressor NN 0	effect NN 0	of IN 0	sympathomimetic_pressor_amines NNS B-noun.communication	is VBZ B-verb.stative	markedly RB B-adv.all	potentiated VBN B-verb.communication	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	monoamine_oxidase_inhibitors NNS B-noun.person	( ( 0	MAOI NNP B-noun.group	) ) 0	. . 0	. . 0
DDI-DrugBank.d633.s16	Concurrent JJ B-adj.all	use NN 0	of IN 0	Mexitil NNP B-noun.person	___ NNP I-noun.person	and CC 0	theophylline PRP 0	may MD 0	lead VB B-verb.cognition	to TO 0	increased VBN B-verb.change	plasma NN 0	theophylline NN 0	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d663.s1	LUCENTIS NNP 0	intravitreal NN 0	injection NN 0	has VBZ 0	been VBN 0	used VBN B-verb.consumption	adjunctively RB B-adv.all	with IN 0	verteporfin RB B-adj.all	photodynamic JJ B-adj.all	therapy NN B-noun.cognition	( ( 0	PDT NNP 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d776.s13	Cyclosporine NNP B-noun.person	, , 0	DIFLUCAN NNP B-noun.group	may MD 0	significantly RB 0	increase VB B-verb.change	cyclosporine JJ B-adj.all	levels NNS B-noun.attribute	in IN 0	renal JJ B-adj.all	transplant NN B-noun.person	patients NNS B-noun.person	with IN 0	or CC 0	without IN 0	renal JJ B-noun.relation	impairment NN I-noun.relation	. . 0	. . 0
DDI-DrugBank.d581.s2	patients NNS B-noun.person	receiving VBG B-verb.social	lithium NN B-noun.substance	and CC 0	Neulasta NNP B-noun.person	should MD 0	have VB 0	more RBR B-adv.all	frequent JJ B-adj.all	monitoring NN B-noun.person	of IN 0	neutrophil NN B-noun.act	counts NNS B-noun.act	. . 0	. . 0
DDI-DrugBank.d633.s0	Since IN 0	MEXITIL NNP B-noun.group	is VBZ B-verb.stative	a DT 0	substrate NN B-noun.person	for IN 0	the DT 0	metabolic JJ B-adj.all	pathways NNS B-noun.artifact	involving VBG B-verb.stative	CYP2D6 NNP B-noun.person	and CC 0	CYP1A2 NNP B-noun.person	enzymes VBZ B-verb.social	, , 0	inhibition NN B-noun.attribute	or CC 0	induction NN B-noun.act	of IN 0	either DT 0	of IN 0	these DT 0	enzymes NNS B-noun.person	would MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	alter VB B-verb.change	mexiletine JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d737.s0	Carbidopa NNP B-noun.person	/ NNP I-noun.person	Levodopa NNP I-noun.person	, , 0	Carbidopa NNP B-noun.person	/ NNP I-noun.person	Levodopa NNP I-noun.person	does VBZ 0	not RB B-adv.all	influence VB B-verb.emotion	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	pramipexole NN B-noun.communication	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	( ( 0	N= $ 0	10 CD B-adj.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d743.s13	Studies NNS B-noun.person	to TO 0	evaluate VB B-verb.communication	potential JJ B-noun.person	interactions NNS I-noun.person	of IN 0	terfenadine NN 0	with IN 0	azithromycin NN B-noun.person	are VBP B-verb.stative	in IN 0	progress NN 0	. . 0	. . 0
DDI-DrugBank.d630.s1	Caution NN B-noun.person	is VBZ 0	advised VBN B-verb.communication	for IN 0	patients NNS B-noun.person	receiving VBG B-verb.social	high JJ I-verb.social	- : 0	dose NN 0	aspirin NN 0	and CC 0	methazolamide NN B-noun.attribute	concomitantly RB B-adv.all	, , 0	as IN 0	anorexia NN 0	, , 0	tachypnea NN B-noun.person	, , 0	lethargy NN B-noun.communication	, , 0	coma NN B-noun.person	and CC 0	death NN B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	high JJ B-noun.group	- : 0	dose NN 0	aspirin NN 0	and CC 0	carbonic_anhydrase_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d623.s1	Aminoglutethimide IN 0	administered VBN B-verb.body	concomitantly RB B-adv.all	with IN 0	depo NN B-noun.feeling	- : 0	subQ_provera_104 NN B-noun.group	may MD 0	significantly RB 0	decrease VB B-verb.communication	the DT 0	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	MPA NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d232.s4	According VBG 0	to TO 0	the DT 0	calculated JJ B-adj.all	level NN B-noun.attribute	of IN 0	risk NN 0	, , 0	guidelines NNS B-noun.person	recommend VBP B-verb.communication	patients NNS B-noun.person	with IN 0	atrial JJ B-adj.all	fibrillation NN B-noun.act	receive VBP B-verb.possession	antithrombotic JJ B-adj.all	therapy NN B-noun.act	either CC 0	as IN 0	a DT 0	vitamin_K_antagonist JJ B-noun.person	or CC 0	aspirin NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d609.s0	An DT 0	inhibitor NN B-noun.person	of IN 0	CYP2C8 NNP B-noun.person	( ( 0	such JJ 0	as IN 0	gemfibrozil NN 0	) ) 0	may MD 0	increase VB B-verb.change	the DT 0	AUC NNP B-noun.group	of IN 0	rosiglitazone NN B-noun.person	and CC 0	an DT 0	inducer NN B-noun.person	of IN 0	CYP2C8 NNP B-noun.person	( ( 0	such JJ 0	as IN 0	rifampin NN 0	) ) 0	may MD 0	decrease VB B-verb.cognition	the DT 0	AUC NNP B-noun.group	of IN 0	rosiglitazone NN B-noun.person	. . 0	. . 0
DDI-MedLine.d231.s1	Moxifloxacin NNP B-noun.person	and CC 0	lomefloxacin NN B-noun.person	are VBP B-verb.stative	fluoroquinolone_antibiotics NNS B-noun.person	used VBN B-verb.consumption	in IN 0	treating VBG B-verb.change	urinary NN B-noun.communication	and CC 0	respiratory JJ B-adj.all	tract NN B-noun.body	infections NNS I-noun.body	. . 0	. . 0
DDI-MedLine.d166.s17	Reduction NN B-noun.process	of IN 0	PTH NNP 0	by IN 0	cinacalcet NN B-noun.person	is VBZ 0	associated VBN B-verb.cognition	with IN 0	a DT 0	decrease NN B-noun.event	in IN 0	darbepoetin NN B-adj.all	requirement NN B-noun.object	. . 0	. . 0
DDI-DrugBank.d684.s3	Some DT 0	examples NNS B-noun.cognition	of IN 0	such JJ B-adj.all	drugs NNS B-noun.artifact	are VBP B-verb.stative	erythromycin NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	ketoconazole NN B-noun.person	, , 0	fluconazole NN B-noun.person	, , 0	calcium_channel_blockers NNS B-noun.person	and CC 0	cimetidine NN B-noun.person	. . 0	___ NNP B-noun.person	. . 0
DDI-DrugBank.d632.s7	Thus RB 0	, , 0	SYMLIN NNP B-noun.group	and CC 0	insulin NN B-noun.person	should MD 0	not RB B-adv.all	be VB B-verb.stative	mixed JJ B-adj.all	and CC 0	must MD 0	be VB 0	administered VBN B-verb.possession	separately RB B-adv.all	. . 0	. . 0
DDI-MedLine.d143.s1	The DT 0	drug NN B-noun.artifact	interaction NN B-noun.act	between IN 0	proton_pump_inhibitors NNS B-noun.person	and CC 0	clopidogrel NN B-noun.artifact	has VBZ 0	been VBN B-verb.stative	the DT 0	subject NN B-noun.artifact	of IN 0	much JJ B-adj.all	study NN B-noun.artifact	in IN 0	recent JJ B-adj.all	years NNS B-noun.feeling	. . 0	. . 0
DDI-MedLine.d159.s6	( ( 0	ii NN 0	) ) 0	acetyl NN B-noun.quantity	- : 0	l SYM 0	- : 0	carnitine NN B-noun.communication	elicits VBZ B-verb.creation	a DT 0	significant JJ B-adj.all	protective JJ B-adj.all	effect NN B-noun.cognition	on IN 0	DEB NNP B-noun.group	induced VBD B-verb.creation	toxicity NN B-noun.attribute	, , 0	which WDT 0	was VBD 0	potentiated VBN B-verb.communication	by IN 0	_ JJ B-adj.all	alpha NN B-noun.act	- : 0	lipoic_acid NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d776.s11	Careful JJ B-adj.all	monitoring NN 0	of IN 0	phenytoin NN B-noun.animal	concentrations NNS B-noun.food	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	DIFLUCAN JJ B-noun.group	and CC 0	phenytoin NN B-noun.person	is VBZ 0	recommended VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d230.s4	In IN 0	groups NNS B-noun.group	1 CD 0	and CC 0	2 CD B-adj.all	, , 0	amiodarone NN B-noun.person	was VBD 0	given VBN B-verb.possession	to TO 0	rats NNS B-noun.animal	by IN 0	intragastric JJ B-noun.person	and CC 0	intravenous JJ B-adj.all	administration NN B-noun.person	, , 0	respectively RB B-adv.all	, , 0	while IN 0	neferine NN B-noun.person	was VBD B-verb.stative	co SYM 0	- : 0	administratered VBN B-verb.communication	by IN 0	intragastric JJ B-adj.all	administration NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d608.s1	However RB 0	, , 0	increased VBD B-verb.change	prothrombin NN B-noun.person	time NN B-noun.person	and CC 0	bleeding NN B-verb.body	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	on IN 0	concomitant JJ B-adj.all	TOLECTIN NNP B-noun.group	and CC 0	warfarin NN B-noun.act	therapy NN B-noun.act	. . 0	. . 0
DDI-MedLine.d208.s0	Implanon NNP B-noun.person	__ POS 0	failure NN B-noun.person	in IN 0	an DT 0	HIV NNP B-noun.group	- : 0	positive JJ B-adj.all	woman NN B-noun.person	on IN 0	antiretroviral JJ B-adj.all	therapy NN 0	resulting VBG B-verb.stative	in IN 0	two CD 0	ectopic JJ B-adj.all	pregnancies NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d194.s11	dasatinib NN B-noun.person	+ : 0	paclitaxel NN B-noun.artifact	vs. NN 0	. . 0
DDI-DrugBank.d764.s0	There EX 0	have VBP 0	been VBN B-verb.stative	no DT 0	studies NNS B-noun.act	of IN 0	the DT 0	interaction NN B-noun.act	of IN 0	methyl_aminolevulinate JJ B-adj.all	cream NN B-noun.person	with IN 0	any DT 0	other JJ 0	drugs NNS B-noun.artifact	, , 0	including VBG B-verb.change	local JJ B-adj.all	anesthetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d704.s6	Therefore RB 0	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	exercised VBN B-verb.social	with IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	warfarin NN B-noun.act	and CC 0	FLOMAX NNP B-noun.group	capsules NNS B-noun.artifact	. . 0	_______ NNP B-noun.person	. . 0
DDI-MedLine.d164.s3	In IN 0	an DT 0	in IN 0	vitro NN B-noun.animal	assay NN B-noun.location	, , 0	lapatinib NN B-noun.person	induced VBD B-verb.creation	HER2 JJ 0	expression NN B-noun.communication	at IN 0	the DT 0	cell NN B-noun.body	surface NN 0	of IN 0	HER2-positive JJ 0	breast NN 0	cancer NN B-adj.all	cell NN B-noun.body	lines NNS B-noun.communication	, , 0	leading VBG B-verb.motion	to TO 0	the DT 0	enhancement NN B-noun.person	of IN 0	Herceptin NNP B-noun.person	- : 0	mediated VBD B-verb.cognition	ADCC NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d621.s1	- : 0	Decreased VBD B-verb.cognition	absorption NN B-noun.act	of IN 0	colestipol NN B-noun.person	, , 0	cholestyramine NN B-noun.person	, , 0	mineral_oil NNP B-noun.person	, , 0	and CC 0	sucralfate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d777.s4	Anticoagulation NNP B-noun.other	and CC I-noun.other	Antiplatelets NNPS I-noun.other	After IN I-noun.other	Treatment NNP I-noun.other	for IN I-noun.other	Myocardial NNP I-noun.other	Infarction NNP I-noun.other	-- : 0	In IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	acute JJ B-adj.all	myocardial JJ B-adj.all	infarction NN B-noun.cognition	, , 0	the DT 0	use NN 0	of IN 0	aspirin NN B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	reduce VB B-verb.change	the DT 0	incidence NN B-noun.event	of IN 0	reinfarction NN B-noun.act	and CC 0	stroke NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d588.s1	Other JJ 0	Antihypertensives NNPS B-noun.person	, , 0	When WRB 0	MYKROX NNP B-noun.group	Tablets NNPS I-noun.group	are VBP 0	used VBN B-verb.consumption	with IN 0	other JJ B-adj.all	antihypertensive_drugs NNS B-noun.object	, , 0	care NN B-noun.group	must MD 0	be VB 0	taken VBN B-verb.cognition	, , 0	especially RB B-adv.all	during IN 0	initial JJ B-adj.all	therapy NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d666.s0	Catecholamine SYM 0	- : 0	depleting VBG B-verb.communication	drugs NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	reserpine NN B-noun.location	) ) 0	may MD 0	have VB B-verb.possession	an DT 0	additive JJ B-adj.all	effect NN B-noun.cognition	when WRB 0	given VBN B-verb.possession	with IN 0	beta JJ B-noun.body	- : 0	blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d578.s7	Methylprednisolone NN 0	may MD 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	chronic JJ B-adj.pert	high JJ B-adj.all	dose NN 0	aspirin NN 0	. . 0	. . 0
DDI-DrugBank.d633.s6	When WRB 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	either DT 0	of IN 0	these DT 0	two CD 0	drugs NNS B-noun.person	with IN 0	mexiletine NN B-noun.person	is VBZ 0	initiated VBN B-verb.creation	, , 0	the DT 0	dose NN B-noun.quantity	of IN 0	mexiletine NN B-noun.person	should MD 0	be VB 0	slowly RB B-adv.all	titrated VBN B-verb.change	to TO 0	desired VBN B-verb.emotion	effect NN I-verb.emotion	. . 0	. . 0
DDI-DrugBank.d776.s22	Another DT 0	study NN B-noun.artifact	at IN 0	a DT 0	400-mg JJ 0	and CC 0	800-mg JJ 0	daily JJ B-adj.pert	dose NN B-noun.act	of IN 0	fluconazole NN B-noun.person	demonstrated VBD B-verb.cognition	that IN 0	DIFLUCAN JJ 0	taken VBN 0	in IN 0	doses NNS B-noun.quantity	of IN 0	400 CD 0	mg NN B-noun.quantity	per IN 0	day NN B-noun.animal	or CC 0	greater JJR B-adj.all	significantly RB B-adv.all	increases VBZ B-verb.change	plasma NN B-noun.state	levels NNS B-noun.state	of IN 0	terfenadine NN B-noun.artifact	when WRB 0	taken VBN 0	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d653.s5	This DT 0	could MD 0	lead VB B-verb.cognition	to TO 0	decreased VBN B-verb.change	salicylate NN B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	or CC 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	salicylate JJ B-adj.all	toxicity NN B-noun.attribute	when WRB 0	corticosteroid NN B-noun.person	is VBZ 0	withdrawn VBN B-verb.contact	. . 0	. . 0
DDI-DrugBank.d775.s13	Some DT 0	drug NN B-noun.person	interactions NNS I-noun.person	are VBP B-verb.stative	, , 0	_ PRP 0	; : 0	birth NN 0	control NN B-noun.act	pills NNS B-noun.artifact	; : 0	corticosteroids NNS B-noun.artifact	; : 0	medicines NNS B-noun.food	for IN 0	angina NN B-noun.artifact	or CC 0	high JJ B-adj.all	blood NN B-noun.phenomenon	pressure NN I-noun.phenomenon	; : 0	medicines NNS B-noun.food	for IN 0	pain NN B-noun.person	; : 0	medicines NNS B-noun.animal	to TO 0	control VB B-verb.social	seizures NNS B-noun.act	such JJ 0	as IN 0	phenytoin NN B-noun.person	or CC 0	carbamazepine NN B-noun.communication	; : 0	certain JJ B-adj.all	antibiotics NNS B-noun.person	given VBN B-verb.possession	by IN 0	injection NN B-noun.act	; : 0	cisplatin NN B-noun.animal	; : 0	edrophonium NN B-noun.person	; : 0	neostigmine NN B-noun.act	; : 0	polymyxin_B NN B-noun.attribute	or CC 0	bacitracin NN B-noun.communication	; : 0	local JJ B-adj.all	anesthetics NNS B-noun.group	such JJ 0	as IN 0	procaine NN B-noun.person	; : 0	general JJ B-adj.all	anesthetics NNS B-noun.person	; : 0	succinylcholine NN B-noun.act	or CC 0	other JJ B-adj.all	muscle_relaxants NNS B-noun.person	. . 0
DDI-DrugBank.d780.s8	Acetazolamide NNP B-noun.person	, , 0	Concurrent JJ 0	use NN 0	of IN 0	acetazolamide NN B-noun.food	and CC 0	procaine_hydrochloride NN B-noun.location	may MD 0	extend VB B-verb.stative	the DT 0	plasma NN B-noun.plant	half NN B-noun.quantity	- : 0	life NN B-noun.time	of IN 0	procaine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d735.s0	A DT 0	total NN B-noun.state	of IN 0	11 CD B-adj.all	clinical JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.group	interaction NN B-noun.act	studies NNS B-noun.artifact	were VBD 0	conducted VBN B-verb.communication	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	to TO 0	evaluate VB B-verb.communication	the DT 0	potential NN B-noun.person	for IN 0	interaction NN B-noun.act	between IN 0	MYCAMINE NNP B-noun.location	and CC 0	mycophenolate_mofetil NNP B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	tacrolimus NN B-noun.person	, , 0	prednisolone NN B-noun.person	, , 0	sirolimus NN 0	, , 0	nifedipine NN B-noun.person	, , 0	fluconazole NN B-noun.person	, , 0	ritonavir NN B-noun.person	, , 0	and CC 0	rifampin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d716.s2	Mazindol NNP B-noun.person	may MD 0	reduce VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	guanethidine NN 0	( ( 0	Ismelin NNP B-noun.other	) ) 0	. . 0	. . 0
DDI-DrugBank.d727.s0	Zidovudine NNP B-noun.person	competitively RB B-adv.all	inhibits VBZ B-verb.stative	the DT 0	intracellular JJ B-adj.all	phosphorylation NN B-noun.artifact	of IN 0	stavudine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d774.s0	Trilostane NNP B-noun.person	may MD 0	interact VB B-verb.change	with IN 0	aminoglutethimide JJ B-adj.all	or CC 0	mitotane NN B-noun.substance	( ( 0	causing VBG B-verb.creation	too RB B-adj.all	great JJ I-adj.all	a DT 0	decrease NN B-noun.event	in IN 0	adrenal JJ B-adj.all	function NN B-noun.act	) ) 0	. . 0	. . 0
DDI-MedLine.d201.s4	The DT 0	aim NN 0	of IN 0	the DT 0	present JJ B-adj.all	study NN B-noun.artifact	was VBD 0	to TO 0	investigate VB B-verb.communication	whether IN 0	HB SYM 0	- : 0	EGF NN B-noun.group	is VBZ B-verb.stative	a DT 0	therapeutic JJ B-adj.all	target NN B-noun.location	for IN 0	T SYM 0	- : 0	ALL RB 0	, , 0	and CC 0	to TO 0	further RBR B-adv.all	elucidate VB B-verb.communication	the DT 0	antitumor NN B-noun.object	effects NNS B-noun.phenomenon	of IN 0	a DT 0	specific JJ B-adj.all	inhibitor NN B-noun.attribute	of IN 0	HB NNP 0	- : 0	EGF NNP B-noun.group	, , 0	cross VBP B-verb.motion	- : 0	reacting_material_197 NN B-noun.person	( ( 0	CRM197 NN 0	) ) 0	. . 0	. . 0
DDI-MedLine.d211.s0	Phase NN B-noun.person	I PRP 0	trial NN B-noun.act	of IN 0	lenalidomide NN B-noun.food	and CC 0	CCI-779 NNP B-noun.other	in IN 0	patients NNS B-noun.person	with IN 0	relapsed JJ B-adj.all	multiple JJ B-adj.all	myeloma NN B-noun.person	, , 0	evidence NN B-noun.attribute	for IN 0	lenalidomide NN B-noun.person	- : 0	CCI-779 NN B-noun.other	interaction NN B-noun.artifact	via IN 0	P SYM 0	- : 0	glycoprotein NN B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d766.s2	In IN 0	vitro NN 0	perfusion NN 0	of IN 0	isolated JJ B-adj.all	rat NN 0	liver NN 0	has VBZ 0	shown VBN B-verb.cognition	that IN 0	cimetidine NN B-noun.person	caused VBD B-verb.communication	a DT 0	significant JJ B-adj.all	reduction NN B-noun.cognition	in IN 0	trimetrexate JJ B-adj.all	metabolism NN B-noun.artifact	and CC 0	that DT 0	acetaminophen NN B-noun.person	altered VBD B-verb.change	the DT 0	relative JJ B-adj.all	concentration NN B-noun.event	of IN 0	trimetrexate JJ B-adj.all	metabolites NNS B-noun.person	possibly RB B-adv.all	by IN 0	competing VBG B-verb.competition	for IN 0	sulfate NN B-noun.animal	metabolites NNS I-noun.animal	. . 0	. . 0
DDI-DrugBank.d716.s1	Changes NNS B-noun.relation	in IN 0	insulin NN B-noun.animal	and CC 0	other JJ 0	diabetes NN B-noun.substance	drug NN B-noun.phenomenon	therapies NNS 0	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	during IN 0	treatment NN B-noun.plant	with IN 0	mazindol NN B-noun.person	. . 0	. . 0
DDI-MedLine.d222.s1	Varenicline NNP B-noun.person	is VBZ B-verb.stative	the DT 0	generic JJ B-adj.all	name NN B-noun.state	for IN 0	Chantix NNP B-noun.person	, , 0	the DT 0	newest JJS B-adj.all	drug NN B-noun.attribute	available JJ B-adj.all	for IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	tobacco NN B-noun.phenomenon	dependence NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d614.s6	Compounds NNS B-noun.person	that WDT 0	quench VBP B-verb.change	active JJ B-adj.all	oxygen NN B-noun.animal	species NNS I-noun.animal	or CC 0	scavenge NN B-noun.plant	radicals NNS B-noun.food	, , 0	such JJ 0	as IN 0	dimethyl_sufloxide JJ 0	, , 0	b SYM 0	- : 0	carotene NN B-noun.person	, , 0	ethanol NN 0	, , 0	formate JJ B-adj.all	and CC 0	mannitol NN B-noun.person	would MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	decrease VB B-verb.change	PDT NNP 0	activity NN B-noun.process	. . 0	. . 0
DDI-MedLine.d180.s1	The DT 0	3-Deazaneplanocin_A NNP B-noun.person	( ( I-noun.person	DZNep NNP I-noun.person	) ) 0	, , 0	one CD 0	of IN 0	S NNP 0	- : 0	adenosylhomocysteine NN B-noun.person	( ( 0	AdoHcy NNP B-noun.person	) ) 0	hydrolase NN 0	inhibitors NNS B-noun.person	, , 0	has VBZ 0	shown VBN B-verb.perception	antitumor NN I-verb.perception	activities NNS B-noun.person	in IN 0	a DT 0	broad JJ B-adj.all	range NN B-noun.location	of IN 0	solid JJ B-adj.all	tumors NNS B-noun.person	and CC 0	acute VB B-verb.possession	myeloid JJ B-adj.all	leukemia NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d642.s1	Concurrent JJ B-adj.all	use NN 0	of IN 0	antibacterial_drugs NNS B-noun.object	with IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.possession	may MD 0	render VB B-verb.possession	oral JJ B-adj.all	contraceptives NNS B-noun.event	less RBR B-adv.all	effective JJ B-adj.all	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d584.s10	Adrenal_steroids NNS B-noun.artifact	or CC 0	ACTH NNP B-noun.group	In IN 0	patients NNS B-noun.person	with IN 0	edema NN B-noun.person	, , 0	concomitant JJ B-adj.all	administration NN B-noun.person	with IN 0	adrenal_cortical_steroids NNS B-noun.group	or CC 0	ACTH NNP B-noun.group	may MD 0	increase VB B-verb.change	the DT 0	edema NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d597.s23	Methotrexate NNP B-noun.person	, , 0	A DT 0	study NN B-noun.artifact	in IN 0	13 CD B-adj.all	rheumatoid JJ B-adj.all	arthritis NN B-noun.substance	( ( 0	RA NNP 0	) ) 0	patients NNS B-noun.person	evaluated VBD B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	meloxicam NN B-noun.person	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	methotrexate NN B-noun.attribute	taken VBN 0	once RB B-adv.all	weekly RB I-adv.all	. . 0	. . 0
DDI-MedLine.d185.s5	On IN 0	day NN 0	8 CD B-adj.all	, , 0	a DT 0	single JJ B-adj.all	panobinostat NN B-noun.artifact	dose NN I-noun.artifact	was VBD B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	ketoconazole NN B-noun.person	. . 0	. . 0
DDI-MedLine.d230.s0	Effects NNS B-noun.phenomenon	of IN 0	neferine NN B-noun.person	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	amiodarone NN B-noun.person	in IN 0	rats NNS B-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d658.s0	When WRB 0	administered VBN B-verb.communication	concurrently RB B-adv.all	, , 0	testolactone NN 0	may MD 0	increase VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	, , 0	. . 0
DDI-DrugBank.d572.s8	HMG SYM 0	- : 0	CoA_reductase_inhibitors NNS B-noun.person	, , 0	No DT 0	clinically RB B-adv.all	significant JJ B-adj.all	pharmacokinetic JJ B-noun.person	interactions NNS I-noun.person	were VBD 0	seen VBN B-verb.perception	when WRB 0	ezetimibe NN B-noun.person	was VBD B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	atorvastatin NN B-noun.food	, , 0	simvastatin NN B-noun.person	, , 0	pravastatin NN B-noun.person	, , 0	lovastatin NN B-noun.person	, , 0	or CC 0	fluvastatin NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d776.s14	Careful JJ B-adj.all	monitoring NN 0	of IN 0	cyclosporine JJ B-adj.all	concentrations NNS B-noun.artifact	and CC 0	serum NN B-noun.body	creatinine NN 0	is VBZ 0	recommended VBN B-verb.communication	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	DIFLUCAN JJ B-noun.group	and CC 0	cyclosporine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d687.s0	Administration NN B-noun.person	of IN I-noun.person	valproic_acid NNP I-noun.person	decreases VBZ B-verb.communication	oral JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	temozolomide NN B-noun.attribute	by IN 0	about IN 0	5 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d706.s0	Catecholamine SYM 0	- : 0	depleting VBG B-verb.communication	drugs NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	reserpine NN B-noun.location	) ) 0	may MD 0	have VB B-verb.possession	an DT 0	additive JJ B-adj.all	effect NN B-noun.cognition	when WRB 0	given VBN B-verb.possession	with IN 0	beta JJ B-noun.body	- : 0	blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d752.s1	Drugs NNS B-noun.person	such JJ 0	as IN 0	erythromycin NN B-noun.person	, , 0	diltiazem NN B-noun.person	, , 0	verapamil RB B-adv.all	, , 0	ketoconazole NN B-noun.person	, , 0	fluconazole NN B-noun.person	and CC 0	itraconazole NN B-noun.person	were VBD 0	shown VBN B-verb.perception	to TO 0	significantly RB 0	increase VB B-verb.change	the DT 0	C NNP 0	max NN 0	and CC 0	AUC NNP B-noun.group	of IN 0	orally RB B-adv.all	administered VBN B-verb.possession	midazolam NN I-verb.possession	. . 0	. . 0
DDI-DrugBank.d619.s0	The DT 0	occurrence NN B-noun.state	of IN 0	stupor NN B-noun.artifact	, , 0	muscular JJ B-adj.all	rigidity NN B-noun.attribute	, , 0	severe JJ B-adj.all	agitation NN B-noun.feeling	, , 0	and CC 0	elevated VBD B-verb.motion	temperature NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	some DT 0	patients NNS B-noun.person	receiving VBG B-verb.communication	the DT 0	combination NN B-noun.event	of IN 0	selegiline NN B-noun.person	and CC 0	meperidine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d736.s3	Thiazides NNS 0	may MD 0	decrease VB B-verb.change	arterial JJ B-adj.all	responsiveness NN B-noun.cognition	to TO 0	norepinephrine VB B-verb.communication	. . 0	. . 0
DDI-DrugBank.d721.s2	The DT 0	bioavailability NN B-noun.cognition	of IN 0	SKELID NNP B-noun.group	is VBZ 0	increased VBN B-verb.change	2 CD B-adj.all	- : 0	4 CD 0	fold VBN B-verb.possession	by IN 0	indomethacin NN B-noun.person	but CC 0	is VBZ B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	altered VBN B-verb.change	by IN 0	coadministration NN B-noun.person	of IN 0	diclofenac NN B-noun.person	. . 0	. . 0
DDI-MedLine.d196.s2	Fenofibrate NNP B-noun.person	is VBZ B-verb.stative	a DT 0	prodrug NN B-noun.person	that WDT 0	is VBZ B-verb.stative	rapidly RB B-adv.all	and CC 0	completely RB B-adv.all	hydrolyzed VBN B-verb.cognition	to TO 0	fenofibric_acid NNP B-noun.location	, , 0	the DT 0	active JJ B-adj.all	moiety NN B-noun.group	. . 0	. . 0
DDI-MedLine.d174.s3	In IN 0	this DT 0	paper NN B-noun.communication	we PRP 0	discuss VBP B-verb.cognition	peculiarities NNS B-noun.person	of IN 0	drug NN B-noun.artifact	interaction NN B-noun.act	between IN 0	cyclooxygenase_inhibitors NNS B-noun.person	and CC 0	acetylsalicylic_acid NNP B-noun.person	, , 0	and CC 0	principles NNS B-noun.attribute	of IN 0	selection NN B-noun.act	of IN 0	adequate JJ B-adj.all	NSAI NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d763.s4	However RB 0	, , 0	on IN 0	the DT 0	basis NN B-noun.cognition	of IN 0	available JJ B-adj.all	data NNS B-noun.cognition	, , 0	no DT 0	dosage NN B-noun.relation	adjustment NN I-noun.relation	for IN 0	ondansetron NN B-noun.person	is VBZ 0	recommended VBN B-verb.communication	for IN 0	patients NNS B-noun.person	on IN 0	these DT 0	drugs.1,3 NNP B-noun.person	_ : 0	Tramadol NNP B-noun.person	, , 0	Although IN 0	no DT 0	pharmacokinetic JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	between IN 0	ondansetron NN B-noun.person	and CC 0	tramadol NN B-noun.person	has VBZ 0	been VBN 0	observed VBN B-verb.perception	, , 0	data NNS B-noun.cognition	from IN 0	2 CD B-adj.all	small JJ B-noun.person	studies NNS I-noun.person	indicate VBP B-verb.cognition	that DT 0	ondansetron NN B-noun.person	may MD 0	be VB 0	associated VBN B-verb.cognition	with IN 0	an DT 0	increase NN B-noun.act	in IN 0	patient NN B-noun.person	controlled VBN B-verb.social	administration NN B-noun.act	of IN 0	tramadol.4,5 NN B-noun.person	_ '' I-noun.person	Chemotherapy NNP I-noun.person	, , 0	Tumor NNP B-noun.location	response NN B-noun.communication	to TO 0	chemotherapy VB B-verb.cognition	in IN 0	the DT 0	P NNP 0	388 CD 0	mouse NN B-noun.quantity	leukemia NN B-noun.state	model NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	ondansetron NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d739.s10	In IN 0	drug NN B-noun.act	- : 0	interaction NN B-noun.act	studies NNS B-noun.artifact	, , 0	the DT 0	recommended VBN B-verb.communication	clinical JJ B-adj.all	dose NN B-noun.quantity	of IN 0	montelukast NN B-noun.person	did VBD 0	not RB B-adv.all	have VB 0	clinically RB B-adv.all	important JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	the DT 0	following VBG 0	drugs NNS B-noun.person	, , 0	theophylline PRP 0	, , 0	prednisone NN B-noun.person	, , 0	prednisolone NN B-noun.person	, , 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	( ( 0	norethindrone NN 0	1 CD 0	mg PRP 0	/ : 0	ethinyl_estradiol JJ 0	35 CD 0	mcg NN 0	) ) 0	, , 0	terfenadine NN B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	and CC 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d705.s1	However RB 0	, , 0	because IN 0	telbivudine NN B-noun.phenomenon	is VBZ 0	eliminated VBN B-verb.cognition	primarily RB B-adv.all	by IN 0	renal JJ B-adj.all	excretion NN B-noun.act	, , 0	co RB 0	__ JJ 0	administration NN B-noun.time	of IN 0	telbivudine NN B-noun.shape	with IN 0	drugs NNS B-noun.artifact	that WDT 0	alter VBP B-verb.change	renal JJ B-adj.all	function NN B-noun.act	may MD 0	alter VB B-verb.change	plasma NN B-noun.act	concentrations NNS B-noun.attribute	of IN 0	telbivudine NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d578.s5	Drugs NNS B-noun.person	such JJ 0	as IN 0	troleandomycin NN B-noun.person	and CC 0	ketoconazole NN B-noun.group	may MD 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	methylprednisolone NN B-noun.attribute	and CC 0	thus RB B-adv.all	decrease VB B-verb.change	its PRP$ 0	clearance NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d721.s3	The DT 0	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.event	of IN 0	digoxin NN B-noun.person	are VBP B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	modified VBN B-verb.change	by IN 0	SKELID JJ 0	coadministration NN 0	. . 0	. . 0
DDI-DrugBank.d656.s2	Plasma NN B-noun.person	levels NNS B-noun.state	of IN 0	piroxicam NN B-noun.group	are VBP 0	depressed VBN B-verb.communication	to TO 0	approximately RB B-verb.consumption	80 CD B-adj.all	% NN 0	of IN 0	their PRP$ 0	normal JJ B-adj.all	values NNS B-noun.attribute	when WRB 0	FELDENE NNP B-noun.person	is VBZ 0	administered VBN B-verb.possession	in IN 0	conjunction NN 0	with IN 0	aspirin NN B-noun.person	( ( 0	3900 CD 0	mg RB 0	/ JJ 0	day NN 0	) ) 0	, , 0	but CC 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	antacids NNS B-noun.animal	has VBZ B-verb.possession	no DT 0	effect NN B-noun.cognition	on IN 0	piroxicam NN B-noun.group	plasma NN B-noun.state	levels NNS B-noun.state	. . 0	Nonsteroidal_anti NNS B-noun.person	- : 0	inflammatory_agents NNS B-noun.person	, , 0	including VBG B-verb.change	FELDENE NNP B-noun.group	, , 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	increase VB B-verb.change	steady JJ B-adj.all	state NN B-noun.state	plasma NN B-noun.plant	lithium NN B-noun.body	levels NNS B-noun.attribute	. . 0	. . 0
DDI-MedLine.d190.s5	The DT 0	addition NN 0	of IN 0	heparinase_III NNP B-noun.person	or CC 0	chondroitin_ABC_lyase NN 0	greatly RB B-adv.all	enhanced JJ B-verb.change	transduction NN B-noun.act	of IN 0	the DT 0	retinal JJ B-adj.all	ganglion NN B-noun.act	cell NN B-noun.artifact	layer NN B-noun.person	and CC 0	increased VBD B-verb.change	the DT 0	depth NN B-noun.attribute	of IN 0	transduction NN B-noun.act	into IN 0	the DT 0	outer JJ B-adj.all	retina NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d194.s4	The DT 0	effect NN B-noun.cognition	of IN 0	dasatinib NN B-noun.person	, , 0	an DT 0	inhibitor NN B-noun.person	of IN 0	Src NNP B-noun.person	and CC 0	Abl NNP B-noun.person	kinases NNS I-noun.person	, , 0	on IN 0	paclitaxel NN B-noun.artifact	sensitivity NN I-noun.artifact	was VBD 0	measured VBN B-verb.cognition	in IN 0	ovarian JJ B-adj.all	cancer NN B-noun.state	cells NNS B-noun.body	and CC 0	HEY NNP 0	xenografts NNS 0	. . 0	. . 0
DDI-DrugBank.d588.s6	Corticosteroids NNS B-noun.person	or CC 0	ACTH NNP B-noun.group	, , 0	May MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	hypokalemia NN B-noun.person	and CC 0	increase NN B-noun.act	salt NN B-noun.act	and CC 0	water NN 0	retention NN 0	. . 0	. . 0
DDI-DrugBank.d610.s4	In IN 0	a DT 0	study NN B-noun.artifact	of IN 0	11 CD B-adj.all	HIV NNP B-noun.group	- : 0	infected JJ B-adj.all	patients NNS B-noun.person	receiving VBG B-verb.communication	methadone NN B-noun.person	- : 0	maintenance NN B-noun.person	therapy NN B-noun.person	( ( 0	40 CD B-adj.all	mg NN B-noun.quantity	and CC 0	90 CD 0	mg PRP$ 0	daily JJ B-noun.event	) ) 0	with IN 0	600 CD 0	mg NN B-noun.quantity	of IN 0	ZIAGEN NNP B-noun.other	twice RB B-adv.all	daily RB B-adv.all	( ( 0	twice RB B-adv.all	the DT 0	currently RB B-adv.all	recommended VBN B-verb.communication	dose NN B-noun.quantity	) ) 0	, , 0	oral JJ B-adj.all	methadone NN B-noun.attribute	clearance NN B-noun.attribute	increased VBD B-verb.change	22 CD B-adj.all	% NN 0	( ( 0	90 CD B-adj.all	% NN 0	CI NNP 0	6 CD B-adj.all	% NN 0	to TO 0	42 CD 0	% NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d746.s1	Monoamine_oxidase_inhibitors NNS B-noun.person	or CC 0	tricyclic_antidepressants NNS B-noun.group	may MD 0	potentiate VB B-verb.communication	the DT 0	action NN B-noun.process	of IN 0	sympathomimetic_amines NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d766.s3	Based VBN B-verb.cognition	on IN 0	an DT 0	in IN 0	vitro NN 0	rat NN 0	liver NN 0	model NN B-noun.person	, , 0	nitrogen NN B-noun.person	substituted VBD B-verb.possession	imidazole_drugs NNS B-noun.artifact	( ( 0	clotrimazole NN B-noun.person	, , 0	ketoconazole NN B-noun.person	, , 0	miconazole NN B-noun.location	) ) 0	were VBD B-verb.stative	potent JJ B-adj.all	, , 0	non RB 0	- : 0	competitive JJ B-adj.all	inhibitors NNS B-noun.attribute	of IN 0	trimetrexate JJ B-adj.all	metabolism NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d147.s8	Imexon NNP B-noun.person	and CC 0	dacarbazine NN B-noun.person	show VBP B-verb.communication	additive JJ B-noun.phenomenon	effects NNS B-noun.phenomenon	in IN 0	vitro NN B-noun.person	but CC 0	not RB B-adv.all	in IN 0	vivo NN B-noun.food	in IN 0	human JJ B-adj.all	A375 NN B-noun.body	melanoma NN B-noun.body	cells NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d641.s4	Patients NNS B-noun.person	with IN 0	mild JJ 0	to TO 0	moderate VB B-verb.change	renal JJ B-adj.all	insufficiency NN B-noun.attribute	should MD 0	avoid VB B-verb.social	taking VBG 0	NSAIDs NNP B-noun.person	with IN 0	short JJ B-adj.all	elimination NN B-noun.person	half NN B-noun.person	- : 0	lives VBZ B-verb.stative	for IN 0	a DT 0	period NN B-noun.time	of IN 0	2 CD B-adj.all	days NNS B-noun.act	before RB 0	, , 0	the DT 0	day NN 0	of IN 0	, , 0	and CC 0	2 CD B-adj.all	days NNS B-noun.artifact	following VBG 0	administration NN B-noun.person	of IN 0	ALIMTA NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d739.s5	- : 0	did VBD 0	not RB B-adv.all	cause VB B-verb.creation	any DT 0	clinically RB B-adj.all	significant JJ B-adj.all	change NN B-noun.relation	in IN 0	plasma NN B-noun.substance	profiles NNS B-noun.artifact	of IN 0	prednisone NN B-noun.substance	or CC 0	prednisolone NN B-noun.substance	following VBG 0	administration NN B-noun.person	of IN 0	either DT 0	oral JJ B-adj.all	prednisone NN B-noun.state	or CC 0	intravenous JJ B-adj.all	prednisolone NN B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d743.s0	Ketoconazole NNP B-noun.person	, , 0	Spontaneous JJ B-adj.all	adverse JJ B-noun.event	reaction NN B-noun.process	reports NNS B-noun.artifact	of IN 0	patients NNS B-noun.person	taking VBG B-verb.social	concomitant JJ B-adj.all	ketoconazole NN B-noun.person	with IN 0	recommended VBN B-verb.communication	doses NNS B-noun.person	of IN 0	terfenadine NN 0	demonstrate VB B-verb.communication	QT NNP 0	interval JJ B-adj.all	prolongation NN B-noun.act	and CC 0	rare JJ B-adj.all	serious JJ B-noun.body	cardiac JJ I-noun.body	events NNS B-noun.person	, , 0	e.g. NNP B-noun.person	. . 0
DDI-DrugBank.d664.s0	May MD 0	increase VB B-verb.change	the DT 0	effect NN B-noun.cognition	of IN 0	oral JJ B-adj.all	blood_thinners NNS B-noun.other	, , 0	for IN 0	example NN 0	warfarin NN 0	( ( 0	Coumadin NNP B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d578.s3	convulsions NNS B-noun.artifact	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	concurrent JJ B-adj.all	use NN 0	of IN 0	methylprednisolone NN B-noun.attribute	and CC 0	cyclosporin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d695.s0	While IN 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	ZAVESCA NNP B-noun.group	___ NNP I-noun.group	appeared VBD B-verb.social	to TO 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	Cerezyme NNP B-noun.person	by IN 0	70 CD B-adj.all	% NN 0	, , 0	these DT 0	results NNS B-noun.communication	are VBP B-verb.stative	not RB B-adv.all	conclusive JJ B-adj.all	because IN 0	of IN 0	the DT 0	small JJ B-adj.all	number NN B-noun.quantity	of IN 0	subjects NNS B-noun.person	studied VBN B-verb.cognition	and CC 0	because IN 0	patients NNS B-noun.person	took VBD B-verb.change	variable JJ B-adj.all	doses NNS B-noun.event	of IN 0	Cerezyme NNP B-noun.location	. . 0	. . 0
DDI-DrugBank.d637.s2	Interaction NN 0	with IN 0	Mixed_Agonist JJ B-noun.other	/ IN I-noun.other	Antagonist_Opioid_Analgesics NNS I-noun.other	, , 0	Agonist NNP B-noun.person	/ POS 0	antagonist_analgesics NNS B-noun.attribute	( ( 0	i.e. FW B-adv.all	, , 0	pentazocine NN B-noun.person	, , 0	nalbuphine NN B-noun.person	, , 0	butorphanol NN 0	, , 0	or CC 0	buprenorphine NN B-noun.location	) ) 0	should MD 0	NOT RB 0	be VB 0	administered VBN B-verb.perception	to TO 0	patients NNS B-noun.person	who WP 0	have VBP 0	received VBN B-verb.possession	or CC 0	are VBP 0	receiving VBG B-verb.communication	a DT 0	course NN B-noun.object	of IN 0	therapy NN 0	with IN 0	a DT 0	proof NN B-noun.communication	opioid_agonist_analgesic JJ I-noun.communication	. . 0	. . 0
DDI-DrugBank.d583.s0	In IN 0	animals NNS 0	the DT 0	duration NN 0	of IN 0	muscle NN B-noun.body	paralysis NN B-noun.event	from IN 0	succinylcholine NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	prolonged VBN B-verb.creation	by IN 0	remifentanil NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d686.s0	Thiabendazole NNP B-noun.person	may MD 0	compete VB B-verb.cognition	with IN 0	other JJ 0	drugs NNS B-noun.artifact	, , 0	such JJ 0	as IN 0	theophylline PRP 0	, , 0	for IN 0	sites NNS B-noun.location	of IN 0	metabolism NN B-noun.food	in IN 0	the DT 0	liver NN B-noun.person	, , 0	thus RB 0	elevating VBG B-verb.social	the DT 0	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	such JJ B-adj.all	compounds NNS B-noun.person	to TO 0	potentially RB B-adj.all	toxic JJ B-adj.all	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d646.s1	An DT 0	additional JJ B-adj.all	clinical JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN 0	interaction NN 0	study NN B-noun.person	showed VBD B-verb.communication	no DT 0	effect NN B-noun.cognition	of IN 0	rifaximin NN 0	on IN 0	the DT 0	presystemic JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	an DT 0	oral JJ B-adj.all	contraceptive NN 0	containing VBG B-verb.stative	ethinyl_estradiol NN 0	and CC 0	norgestimate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d583.s2	In IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	with IN 0	atracurium NN B-noun.artifact	, , 0	mivacurium NN B-noun.person	, , 0	esmolol NN B-noun.person	, , 0	echothiophate NN B-noun.person	, , 0	neostigmine NN B-noun.person	, , 0	physostigmine NN B-noun.person	, , 0	and CC 0	midazolam NN B-noun.body	revealed VBD B-verb.perception	no DT 0	inhibition NN B-noun.attribute	of IN 0	remifentanil NN B-noun.object	hydrolysis NN I-noun.object	in IN 0	whole JJ B-adj.all	human JJ B-adj.all	blood NN B-noun.act	by IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d586.s3	Some DT 0	examples NNS B-noun.cognition	of IN 0	such JJ B-adj.all	drugs NNS B-noun.artifact	are VBP B-verb.stative	erythromycin NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	ketoconazole NN B-noun.person	, , 0	fluconazole NN B-noun.person	, , 0	calcium_channel_blockers NNS B-noun.person	and CC 0	cimetidine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d204.s11	Synergism NN B-noun.artifact	was VBD B-verb.stative	also RB B-adv.all	noted VBD B-verb.perception	when WRB 0	methylglyoxal NN B-noun.person	was VBD 0	combined VBN B-verb.change	with IN 0	carbenicillin NN B-noun.substance	and CC 0	amikacin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d710.s0	Cimetidine NNP B-noun.person	, , 0	The DT 0	effects NNS B-noun.phenomenon	of IN 0	chronic JJ B-adj.pert	cimetidine NN B-noun.location	use NN 0	on IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	rimantadine NN 0	are VBP 0	not RB B-adv.all	known VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d776.s26	A DT 0	controlled JJ B-adj.all	study NN B-noun.person	found VBD B-verb.communication	that IN 0	concomitant JJ B-adj.all	fluconazole NN B-noun.communication	200 CD 0	mg NN B-noun.quantity	once RB B-adv.all	daily JJ B-adj.pert	and CC 0	cisapride JJ 0	20 CD 0	mg DT 0	four CD B-adj.all	times NNS B-noun.event	a DT 0	day NN B-noun.person	yielded VBD B-verb.possession	a DT 0	significant JJ B-adj.all	increase NN B-noun.event	in IN 0	cisapride JJ B-adj.all	plasma NN B-noun.substance	levels NNS B-noun.state	and CC 0	prolongation NN B-noun.act	of IN 0	QTc NNP B-noun.person	interval NN I-noun.person	. . 0	. . 0
DDI-DrugBank.d776.s4	DIFLUCAN JJ B-noun.substance	reduces VBZ B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	tolbutamide NN 0	, , 0	glyburide NN 0	, , 0	and CC 0	glipizide NN B-noun.attribute	and CC 0	increases VBZ B-verb.change	the DT 0	plasma NN B-noun.substance	concentration NN B-noun.event	of IN 0	these DT 0	agents NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d200.s2	All DT 0	patients NNS B-noun.person	had VBD 0	indications NNS B-noun.motive	for IN 0	antihypertensive JJ B-adj.all	therapy NN B-noun.person	and CC 0	were VBD 0	randomized VBN B-verb.communication	either RB 0	to TO 0	fixed VBN B-verb.consumption	combination NN 0	amlodipine NN 0	/ : 0	valsartan NN B-noun.attribute	( ( 0	n=43 NN 0	) ) 0	or CC 0	to TO 0	therapy NN B-noun.act	which WDT 0	corresponded VBD B-verb.stative	to TO 0	the DT 0	hospital NN B-noun.artifact	formulary NN B-noun.act	( ( 0	n=43 NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d633.s2	In IN 0	another DT 0	formal JJ B-adj.all	study NN B-noun.artifact	( ( 0	n UH 0	= $ 0	8 CD B-adj.all	extensive JJ B-adj.all	and CC 0	n PRP 0	= $ 0	7 CD B-adj.all	poor JJ B-adj.all	metabolizers NNS B-noun.person	of IN 0	CYP2D6 NNP B-noun.location	) ) 0	, , 0	coadministration NN B-noun.person	of IN 0	propafenone NN B-noun.person	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	kinetics NNS B-noun.cognition	of IN 0	mexiletine NN B-noun.person	in IN 0	the DT 0	poor JJ B-adj.all	CYP2D6 NNP B-noun.person	metabolizer NN I-noun.person	group NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d645.s7	Terbinafine JJ B-adj.all	clearance NN B-noun.attribute	is VBZ 0	increased VBN B-verb.change	100 CD 0	% NN 0	by IN 0	rifampin NN B-noun.person	, , 0	a DT 0	CyP450 JJ 0	enzyme NN B-noun.person	inducer NN I-noun.person	, , 0	and CC 0	decreased VBD B-verb.change	33 CD 0	% NN 0	by IN 0	cimetidine NN B-noun.person	, , 0	a DT 0	CyP450 JJ 0	enzyme NN B-noun.person	inhibitor NN B-noun.person	. . 0	. . 0
DDI-MedLine.d206.s8	Curcumin NNP B-noun.person	can MD 0	be VB B-verb.stative	a DT 0	useful JJ B-adj.all	antidepressant NN B-noun.attribute	especially RB B-adv.all	in IN 0	cases NNS B-noun.state	which WDT 0	respond VBP 0	to TO 0	drugs NNS B-noun.person	having VBG B-verb.body	mixed JJ B-adj.ppl	effects NNS B-noun.phenomenon	on IN 0	serotonin NN B-noun.person	and CC 0	catecholamines NNS B-noun.animal	levels NNS B-noun.state	in IN 0	the DT 0	brain NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d666.s3	Pindolol NNP B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	increase VB B-verb.change	serum NN 0	thioridazine NN 0	levels NNS B-noun.attribute	when WRB 0	both DT 0	drugs NNS B-noun.artifact	are VBP B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d633.s20	Additionally RB B-adv.all	, , 0	in IN 0	one CD 0	controlled VBN B-verb.social	study NN B-noun.artifact	in IN 0	five CD 0	normal JJ B-adj.all	subjects NNS B-noun.person	and CC 0	seven CD 0	patients NNS B-noun.person	, , 0	the DT 0	clearance NN B-noun.act	of IN 0	caffeine NN B-noun.person	was VBD 0	decreased VBN B-verb.change	50 CD B-adj.all	% NN 0	following VBG B-verb.stative	the DT 0	administration NN B-noun.time	of IN 0	Mexitil NNP B-noun.person	__ NNP I-noun.person	. . 0	. . 0
DDI-MedLine.d203.s13	Having VBG 0	moderate JJ 0	to TO 0	severe JJ B-adj.all	pain NN B-noun.cognition	( ( 0	ARRR=1.54 NN B-noun.person	, , 0	95 CD 0	% NN 0	CI=1.08 SYM 0	- : 0	2.20 CD 0	) ) 0	and CC 0	the DT 0	prescribing NN B-noun.person	of IN 0	an DT 0	anxiolytic JJ B-adj.all	or CC 0	hypnotic JJ B-adj.all	( ( 0	ARRR=1.33 NN B-noun.person	, , 0	95 CD 0	% NN 0	CI=1.02 SYM 0	- : 0	1.74 CD 0	) ) 0	increased VBD B-verb.change	the DT 0	risk NN 0	of IN 0	potential JJ B-adj.all	inappropriate JJ B-adj.all	antidepressant JJ B-adj.all	use NN B-noun.person	. . 0	. . 0
DDI-MedLine.d198.s4	Mapping NN B-noun.person	of IN 0	residues NNS B-noun.phenomenon	important JJ B-adj.all	to TO 0	alcohol VB B-verb.social	modulation NN B-noun.act	of IN 0	ionotropic JJ B-adj.pert	receptors NNS B-noun.person	for IN 0	glycine NN B-noun.person	, , 0	__ PRP$ 0	-aminobutyric JJ B-adj.all	acid NN B-noun.person	, , 0	and CC 0	acetylcholine VB 0	onto IN 0	GLIC NNP 0	revealed VBD B-verb.perception	their PRP$ 0	proximity NN B-noun.attribute	to TO 0	transmembrane VB B-verb.social	cavities NNS B-noun.act	that WDT 0	may MD 0	accommodate VB B-verb.cognition	one CD 0	or CC 0	more JJR B-noun.quantity	alcohol NN B-adj.all	molecules NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d619.s2	This DT 0	is VBZ B-verb.stative	typical JJ B-adj.all	of IN 0	the DT 0	interaction NN B-noun.act	of IN 0	meperidine NN B-noun.person	and CC 0	MAOIs NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d680.s3	Therefore RB 0	, , 0	when WRB 0	coadministered VBN B-verb.communication	with IN 0	pantoprazole NN B-noun.person	, , 0	adjustment NN B-noun.person	of IN 0	the DT 0	dosage NN B-noun.quantity	of IN 0	pantoprazole NN B-noun.communication	or CC 0	of IN 0	such JJ B-adj.all	drugs NNS B-noun.artifact	may MD 0	not RB 0	be VB B-verb.stative	necessary JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d632.s3	When WRB 0	the DT 0	rapid JJ B-adj.all	onset NN B-noun.event	of IN 0	a DT 0	concomitant NN B-noun.person	orally RB B-adv.all	administered VBN B-verb.possession	agent NN B-noun.person	is VBZ B-verb.stative	a DT 0	critical JJ B-adj.all	determinant NN B-noun.cognition	of IN 0	effectiveness NN B-noun.cognition	( ( 0	such JJ 0	as IN 0	analgesics NNS B-noun.group	) ) 0	, , 0	the DT 0	agent NN B-noun.person	should MD 0	be VB 0	administered VBN B-verb.possession	at IN 0	least JJS 0	1 CD B-adj.all	hour NN 0	prior RB 0	to TO 0	or CC 0	2 CD B-adj.all	hours NNS B-noun.person	after IN 0	SYMLIN NNP B-noun.group	injection NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d694.s2	No DT 0	dosage NN B-noun.phenomenon	adjustment NN B-noun.process	of IN 0	digoxin NN B-noun.substance	or CC 0	JANUVIA NNP B-noun.group	is VBZ 0	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d761.s3	Fat SYM 0	- : 0	soluble_Vitamin_Supplements NNS B-noun.person	and CC 0	Analogues NNP B-noun.person	, , 0	A DT 0	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	study NN B-noun.artifact	showed VBD B-verb.communication	a DT 0	30 CD B-adj.all	% NN 0	reduction NN B-noun.act	in IN 0	beta JJ 0	- : 0	carotene NN B-noun.substance	supplement NN B-noun.artifact	absorption NN B-noun.artifact	when WRB 0	concomitantly RB B-adv.all	administered VBN B-verb.possession	with IN 0	XENICAL NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d776.s6	Coumarin NNP B-noun.person	- : 0	type_anticoagulants NNS B-noun.person	, , 0	Prothrombin NNP B-noun.person	time NN B-noun.animal	may MD 0	be VB 0	increased VBN B-verb.change	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	concomitant JJ B-adj.all	DIFLUCAN NNP B-noun.group	and CC 0	coumarin NN B-noun.person	- : 0	type_anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d688.s2	Administration NN B-noun.person	of IN 0	a DT 0	higher JJR B-adj.all	dose NN B-noun.person	of IN 0	indinavir NN B-noun.person	should MD 0	be VB 0	considered VBN B-verb.cognition	when WRB 0	coadministering VBG B-verb.communication	with IN 0	megestrol_acetate JJ B-noun.person	. . 0	. . 0
DDI-MedLine.d154.s5	In IN 0	experiment NN B-noun.communication	2 CD 0	, , 0	the DT 0	same JJ B-adj.all	regimen NN B-noun.person	of IN 0	GSLS NNP B-noun.group	was VBD 0	administered VBN B-verb.perception	to TO 0	chickens NNS B-noun.animal	inoculated VBN B-verb.contact	with IN 0	inactivated_AI_vaccines NNS B-noun.food	, , 0	and CC 0	an DT 0	enhanced JJ B-adj.all	serum NN B-noun.body	antibody NN 0	response NN B-noun.communication	to TO 0	AI NNP 0	vaccination NN 0	was VBD 0	also RB B-adv.all	observed VBN B-verb.perception	. . 0	. . 0
DDI-MedLine.d151.s4	The DT 0	risk NN 0	of IN 0	gastrointestinal JJ B-adj.all	bleeding NN B-noun.act	during IN 0	the DT 0	treatment NN B-noun.plant	with IN 0	antiagregants NNS B-noun.person	and CC 0	anticoagulants NNS B-noun.person	, , 0	the DT 0	risk NN 0	of IN 0	bradycardia NNS B-noun.food	in IN 0	beta JJ 0	- : 0	blockade NN B-noun.attribute	, , 0	possible JJ B-adj.all	interactions NNS B-noun.person	with IN 0	other JJ 0	medications NNS B-noun.person	lowering VBG B-verb.motion	the DT 0	heart NN B-noun.body	rate NN B-noun.time	are VBP 0	discussed VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d192.s5	In IN 0	direct JJ 0	contrast NN 0	, , 0	in IN 0	rats NNS B-noun.animal	made VBD B-verb.social	opiate JJ B-adj.all	dependent JJ B-noun.person	and CC 0	conditioned VBN B-verb.communication	in IN 0	a DT 0	state NN B-noun.state	of IN 0	withdrawal NN B-noun.person	, , 0	intra JJ B-adj.all	- : 0	BLA NNP B-noun.group	D2 # 0	, , 0	but CC 0	not RB B-adv.all	D1 JJ 0	, , 0	receptor NN B-noun.person	blockade NN B-noun.person	blocked VBD B-verb.contact	opiate JJ B-adj.all	reward NN B-noun.possession	encoding NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d771.s1	Scopolamine NN B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	care NN B-noun.food	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	capable JJ B-adj.all	of IN 0	causing VBG B-verb.creation	CNS NNP 0	effects NNS 0	such JJ 0	as IN 0	sedatives NNS B-noun.person	, , 0	tranquilizers NNS B-noun.person	, , 0	or CC 0	alcohol NN B-noun.possession	. . 0	. . 0
DDI-DrugBank.d638.s2	Human JJ B-adj.all	pharmacologic JJ B-adj.pert	studies NNS B-noun.group	have VBP 0	shown VBN B-verb.cognition	that IN 0	Ritalin NNP B-noun.person	may MD 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	coumarin_anticoagulants NNS B-noun.location	, , 0	anticonvulsants NNS B-noun.person	( ( 0	phenobarbital JJ B-adv.all	, , 0	diphenylhydantoin NN B-noun.person	, , 0	primidone NN 0	) ) 0	, , 0	phenylbutazone NN B-noun.person	, , 0	and CC 0	tricyclic_drugs NNS B-noun.act	( ( 0	imipramine NN B-noun.person	, , 0	clomipramine NN B-noun.person	, , 0	desipramine NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d585.s6	Because IN 0	antacids NNS B-noun.animal	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	anticholinergic_agents NNS B-noun.location	, , 0	simultaneous JJ B-adj.all	use NN B-noun.act	of IN 0	these DT 0	drugs NNS B-noun.artifact	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d776.s40	The DT 0	data NNS B-noun.cognition	presently RB B-adv.all	available JJ B-adj.all	indicate NN B-noun.cognition	that IN 0	the DT 0	decreases NNS B-noun.food	in IN 0	some DT 0	individual JJ B-adj.all	ethinyl_estradiol NN B-noun.act	and CC 0	levonorgestrel NN B-noun.person	AUC NNP I-noun.person	values NNS B-noun.attribute	with IN 0	fluconazole JJ B-adj.all	treatment NN B-noun.plant	are VBP B-verb.stative	likely JJ B-adj.all	the DT 0	result NN B-noun.act	of IN 0	random JJ B-noun.phenomenon	variation NN I-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d614.s1	However RB 0	, , 0	it PRP 0	is VBZ B-verb.stative	possible JJ B-adj.all	that IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	other JJ B-adj.all	photosensitizing_agents NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	tetracyclines NNS B-noun.artifact	, , 0	sulfonamides VBZ B-verb.motion	, , 0	phenothiazines NNS B-noun.body	, , 0	sulfonylurea NN 0	hypoglycemia NN 0	agents NNS B-noun.person	, , 0	thiazide_diuretics NNS B-noun.person	, , 0	and CC 0	griseofulvin NN 0	) ) 0	could MD 0	increase VB B-verb.change	the DT 0	photosensitivity NN B-noun.phenomenon	reaction NN B-noun.process	. . 0	. . 0
DDI-MedLine.d143.s6	Regulatory JJ B-noun.person	agencies NNS I-noun.person	state VBP B-verb.cognition	that IN 0	the DT 0	combination NN B-noun.event	of IN 0	clopidogrel NN B-noun.artifact	and CC 0	the DT 0	CYP2C19 JJ B-adj.all	inhibitors NNS B-noun.person	omeprazole NN B-noun.person	and CC 0	esomeprazole NN B-noun.communication	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-MedLine.d195.s4	In IN 0	the DT 0	present JJ B-adj.all	study NN B-noun.artifact	piperine NN 0	( ( 0	10 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	significantly RB B-adv.all	increased VBD B-verb.change	the DT 0	dose NN B-noun.person	- : 0	dependent JJ B-adj.all	antinociceptive JJ B-adj.all	activity NN B-noun.process	of IN 0	ibuprofen NNS B-noun.person	evaluated VBN B-verb.communication	by IN 0	both DT 0	acetic_acid JJ 0	writhing NN B-verb.creation	and CC 0	formalin JJ B-adj.all	test NN B-noun.person	, , 0	when WRB 0	it PRP 0	was VBD 0	administered VBN B-verb.possession	with IN 0	ibuprofen NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d701.s1	- : 0	Antacids NNPS B-noun.person	; : 0	Diarrhea NNP B-noun.person	medicine NN 0	containing VBG B-verb.stative	kaolin NN B-noun.substance	or CC 0	attapulgite VB B-verb.emotion	; : 0	Ketoconazole NNP B-noun.person	; : 0	Central_nervous_system_(CNS)_depressants NNS B-noun.artifact	; : 0	Other JJ 0	anticholinergics NNS B-noun.attribute	; : 0	Tricyclic_antidepressants NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	Elavil NNP B-noun.person	, , 0	Asendin NNP B-noun.person	, , 0	Anafranil NNP B-noun.person	, , 0	Pertofrane NNP B-noun.person	, , 0	Sinequan NNP B-noun.person	, , 0	Tofranil NNP B-noun.person	, , 0	Aventyl NNP B-noun.person	, , 0	Surmontil NNP B-noun.location	) ) 0	; : 0	Potassium_chloride JJ 0	( ( 0	e.g. UH 0	, , 0	Kay_Ciel NNP B-noun.group	) ) 0	. . 0
DDI-DrugBank.d781.s12	Gentamicin NNP B-noun.person	, , 0	Animal NNP B-noun.person	data NNS B-noun.cognition	have VBP 0	suggested VBN B-verb.communication	the DT 0	possibility NN B-noun.state	of IN 0	interaction NN B-noun.act	between IN 0	perindopril NN B-noun.person	and CC 0	gentamicin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d761.s6	Glyburide NNP B-noun.person	, , 0	In IN 0	12 CD B-adj.all	normal JJ B-adj.pert	- : 0	weight NN B-noun.artifact	subjects NNS B-noun.artifact	receiving VBG B-verb.communication	orlistat NN B-noun.communication	80 CD 0	mg IN 0	three CD 0	times NNS B-noun.event	a DT 0	day NN B-noun.person	for IN 0	5 CD B-adj.all	days NNS B-noun.person	, , 0	orlistat NN B-noun.artifact	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.time	or CC 0	pharmacodynamics NNS B-noun.person	( ( 0	blood NN B-noun.act	glucose NN B-noun.act	- : 0	lowering VBG B-verb.motion	) ) 0	of IN 0	glyburide NN 0	. . 0	. . 0
DDI-MedLine.d145.s2	The DT 0	purpose NN B-noun.attribute	of IN 0	this DT 0	study NN B-noun.artifact	was VBD 0	to TO 0	investigate VB B-verb.stative	both PDT 0	the DT 0	effect NN B-noun.cognition	and CC 0	mechanisms NNS B-noun.person	of IN 0	IGF1R JJ B-noun.phenomenon	inhibition NN I-noun.phenomenon	by IN 0	tyrphostin_AG1024 NNP B-noun.person	in IN 0	the DT 0	presence NN B-noun.person	or CC 0	absence NN B-noun.act	of IN 0	doxorubicin NN B-noun.food	in IN 0	a DT 0	panel NN B-noun.person	of IN 0	six CD 0	osteosarcoma NN 0	cell NN 0	lines NNS B-noun.communication	and CC 0	a DT 0	self PRP 0	- : 0	established VBD B-verb.cognition	doxorubicin NN B-noun.person	- : 0	resistant JJ B-adj.all	cell NN B-noun.body	line NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d653.s8	There EX 0	are VBP 0	reports NNS B-noun.artifact	of IN 0	enhanced VBN B-verb.change	as RB 0	well RB 0	as IN 0	diminished JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	anticoagulants NNS B-noun.animal	when WRB 0	given VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	corticosteroids NNS B-noun.food	. . 0	. . 0
DDI-DrugBank.d776.s25	Cisapride NNP B-noun.person	, , 0	There EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	cardiac JJ 0	events NNS 0	, , 0	including VBG B-verb.change	torsade NN B-noun.attribute	de IN 0	pointes NNS B-noun.cognition	in IN 0	patients NNS B-noun.person	to TO 0	whom WP 0	fluconazole NN B-noun.person	and CC 0	cisapride NN B-noun.person	were VBD 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d736.s5	Thiazide_drugs NNS B-noun.artifact	may MD 0	increase VB B-verb.change	the DT 0	responsiveness NN B-noun.cognition	of IN 0	tubocurarine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d653.s1	Drugs NNS B-noun.artifact	that WDT 0	induce VBP B-verb.emotion	hepatic JJ B-adj.all	enzymes NNS B-noun.event	such JJ 0	as IN 0	phenobarbital JJ B-adj.all	, , 0	phenytoin NN B-noun.person	and CC 0	rifampin NN B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	corticosteroids NNS B-noun.food	and CC 0	may MD 0	require VB B-verb.stative	increases NNS B-noun.event	in IN 0	corticosteroid JJ B-adj.all	dose NN B-noun.quantity	to TO 0	achieve VB B-verb.social	the DT 0	desired VBN B-verb.emotion	response NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d590.s4	For IN 0	information NN B-noun.cognition	on IN 0	drug NN B-noun.person	interactions NNS I-noun.person	associated VBN B-verb.cognition	with IN 0	ranitidine NN B-noun.person	, , 0	refer VBP B-verb.cognition	to TO 0	the DT 0	ZANTAC NNP B-noun.group	____ POS 0	package NN B-noun.artifact	insert NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d199.s3	EA NNP 0	signs NNS B-noun.communication	were VBD 0	observed VBN B-verb.perception	in IN 0	all DT 0	7 CD B-adj.all	patients NNS B-noun.person	in IN 0	association NN 0	with IN 0	propofol NN B-noun.group	TIVA NNP B-noun.group	but CC 0	did VBD 0	not RB B-adv.all	recur VB B-verb.perception	in IN 0	any DT 0	of IN 0	123 CD 0	subsequent JJ B-adj.all	anesthetics NNS B-noun.act	sessions NNS B-noun.act	during IN 0	which WDT 0	low JJ 0	- : 0	dose NN B-noun.person	ketamine NN B-noun.person	was VBD 0	added VBN B-verb.change	to TO 0	propofol VB B-verb.communication	. . 0	. . 0
DDI-DrugBank.d572.s0	Cholestyramine NN B-noun.person	, , 0	Concomitant NNP B-noun.person	cholestyramine NN I-noun.person	administration NN B-noun.person	decreased VBD B-verb.change	the DT 0	mean JJ B-adj.all	AUC NNP B-noun.group	of IN 0	total JJ B-adj.all	ezetimibe NN B-noun.person	approximately RB B-adv.all	55 CD 0	% NN 0	. . 0	. . 0
DDI-DrugBank.d628.s3	During IN 0	maintenance NN B-noun.state	of IN 0	anesthesia NN B-noun.state	or CC 0	sedation NN B-noun.act	, , 0	the DT 0	rate NN B-noun.time	of IN 0	DIPRIVAN NNP B-noun.group	Injectable NNP I-noun.group	Emulsion NNP I-noun.group	administration NN I-noun.group	should MD 0	be VB 0	adjusted VBN B-verb.change	according VBG 0	to TO 0	the DT 0	desired VBN B-verb.emotion	level NN B-noun.state	of IN 0	anesthesia NN B-noun.state	or CC 0	sedation NN B-noun.act	and CC 0	may MD 0	be VB 0	reduced VBN B-verb.change	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	supplemental JJ B-adj.all	analgesic_agents NNS B-noun.group	( ( 0	eg UH 0	, , 0	nitrous_oxide JJ B-noun.other	or CC 0	opioids NNS B-noun.body	) ) 0	. . 0	. . 0
DDI-DrugBank.d711.s0	Because IN 0	tetracyclines NNS B-noun.communication	have VBP 0	been VBN 0	shown VBN B-verb.perception	to TO 0	depress VB B-verb.motion	plasma NN 0	prothrombin NN 0	activity NN B-noun.state	, , 0	patients NNS B-noun.person	who WP 0	are VBP B-verb.stative	on IN 0	anticoagulant JJ B-adj.all	therapy NN B-noun.act	may MD 0	require VB B-verb.stative	downward JJ B-adj.all	adjustment NN B-noun.act	of IN 0	their PRP$ 0	anticoagulant JJ B-adj.all	dosage NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d701.s0	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	_ '' 0	Pirenzepine NNP B-noun.location	may MD 0	interact VB B-verb.change	with IN 0	the DT 0	following VBG 0	drugs NNS B-noun.person	, , 0	which WDT 0	may MD 0	affect VB B-verb.change	the DT 0	effect NN B-noun.cognition	of IN 0	Pirenzepine NNP B-noun.location	or CC 0	whose WP$ 0	effects NNS B-noun.phenomenon	may MD 0	be VB 0	affected VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d606.s1	Sympathomimetics NNS B-noun.person	may MD 0	reduce VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	methyldopa NN B-noun.food	, , 0	mecamylamine NN B-noun.person	, , 0	reserpine NN B-noun.person	and CC 0	veratrum_alkaloids NNS B-noun.plant	. . 0	. . 0
DDI-DrugBank.d763.s7	ondansetron NN B-noun.person	did VBD 0	not RB B-adv.all	increase VB B-verb.change	blood NN B-noun.body	levels NNS B-noun.attribute	of IN 0	high JJ B-noun.group	- : 0	dose NN B-noun.person	methotrexate NN B-noun.person	. . 0	. . 0
DDI-MedLine.d195.s5	Ibuprofen NNP B-noun.person	plasma NN I-noun.person	concentration NN B-noun.person	was VBD B-verb.stative	also RB B-adv.all	increased VBN B-verb.change	when WRB 0	it PRP 0	was VBD 0	administered VBN B-verb.possession	with IN 0	piperine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d185.s7	In IN 0	the DT 0	presence NN B-noun.person	of IN 0	ketoconazole NN B-noun.shape	, , 0	there EX 0	was VBD B-verb.stative	1.6- JJ B-adj.all	and CC 0	1.8-fold JJ B-adj.all	increase NN B-noun.event	in IN 0	C NNP 0	( ( 0	max NN 0	) ) 0	and CC 0	AUC NNP B-noun.group	of IN 0	panobinostat NN B-noun.artifact	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d572.s7	Gemfibrozil NNP B-noun.person	, , 0	In IN 0	a DT 0	pharmacokinetic JJ B-adj.all	study NN B-noun.artifact	, , 0	concomitant JJ B-adj.all	gemfibrozil NN B-noun.artifact	administration NN B-noun.person	increased VBD B-verb.change	total JJ B-adj.all	ezetimibe NN B-noun.person	concentrations NNS B-noun.person	approximately RB B-adv.all	1.7-fold JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d626.s0	Alcohol NNP B-noun.person	( ( 0	this DT 0	combination NN B-noun.group	may MD 0	make VB B-verb.cognition	you PRP 0	very RB B-adv.all	sick JJ 0	) ) 0	and CC 0	primaquine NN B-noun.person	. . 0
DDI-DrugBank.d776.s7	In IN 0	post NN B-noun.act	- : 0	marketing NN B-verb.communication	experience NN B-noun.cognition	, , 0	as IN 0	with IN 0	other JJ B-adj.all	azole_antifungals NNS B-noun.person	, , 0	bleeding VBG B-verb.body	events NNS B-adv.all	( ( 0	bruising VBG B-verb.contact	, , 0	epistaxis NN B-noun.person	, , 0	gastrointestinal JJ B-adj.all	bleeding NN B-noun.act	, , 0	hematuria NN B-noun.person	, , 0	and CC 0	melena NN B-noun.location	) ) 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	association NN 0	with IN 0	increases NNS B-noun.food	in IN 0	prothrombin NN B-adj.all	time NN B-noun.time	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	fluconazole NN I-verb.communication	concurrently RB B-adv.all	with IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d603.s3	ProAmatine NNP B-noun.person	___ NNP I-noun.person	has VBZ 0	been VBN 0	used VBN B-verb.consumption	in IN 0	patients NNS B-noun.person	concomitantly RB B-adv.all	treated VBN B-verb.change	with IN 0	salt NN B-noun.food	- : 0	retaining VBG B-verb.possession	steroid JJ B-adj.all	therapy NN 0	( ( 0	i.e. FW B-adv.all	, , 0	fludrocortisone_acetate VBP B-verb.emotion	) ) 0	, , 0	with IN 0	or CC 0	without IN 0	salt NN 0	supplementation NN 0	. . 0	. . 0
DDI-MedLine.d166.s2	Medical JJ B-adj.all	treatment NN B-noun.feeling	with IN 0	cinacalcet NN B-noun.person	is VBZ B-verb.stative	effective JJ B-adj.all	in IN 0	reducing VBG B-verb.change	plasma NN B-noun.substance	parathyroid NN 0	hormone NN 0	( ( 0	PTH NNP 0	) ) 0	levels NNS B-noun.state	, , 0	but CC 0	its PRP$ 0	effect NN B-noun.cognition	on IN 0	darbepoetin NN 0	dosing NN 0	is VBZ B-verb.stative	unknown JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d784.s3	Mean VB B-verb.stative	oxybutynin_chloride JJ 0	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	were VBD B-verb.stative	approximately RB B-adv.all	2 CD 0	fold VBD B-verb.stative	higher JJR B-adj.all	when WRB 0	DITROPAN_XL NN B-noun.person	was VBD 0	administered VBN B-verb.possession	with IN 0	ketoconazole NN B-noun.person	, , 0	a DT 0	potent JJ B-noun.person	CYP3A4 NNP I-noun.person	inhibitor NN I-noun.person	. . 0	. . 0
DDI-DrugBank.d667.s0	Severe JJ 0	hypertension NN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	when WRB 0	oxytocin NN B-noun.person	was VBD 0	given VBN B-verb.possession	three CD 0	to TO 0	four CD 0	hours NNS 0	following VBG B-verb.stative	prophylactic JJ B-adj.all	administration NN B-noun.time	of IN 0	a DT 0	vasoconstrictor NN B-noun.person	in IN 0	conjunction NN 0	with IN 0	caudal NN B-noun.artifact	block NN 0	anesthesia NN 0	. . 0	. . 0
DDI-DrugBank.d633.s5	Addition NN 0	of IN 0	mexiletine NN B-noun.person	to TO 0	propafenone NN B-noun.person	did VBD 0	not RB B-adv.all	lead VB B-verb.stative	to TO 0	further RBR B-verb.possession	electrocardiographic JJ B-adj.all	parameters NNS B-noun.event	changes NNS B-noun.phenomenon	of IN 0	QRS NNP B-noun.group	, , 0	QTc NNP B-noun.person	, , 0	RR NNP 0	, , 0	and CC 0	PR NNP 0	intervals NNS 0	than IN 0	propafenone NN 0	alone RB 0	. . 0	. . 0
DDI-MedLine.d182.s20	o SYM 0	- : 0	Cymen-5-ol NN B-noun.time	/ '' 0	zinc_chloride RB 0	in IN 0	toothpaste NN B-noun.act	showed VBD B-verb.communication	greater JJR B-adj.all	effects NNS B-noun.phenomenon	than IN 0	placebo NN 0	( ( 0	120s NNS B-noun.other	log10 WDT I-noun.other	kill=7.35 VBP I-noun.other	_ # I-noun.other	0.40 CD I-noun.other	and CC I-noun.other	4.02 CD I-noun.other	_ # I-noun.other	0.40 CD I-noun.other	, , 0	respectively RB B-adv.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d765.s0	CYP3A4 NNP B-noun.group	Inhibitors NNPS I-noun.group	, , 0	Ketoconazole NNP B-noun.person	, , 0	an DT 0	inhibitor NN B-noun.person	of IN 0	the DT 0	drug NN B-noun.artifact	metabolizing NN B-noun.person	enzyme NN B-noun.person	CYP3A4 NNP I-noun.person	, , 0	significantly RB B-adv.all	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	tolterodine NN 0	when WRB 0	coadministered VBN B-verb.communication	to TO 0	subjects NNS B-noun.person	who WP 0	were VBD B-verb.stative	poor JJ B-adj.all	metabolizers NNS B-noun.person	( ( 0	see VB 0	CLINICAL NNP B-noun.group	PHARMACOLOGY NNP I-noun.group	, , 0	Variability NNP B-noun.person	in IN 0	Metabolism NNP B-noun.other	and CC 0	Drug NNP B-noun.person	- : 0	Drug NN B-noun.person	Interactions NNS I-noun.person	) ) 0	. . 0	. . 0
DDI-MedLine.d216.s5	In IN 0	the DT 0	ticlopidine NN B-noun.location	and CC 0	itraconazole JJ B-adj.all	phases NNS B-noun.time	, , 0	the DT 0	areas NNS B-noun.location	under IN 0	the DT 0	effect NN B-noun.cognition	- : 0	time NN B-noun.time	curves NNS B-noun.person	( ( 0	self NN B-noun.person	- : 0	reported VBD B-verb.communication	drowsiness NN B-noun.person	and CC 0	performance NN B-noun.act	) ) 0	were VBD B-verb.stative	significantly RB B-adv.all	higher JJR B-adj.all	than IN 0	those DT 0	in IN 0	the DT 0	placebo NN B-noun.state	phase NN B-noun.time	( ( 0	P NNP 0	< $ 0	0.05 CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d688.s0	Pharmacokinetic JJ B-adj.all	studies NNS B-noun.group	show VBP B-verb.communication	that IN 0	there EX 0	are VBP B-verb.stative	no DT 0	significant JJ B-adj.all	alterations NNS B-noun.person	in IN 0	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.event	of IN 0	zidovudine NN B-noun.act	or CC 0	rifabutin VB B-verb.social	to TO 0	warrant JJ B-adj.all	dosage NN B-noun.communication	adjustment NN B-noun.communication	when WRB 0	megestrol_acetate NN B-noun.person	is VBZ 0	administered VBN B-verb.possession	with IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d164.s5	Lapatinib NNP B-noun.person	may MD 0	have VB B-verb.change	the DT 0	potential NN B-noun.person	to TO 0	convert VB B-verb.communication	Herceptin NNP B-noun.person	- : 0	refractory NN B-noun.person	to TO 0	Herceptin NNP B-noun.person	- : 0	sensitive JJ B-adj.all	tumors NNS B-noun.person	in IN 0	HER2-positive JJ 0	breast NN 0	cancer NN B-noun.state	by IN 0	up SYM 0	- : 0	regulation NN B-noun.act	of IN 0	the DT 0	cell NN B-noun.body	surface NN 0	expression NN B-noun.communication	of IN 0	HER2 NN 0	. . 0	. . 0
DDI-MedLine.d179.s2	This DT 0	study NN B-noun.artifact	was VBD 0	aimed VBN B-verb.cognition	to TO 0	investigate VB B-verb.communication	the DT 0	efficacy NN B-noun.phenomenon	of IN 0	single JJ B-adj.all	use NN 0	of IN 0	sunitinib NN B-noun.food	and CC 0	that IN 0	of IN 0	concurrent JJ B-adj.all	or CC 0	sequential JJ B-adj.all	administration NN B-noun.time	of IN 0	sunitinib NN B-noun.food	and CC 0	docetaxel NN B-noun.artifact	in IN 0	NSCLC NNP 0	cell NN B-noun.body	lines NNS B-noun.communication	that WDT 0	are VBP B-verb.stative	resistant JJ B-adj.all	to TO 0	EGFR NNP B-noun.person	TKIs NNP I-noun.person	. . 0	. . 0
DDI-DrugBank.d594.s0	Interactions NNS B-noun.person	with IN 0	cylcopholsphamide NN 0	, , 0	fludarabine NN B-noun.person	and CC 0	vidarabine NN B-noun.person	. . 0
DDI-DrugBank.d660.s1	In IN 0	Trial NNP B-noun.other	1 CD I-noun.other	, , 0	the DT 0	proportions NNS B-noun.person	of IN 0	patients NNS B-noun.person	in IN 0	the DT 0	placebo NN B-noun.plant	and CC 0	Synagis NNP B-noun.person	___ NNP I-noun.person	groups NNS I-noun.person	who WP 0	received VBD B-verb.possession	routine JJ B-adj.all	childhood NN B-noun.body	vaccines NNS I-noun.body	, , 0	influenza_vaccine NN 0	, , 0	bronchodilators NNS B-noun.person	or CC 0	corticosteroids NNS B-noun.plant	were VBD B-verb.stative	similar JJ B-adj.all	and CC 0	no DT 0	incremental JJ B-adj.all	increase NN B-noun.event	in IN 0	adverse JJ B-adj.all	reactions NNS B-noun.person	was VBD 0	observed VBN B-verb.perception	among IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	these DT 0	agents NNS B-noun.person	. . 0	___ NNP B-noun.person	. . 0
DDI-DrugBank.d597.s13	In IN 0	vitro NN 0	testing NN 0	found VBD B-verb.possession	no DT 0	protein NN B-noun.substance	binding JJ B-verb.contact	drug NN 0	interaction NN 0	between IN 0	digoxin NN B-noun.person	and CC 0	meloxicam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d776.s19	Careful JJ B-adj.all	monitoring NN 0	of IN 0	serum NN 0	theophylline NN 0	concentrations NNS B-noun.artifact	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	DIFLUCAN JJ B-noun.group	and CC 0	theophylline PRP 0	is VBZ 0	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d636.s0	Some DT 0	anticonvulsants NNS B-noun.object	may MD 0	interact VB B-verb.change	with IN 0	Mephenytoin NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d652.s1	Additive JJ B-adj.all	sedative JJ B-adj.all	effects NNS B-noun.phenomenon	can MD 0	occur VB B-verb.cognition	when WRB 0	metoclopramide NN B-noun.attribute	is VBZ 0	given VBN B-verb.possession	with IN 0	alcohol NN B-noun.food	, , 0	sedatives NNS B-noun.person	, , 0	hypnotics NNS B-noun.person	, , 0	narcotics NNS B-noun.person	, , 0	or CC 0	tranquilizers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d775.s3	The DT 0	use NN 0	of IN 0	MIVACRON NNP B-noun.group	before IN 0	succinylcholine NN 0	to TO 0	attenuate VB B-verb.social	some DT 0	of IN 0	the DT 0	side NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	succinylcholine NN B-noun.person	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d688.s3	The DT 0	effects NNS B-noun.phenomenon	of IN 0	indinavir NN B-noun.person	, , 0	zidovudine NN B-noun.person	or CC 0	rifabutin VB B-verb.contact	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	megestrol_acetate JJ B-noun.location	were VBD B-verb.stative	not RB B-adv.all	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d574.s0	This DT 0	medicine NN B-noun.attribute	is VBZ B-verb.stative	generally RB B-adv.all	safe JJ B-adj.all	with IN 0	other JJ 0	medications NNS B-noun.person	, , 0	but CC 0	patient NN B-noun.person	should MD 0	consult VB B-verb.communication	doctor NN B-noun.person	or CC 0	pharmacist NN B-noun.person	if IN 0	patient NN B-noun.person	is VBZ 0	taking VBG B-verb.possession	a DT 0	blood NN B-noun.person	thinner NN B-noun.person	( ( 0	anticoagulant JJ B-adj.all	) ) 0	, , 0	cyclosporin NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	or CC 0	methotrexate NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d776.s8	Careful JJ B-adj.all	monitoring NN 0	of IN 0	prothrombin NN B-noun.person	time NN B-noun.person	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	DIFLUCAN JJ B-noun.group	and CC 0	coumarin NN B-noun.person	- : 0	type_anticoagulants NNS B-noun.person	is VBZ 0	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d692.s1	In IN 0	vitro NN B-noun.animal	studies NNS I-noun.animal	indicate VBP B-verb.cognition	that DT 0	moxifloxacin NN B-noun.communication	does VBZ 0	not RB B-adv.all	inhibit VB B-verb.change	CYP3A4 NNP B-noun.group	, , 0	CYP2D6 NNP B-noun.person	, , 0	CYP2C9 NNP B-noun.person	, , 0	CYP2C19 NNP B-noun.person	, , 0	or CC 0	CYP1A2 JJ 0	indicating VBG B-verb.communication	that DT 0	moxifloxacin NN B-noun.person	is VBZ B-verb.stative	unlikely JJ B-adj.all	to TO 0	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	drugs NNS B-noun.artifact	metabolized VBN B-verb.change	by IN 0	these DT 0	cytochrome VBP B-verb.stative	P450 JJ 0	isozymes NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d588.s10	Salicylates NNS B-noun.person	and CC 0	Other NNP 0	Non NNP B-noun.person	- : 0	Steroidal_Anti SYM 0	- : 0	Inflammatory_Drugs NNS B-noun.time	, , 0	May MD 0	decrease VB B-verb.cognition	the DT 0	antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	MYKROX NNP B-noun.group	Tablets NNPS I-noun.group	. . 0	. . 0
DDI-DrugBank.d743.s9	Macrolides NNS B-noun.person	, , 0	Clinical JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.act	indicate VBP B-verb.cognition	that DT 0	erythromycin NN B-noun.person	and CC 0	clarithromycin NN B-noun.person	can MD 0	exert VB B-verb.social	an DT 0	effect NN B-noun.cognition	on IN 0	terfenadine NN B-noun.artifact	metabolism NN B-noun.artifact	by IN 0	a DT 0	mechanism NN B-noun.object	which WDT 0	may MD 0	be VB B-verb.stative	similar JJ B-adj.all	to TO 0	that DT 0	of IN 0	ketoconazole NN B-noun.shape	, , 0	but CC 0	to TO 0	a DT 0	lesser JJR B-adj.all	extent NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d775.s1	Prior JJ B-adj.all	administration NN B-noun.time	of IN 0	succinylcholine NN B-noun.person	can MD 0	potentiate VB B-verb.communication	the DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	effects NNS B-noun.phenomenon	of IN 0	nondepolarizing_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d735.s5	Patients NNS B-noun.person	receiving VBG B-verb.communication	sirolimus NN B-noun.attribute	or CC 0	nifedipine NN B-noun.person	in IN 0	combination NN 0	with IN 0	MYCAMINE NNP B-noun.group	should MD 0	be VB 0	monitored VBN B-verb.perception	for IN 0	sirolimus NN B-noun.act	or CC 0	nifedipine JJ B-adj.all	toxicity NN B-noun.attribute	and CC 0	sirolimus NN B-noun.attribute	or CC 0	nifedipine JJ B-adj.all	dosage NN B-noun.artifact	should MD 0	be VB 0	reduced VBN B-verb.change	if IN 0	necessary JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d654.s1	Due JJ 0	to TO 0	low JJ B-adj.all	systemic JJ B-adj.all	exposure NN B-noun.cognition	to TO 0	retapamulin VB B-verb.contact	following VBG B-verb.stative	topical JJ B-adj.all	application NN B-noun.act	in IN 0	patients NNS B-noun.person	, , 0	dosage NN B-noun.artifact	adjustments NNS B-noun.person	for IN 0	retapamulin NN B-noun.act	are VBP B-verb.stative	unnecessary JJ B-adj.all	when WRB 0	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	CYP3A4 JJ B-adj.all	inhibitors NNS B-noun.person	, , 0	such JJ 0	as IN 0	ketoconazole NN B-noun.person	. . 0	. . 0
DDI-MedLine.d164.s4	Furthermore RB B-adv.all	, , 0	we PRP 0	present VBP B-verb.creation	a DT 0	case NN B-noun.state	report NN B-noun.communication	in IN 0	which WDT 0	a DT 0	second JJ B-noun.person	Herceptin NNP I-noun.person	treatment NN I-noun.person	following VBG 0	lapatinib NN B-noun.person	resulted VBD B-verb.communication	in IN 0	the DT 0	marked JJ B-adj.all	shrinkage NN B-noun.communication	of IN 0	multiple JJ B-adj.all	metastatic JJ B-adj.all	tumors NNS B-noun.person	in IN 0	HER2-positive JJ 0	breast NN 0	cancer NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d596.s5	Effect NN 0	of IN 0	Other NNP B-noun.person	Drugs NNP I-noun.person	on IN 0	the DT 0	Metabolism NNP B-noun.other	of IN I-noun.other	Exelon NNP I-noun.other	, , 0	Drugs NNP B-noun.person	that WDT 0	induce VBP B-verb.emotion	or CC 0	inhibit VB B-verb.body	CYP450 JJ 0	metabolism NN B-noun.attribute	are VBP B-verb.stative	not RB B-adv.all	expected VBN B-verb.cognition	to TO 0	alter VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	rivastigmine NN B-noun.location	. . 0	. . 0
DDI-MedLine.d232.s8	The DT 0	novel JJ B-adj.all	oral JJ B-adj.all	anticoagulants NNS B-noun.person	in IN 0	development NN B-noun.location	may MD 0	overcome VB B-verb.cognition	some DT 0	of IN 0	the DT 0	limitations NNS B-noun.time	of IN 0	vitamin_K_antagonists NNS B-noun.person	and CC 0	address VB B-verb.communication	their PRP$ 0	underuse NN 0	and CC 0	safety NN B-noun.artifact	concerns NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d185.s0	Effect NN 0	of IN 0	ketoconazole NN B-noun.person	- : 0	mediated VBD B-verb.stative	CYP3A4 JJ B-adj.all	inhibition NN B-noun.attribute	on IN 0	clinical JJ B-adj.all	pharmacokinetics NNS B-noun.person	of IN 0	panobinostat NN B-noun.person	( ( 0	LBH589 NN 0	) ) 0	, , 0	an DT 0	orally RB B-adv.all	active JJ B-adj.all	histone_deacetylase_inhibitor NN B-noun.other	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d577.s1	It PRP 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	that DT 0	sulfamethoxazole NN B-noun.group	may MD 0	prolong VB B-verb.stative	the DT 0	prothrombin NN B-noun.person	time NN B-noun.person	in IN 0	patients NNS B-noun.person	who WP 0	are VBP 0	receiving VBG B-verb.communication	the DT 0	anticoagulant JJ B-adj.all	warfarin NN B-noun.communication	. . 0	. . 0
DDI-MedLine.d194.s17	Inhibition NNP B-noun.person	of IN 0	Src NNP B-noun.person	family NN I-noun.person	and CC 0	Abl NNP B-noun.person	kinases NNS I-noun.person	with IN 0	either DT 0	siRNAs CD B-noun.other	or CC 0	dasatinib NN B-noun.substance	enhances NNS B-noun.phenomenon	paclitaxel VBP B-verb.communication	sensitivity NN B-noun.feeling	of IN 0	ovarian JJ B-adj.all	cancer NN B-noun.state	cells NNS B-noun.body	through IN 0	p27(Kip1)-mediated VBN B-verb.possession	suppression NN B-noun.possession	of IN 0	Bcl-2 NN B-noun.food	and CC 0	Cdk1 JJ B-adj.all	expression NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d650.s2	Because IN 0	pergolide_mesylate JJ B-noun.person	is VBZ B-verb.stative	approximately RB B-adv.all	90 CD B-adj.all	% NN 0	bound NN 0	to TO 0	plasma VB B-verb.creation	proteins NNS I-verb.creation	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	exercised VBN B-verb.communication	if IN 0	pergolide_mesylate JJ B-noun.person	is VBZ 0	coadministered VBN B-verb.contact	with IN 0	other JJ 0	drugs NNS B-noun.artifact	known VBN B-verb.cognition	to TO 0	affect VB B-verb.change	protein NN B-noun.substance	binding NN B-verb.contact	. . 0	. . 0
DDI-DrugBank.d776.s36	This DT 0	effect NN B-noun.cognition	on IN 0	midazolam NN B-noun.person	appears VBZ B-verb.perception	to TO 0	be VB B-verb.stative	more RBR B-adv.all	pronounced JJ B-adj.all	following VBG B-verb.stative	oral JJ B-adj.all	administration NN B-noun.time	of IN 0	fluconazole NN B-noun.attribute	than IN 0	with IN 0	fluconazole NN B-noun.substance	administered VBN B-verb.body	intravenously RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d689.s3	The DT 0	pressor NN 0	response NN B-noun.communication	of IN 0	adrenergic_agents NNS B-noun.group	may MD 0	also RB 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	tricyclic_antidepressants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d597.s7	Cholestyramine NN B-noun.person	, , 0	Pretreatment NNP B-noun.person	for IN 0	four CD 0	days NNS B-noun.person	with IN 0	cholestyramine NN B-noun.person	significantly RB B-adv.all	increased VBD B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	meloxicam NN B-noun.food	by IN 0	50 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d638.s0	Ritalin NNP B-noun.person	may MD 0	decrease VB B-verb.cognition	the DT 0	hypotensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	guanethidine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d596.s6	Single JJ B-adj.all	dose NN B-noun.communication	pharmacokinetic JJ B-adj.all	studies NNS B-noun.group	demonstrated VBD B-verb.cognition	that IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	rivastigmine NN B-noun.location	is VBZ B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	affected VBN B-verb.change	by IN 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	digoxin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	diazepam NN B-noun.person	, , 0	or CC 0	fluoxetine NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d784.s7	Concurrent JJ B-adj.all	ingestion NN B-noun.act	of IN 0	antacid NN B-noun.attribute	( ( 0	20 CD B-adj.all	mL CD B-noun.quantity	of IN 0	antacid NN 0	containing VBG B-verb.stative	aluminum_hydroxide RB 0	, , 0	magnesium_hydroxide JJ 0	, , 0	and CC 0	simethicone NN 0	) ) 0	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	affect VB B-verb.change	the DT 0	exposure NN B-noun.cognition	of IN 0	oxybutynin NN B-noun.substance	or CC 0	desethyloxybutynin NN B-noun.communication	. . 0	___ NNP B-noun.person	. . 0
DDI-MedLine.d207.s1	An DT 0	increase NN B-noun.event	in IN 0	serum NN B-noun.body	osmolality NN B-noun.attribute	and CC 0	serum VB B-verb.social	osmolal JJ 0	gap NN 0	with IN 0	or CC 0	without IN 0	high JJ B-adj.all	- : 0	anion NN B-noun.person	- : 0	gap NN B-verb.creation	metabolic JJ B-adj.all	acidosis NN B-noun.person	is VBZ B-verb.stative	an DT 0	important JJ B-adj.all	clue NN B-noun.group	to TO 0	exposure VB B-verb.communication	to TO 0	one CD 0	of IN 0	the DT 0	toxic JJ B-adj.all	alcohols NNS B-noun.artifact	, , 0	which WDT 0	include VBP B-verb.stative	methanol NN I-verb.stative	, , 0	ethylene_glycol NN 0	, , 0	diethylene_glycol NN B-noun.person	, , 0	propylene_glycol NN B-noun.person	, , 0	or CC 0	isopropanol NN B-noun.substance	. . 0	. . 0
DDI-MedLine.d187.s7	Pharmacological JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	other JJ 0	cannabinoids NNS B-noun.communication	or CC 0	medication NN B-noun.artifact	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	THC NNP B-noun.group	have VBP B-verb.stative	not RB I-verb.stative	yet RB 0	been VBN 0	studied VBN B-verb.cognition	in IN 0	detail NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d723.s0	Other JJ 0	eye NN 0	drops NNS B-noun.shape	or CC 0	medications NNS B-noun.substance	such JJ 0	as IN 0	acetylcholine_chloride JJ 0	( ( 0	Miochol NNP 0	) ) 0	and CC 0	carbachol NN B-noun.person	( ( 0	Carboptic NNP B-noun.person	, , 0	Isopto_Carbachol NN 0	) ) 0	may MD 0	decrease VB B-verb.cognition	the DT 0	effects NNS B-noun.phenomenon	of IN 0	suprofen JJ B-adj.all	ophthalmic JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d165.s3	This DT 0	complex NN B-noun.group	has VBZ B-verb.possession	a DT 0	unique JJ B-adj.all	ability NN B-noun.cognition	to TO 0	deliver VB B-verb.social	bio NN B-noun.person	- : 0	available JJ B-adj.all	calcium NN B-noun.artifact	and CC 0	phosphate NN B-noun.time	when WRB 0	they PRP 0	are VBP 0	needed VBN B-verb.consumption	most RBS 0	. . 0	. . 0
DDI-DrugBank.d572.s10	Patients NNS B-noun.person	who WP 0	take VBP B-verb.cognition	both DT 0	ezetimibe NN B-noun.person	and CC 0	cyclosporine NN B-noun.person	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d753.s0	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	including VBG B-verb.social	sedatives NNS B-noun.act	, , 0	hypnotics NNS B-noun.person	, , 0	tranquilizers NNS B-noun.person	, , 0	general JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	other JJ 0	opioids NNS B-noun.person	, , 0	tricyclic_antidepressants NNS B-noun.person	, , 0	monoamine_oxidase_(MAO)_inhibitors NNS B-noun.person	, , 0	and CC 0	alcohol NN B-noun.act	may MD 0	produce VB B-verb.cognition	additive JJ B-adj.all	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d597.s26	Warfarin NNP B-noun.person	, , 0	Anticoagulant JJ B-adj.all	activity NN B-noun.state	should MD 0	be VB 0	monitored VBN B-verb.perception	, , 0	particularly RB B-adv.all	in IN 0	the DT 0	first JJ B-adj.all	few JJ B-noun.animal	days NNS B-noun.phenomenon	after IN 0	initiating VBG B-verb.motion	or CC 0	changing VBG B-verb.change	MOBIC NNP 0	therapy NN 0	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	warfarin NN B-noun.act	or CC 0	similar JJ B-adj.all	agents NNS B-noun.person	, , 0	since IN 0	these DT 0	patients NNS B-noun.person	are VBP B-verb.stative	at IN 0	an DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	bleeding NN B-noun.act	. . 0	. . 0
DDI-MedLine.d217.s2	This DT 0	study NN B-noun.communication	investigates VBZ B-verb.communication	the DT 0	ability NN B-noun.cognition	of IN 0	cyclooxygenase-2_inhibitors NNS B-noun.person	to TO 0	sensitize VB B-verb.change	cells NNS B-noun.body	from IN 0	different JJ B-adj.all	origins NNS B-noun.cognition	to TO 0	several JJ B-adj.all	chemotherapeutic_agents NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d613.s1	In IN 0	1984 CD 0	, , 0	Drs NNP B-noun.person	Rimmer NNP I-noun.person	and CC 0	Richens NNP B-noun.person	at IN 0	the DT 0	University NNP B-noun.other	of IN I-noun.other	Wales NNP I-noun.other	reported VBD B-verb.communication	that IN 0	administering VBG B-verb.perception	vigabatrin NN B-noun.person	with IN 0	phenytoin NN B-noun.person	lowered VBD B-verb.motion	the DT 0	serum NN B-noun.body	phenytoin NN I-noun.body	concentration NN B-noun.event	in IN 0	patients NNS B-noun.person	with IN 0	treatment NN B-noun.person	- : 0	resistant JJ B-adj.all	epilepsy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d678.s1	The DT 0	metabolism NN B-noun.attribute	of IN 0	Metopirone NNP B-noun.person	is VBZ 0	accelerated VBN B-verb.change	by IN 0	phenytoin NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d608.s3	In IN 0	adult NN 0	diabetic NN B-noun.person	patients NNS B-noun.person	under IN 0	treatment NN B-noun.plant	with IN 0	either DT 0	sulfonylureas NNS B-noun.location	or CC 0	insulin VBP B-verb.contact	there EX 0	is VBZ B-verb.stative	no DT 0	change NN B-noun.act	in IN 0	the DT 0	clinical JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	either DT 0	TOLECTIN NNP B-noun.location	or CC 0	the DT 0	hypoglycemic_agents NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d193.s0	Ticagrelor NNP 0	( ( 0	Brilinta)--better JJR 0	than IN 0	clopidogrel NN B-noun.person	( ( 0	Plavix NNP B-noun.person	) ) 0	. . 0
DDI-DrugBank.d680.s7	Patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	proton_pump_inhibitors NNS B-noun.person	and CC 0	warfarin NN 0	concomitantly RB 0	should MD 0	be VB 0	monitored VBN B-verb.perception	for IN 0	increases NNS B-noun.event	in IN 0	INR NNP 0	and CC 0	prothrombin NN B-noun.person	time NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d781.s16	However RB 0	, , 0	the DT 0	extent NN B-noun.attribute	of IN 0	biotransformation NN B-noun.cognition	of IN 0	perindopril NN B-noun.person	to TO 0	the DT 0	active JJ B-adj.all	metabolite NN B-noun.food	, , 0	perindoprilat NN B-noun.person	, , 0	is VBZ 0	reduced VBN B-verb.change	approximately RB B-adv.all	43 CD B-adj.all	% NN 0	, , 0	resulting VBG B-verb.stative	in IN 0	a DT 0	reduction NN B-noun.act	in IN 0	the DT 0	plasma NN B-noun.group	ACE NNP 0	inhibition NN 0	curve NN B-noun.communication	of IN 0	approximately RB B-adv.all	20 CD B-adj.all	% NN 0	, , 0	probably RB B-adv.all	clinically RB B-adv.all	insignificant JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d669.s1	Concurrent NNP B-noun.person	and/or CC 0	sequential JJ B-adj.all	systemic JJ B-noun.cognition	or CC 0	topical JJ B-adj.all	use NN 0	of IN 0	other JJ 0	potentially RB B-adj.all	neurotoxic JJ I-adj.all	and/or CC 0	nephrotoxic JJ B-adj.all	drugs NNS B-noun.artifact	, , 0	such JJ 0	as IN 0	amphotericin_B JJ 0	, , 0	aminoglycosides NNS B-noun.person	, , 0	bacitracin NN B-noun.person	, , 0	polymyxin_B NNP B-noun.person	, , 0	colistin NN B-noun.person	, , 0	viomycin NN B-noun.person	, , 0	or CC 0	cisplatin NN B-noun.substance	, , 0	when WRB 0	indicated VBN B-verb.communication	, , 0	requires VBZ B-verb.stative	careful JJ B-adj.all	monitoring NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d700.s11	Therefore RB 0	, , 0	it PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.feeling	are VBP B-verb.stative	co- JJ 0	administered VBN B-verb.possession	with IN 0	Myfortic NNP B-noun.person	with IN 0	caution NN B-noun.cognition	and CC 0	additional JJ B-adj.all	birth NN 0	control NN B-noun.act	methods NNS B-noun.person	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d695.s1	Combination NN B-noun.person	therapy NN 0	with IN 0	Cerezyme NNP B-noun.person	___ NNP I-noun.person	( ( 0	imiglucerase NN B-noun.event	) ) 0	and CC 0	ZAVESCA NNP B-noun.group	___ NNP I-noun.group	is VBZ B-verb.stative	not RB B-adv.all	indicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d761.s7	Nifedipine NNP B-noun.person	( ( 0	extended VBN B-verb.body	- : 0	release NN B-noun.act	tablets NNS B-noun.artifact	) ) 0	, , 0	In IN 0	17 CD B-adj.all	normal JJ B-adj.pert	- : 0	weight NN B-noun.artifact	subjects NNS B-noun.artifact	receiving VBG B-verb.change	XENICAL NNP B-noun.group	120 CD 0	mg IN 0	three CD 0	times NNS B-noun.event	a DT 0	day NN B-noun.person	for IN 0	6 CD B-adj.all	days NNS B-noun.time	, , 0	XENICAL NNP B-noun.group	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	bioavailability NN B-noun.cognition	of IN 0	nifedipine NN B-noun.person	( ( 0	extended VBN B-verb.body	- : 0	release NN B-noun.act	tablets NNS B-noun.artifact	) ) 0	. . 0	. . 0
DDI-MedLine.d143.s0	[ SYM 0	Interaction NN B-noun.act	between IN 0	clopidogrel NN B-noun.artifact	and CC 0	proton_pump_inhibitors NNS B-noun.person	] POS 0	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d617.s6	heparin NN B-noun.animal	, , 0	warfarin NN B-noun.location	, , 0	diazepam NN B-noun.person	, , 0	insulin NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d572.s9	Cyclosporine NNP B-noun.person	, , 0	The DT 0	total JJ B-adj.all	ezetimibe NN B-noun.state	level NN I-noun.state	increased VBD B-verb.change	12-fold JJ I-verb.change	in IN 0	one CD 0	renal JJ B-adj.all	transplant NN B-noun.person	patient NN B-noun.person	receiving VBG B-verb.body	multiple JJ B-adj.all	medications NNS B-noun.person	, , 0	including VBG B-verb.change	cyclosporine NN I-verb.change	. . 0	. . 0
DDI-MedLine.d218.s3	We PRP 0	sought VBD B-verb.social	to TO 0	evaluate VB B-verb.communication	whether IN 0	initiation NN B-noun.act	of IN 0	an DT 0	antidepressant NN B-noun.attribute	increases VBZ B-verb.change	the DT 0	risk NN 0	of IN 0	hospitalization NN B-noun.act	for IN 0	gastrointestinal JJ B-adj.all	bleeding NN B-noun.act	in IN 0	warfarin NN B-noun.location	users NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d693.s1	When WRB 0	daily JJ B-adj.pert	doses NNS B-noun.event	of IN 0	sulfasalazine NN B-noun.communication	2 CD B-adj.all	g NN B-noun.quantity	and CC 0	weekly JJ B-adj.all	doses NNS B-noun.event	of IN 0	methotrexate JJ B-adj.all	7.5 CD 0	mg PRP 0	were VBD 0	coadministered VBN B-verb.communication	to TO 0	15 CD B-adj.all	rheumatoid JJ B-adj.all	arthritis NN B-noun.group	patients NNS B-noun.person	in IN 0	a DT 0	drug NN B-noun.person	- : 0	drug NN B-noun.group	interaction NN B-noun.act	study NN B-noun.artifact	, , 0	the DT 0	pharmacokinetic JJ B-adj.all	disposition NN B-noun.act	of IN 0	the DT 0	drugs NNS B-noun.artifact	was VBD B-verb.stative	not RB B-adv.all	altered VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d772.s1	TERAZOL NN B-noun.communication	3 CD B-adj.all	Vaginal NNP B-noun.person	Cream NNP I-noun.person	0.8 CD 0	% NN 0	The DT 0	levels NNS B-noun.state	of IN 0	estradiol NN B-noun.substance	( ( 0	E2 NN 0	) ) 0	and CC 0	progesterone NN B-noun.person	did VBD 0	not RB B-adv.all	differ VB B-verb.cognition	significantly RB B-adv.all	when WRB 0	0.8 CD 0	% NN 0	terconazole NN B-verb.communication	vaginal JJ B-adj.all	cream NN B-noun.person	was VBD 0	administered VBN B-verb.perception	to TO 0	healthy JJ B-adj.all	female NN B-noun.person	volunteers NNS B-noun.person	established VBN B-verb.social	on IN 0	a DT 0	low JJ B-adj.all	dose NN 0	oral JJ B-adj.all	contraceptive NN B-noun.person	. . 0	___ NNP B-noun.person	. . 0
DDI-DrugBank.d743.s7	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	itraconazole NN B-noun.artifact	and CC 0	terfenadine NN B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d776.s3	one CD 0	fatality NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	from IN 0	hypoglycemia NN B-noun.person	in IN 0	association NN 0	with IN 0	combined JJ B-adj.all	DIFLUCAN JJ B-noun.group	and CC 0	glyburide NN 0	use NN 0	. . 0	. . 0
DDI-DrugBank.d634.s3	Digitalis_glycosides NNS B-noun.artifact	, , 0	Serum NNP B-noun.person	digitalis NN I-noun.person	levels NNS B-noun.state	may MD 0	be VB 0	increased VBN B-verb.change	when WRB 0	hyperthyroid NN B-noun.person	patients NNS B-noun.person	on IN 0	a DT 0	stable JJ B-adj.all	digitalis_glycoside JJ B-noun.other	regimen NNS B-noun.person	become VBN B-verb.emotion	euthyroid NN I-verb.emotion	, , 0	. . 0
DDI-DrugBank.d769.s0	Coumarin NNP B-noun.person	- : 0	Derivative_Anticoagulants NNS B-noun.person	, , 0	Prolongation NNP B-noun.person	of IN 0	prothrombin NN B-adj.all	time NN B-noun.time	( ( 0	PT NNP 0	) ) 0	and CC 0	International NNP B-noun.other	Normalized NNP I-noun.other	Ratio NNP I-noun.other	( ( 0	INR NNP 0	) ) 0	were VBD 0	observed VBN B-verb.perception	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	ZOLINZA NNP B-noun.person	concomitantly RB B-adv.all	with IN 0	coumarin NN B-noun.person	- : 0	derivative_anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d776.s20	Terfenadine NN B-noun.person	, , 0	Because IN 0	of IN 0	the DT 0	occurrence NN B-noun.state	of IN 0	serious JJ B-adj.all	cardiac NN B-noun.animal	dysrhythmias NNS I-noun.animal	secondary JJ B-adj.all	to TO 0	prolongation NN B-noun.act	of IN 0	the DT 0	QTc NNP B-noun.person	interval NN I-noun.person	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	azole_antifungals NNS B-noun.food	in IN 0	conjunction NN 0	with IN 0	terfenadine NN B-noun.artifact	, , 0	interaction NN B-noun.act	studies NNS B-noun.artifact	have VBP 0	been VBN 0	performed VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d599.s4	If IN 0	glucocorticoid JJ B-adj.all	replacement NN B-noun.person	is VBZ 0	required VBN B-verb.stative	, , 0	the DT 0	glucocorticoid NN 0	dose NN 0	should MD 0	be VB 0	carefully RB B-adv.all	adjusted VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d781.s15	Food NNP B-noun.person	Interaction NNP I-noun.person	, , 0	Oral NNP B-noun.location	administration NN I-noun.location	of IN 0	ACEON NNP B-noun.group	___ POS 0	Tablets NNS B-noun.location	with IN 0	food NN B-noun.food	does VBZ 0	not RB B-adv.all	significantly RB B-adv.all	lower JJR B-adj.all	the DT 0	rate NN B-noun.time	or CC 0	extent NN B-noun.attribute	of IN 0	perindopril NN B-noun.time	absorption NN I-noun.time	relative JJ B-adj.all	to TO 0	the DT 0	fasted VBN B-adj.all	state NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d597.s4	however RB 0	, , 0	as IN 0	with IN 0	other JJ 0	NSAIDs NNP B-noun.person	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	meloxicam NN B-noun.person	and CC 0	aspirin NN B-noun.person	is VBZ B-verb.stative	not RB I-verb.stative	generally RB B-adv.all	recommended VBN B-verb.communication	because IN 0	of IN 0	the DT 0	potential NN B-noun.person	for IN 0	increased VBN B-verb.change	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d633.s12	ECG NNP B-noun.cognition	intervals NNS I-noun.cognition	( ( 0	PR NNP 0	, , 0	QRS NNP 0	, , 0	and CC 0	QT NNP 0	) ) 0	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	concurrent JJ B-noun.person	Mexitil NNP I-noun.person	___ NNP I-noun.person	and CC 0	digoxin NN B-noun.person	, , 0	diuretics NNS B-noun.person	, , 0	or CC 0	propranolol NN B-noun.possession	. . 0	. . 0
DDI-MedLine.d185.s13	Considering VBG B-verb.communication	the DT 0	variability NN B-noun.attribute	in IN 0	exposure NN B-noun.state	following VBG B-verb.possession	enzyme JJ B-adj.all	inhibition NN B-noun.attribute	and CC 0	the DT 0	fact NN B-noun.state	that IN 0	chronic JJ B-adj.all	dosing NN B-noun.act	of IN 0	panobinostat NN B-noun.location	was VBD B-verb.stative	not RB B-adv.all	studied VBN B-verb.cognition	with IN 0	CYP3A NNP B-noun.person	inhibitors NNS I-noun.person	, , 0	close JJ B-adj.all	monitoring NN B-noun.person	of IN 0	panobinostat NN B-noun.person	- : 0	related JJ B-adj.all	adverse JJ 0	events NNS 0	is VBZ B-verb.stative	necessary JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d577.s4	At IN 0	a DT 0	1.6-g JJ B-adj.all	dose NN B-noun.quantity	, , 0	sulfamethoxazole NN B-noun.person	produced VBD B-verb.creation	a DT 0	slight JJ B-adj.all	but CC 0	significant JJ B-adj.all	increase NN B-noun.event	in IN 0	the DT 0	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	phenytoin NN B-noun.person	but CC 0	did VBD 0	not RB B-adv.all	produce VB B-verb.creation	a DT 0	corresponding JJ B-noun.artifact	decrease NN I-noun.artifact	in IN 0	the DT 0	metabolic JJ B-adj.all	clearance NN B-noun.event	rate NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d597.s24	Meloxicam NNP B-noun.person	did VBD 0	not RB B-adv.all	have VB B-verb.stative	a DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	single JJ B-adj.all	doses NNS B-noun.event	of IN 0	methotrexate NN B-noun.food	. . 0	. . 0
DDI-MedLine.d190.s2	AAV2 NN B-noun.artifact	containing VBG B-verb.stative	cDNA NNS I-verb.stative	encoding VBG B-verb.social	enhanced VBN B-verb.change	green JJ B-adj.all	fluorescent NN B-noun.substance	protein NN B-noun.substance	( ( 0	GFP NNP 0	) ) 0	, , 0	under IN 0	the DT 0	control NN B-noun.act	of IN 0	a DT 0	chicken NN B-noun.food	__ : 0	-actin JJ B-adj.all	promoter NN B-noun.attribute	, , 0	was VBD 0	delivered VBN B-verb.social	by IN 0	intravitreal JJ B-adj.all	injection NN B-noun.act	to TO 0	adult VB B-verb.emotion	mice NNS I-verb.emotion	in IN 0	conjunction NN 0	with IN 0	enzymes NNS B-noun.person	including VBG B-verb.social	collagenase NN B-noun.act	, , 0	hyaluronan_lyase NNP B-noun.person	, , 0	heparinase_III NNP B-noun.person	, , 0	or CC 0	chondroitin_ABC_lyase NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d661.s1	If IN 0	ZEMURON NNP B-noun.group	___ NNP I-noun.group	is VBZ 0	administered VBN B-verb.possession	following VBG 0	administration NN B-noun.person	of IN 0	succinylcholine NN B-noun.person	, , 0	it PRP 0	should MD 0	not RB 0	be VB 0	given VBN B-verb.possession	until IN 0	recovery NN B-noun.process	from IN 0	succinylcholine NN B-noun.person	has VBZ 0	been VBN 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d769.s2	Other JJ 0	HDAC_Inhibitors NNS 0	Severe JJ B-adj.all	thrombocytopenia NN B-noun.state	and CC 0	gastrointestinal JJ B-adj.all	bleeding NN B-noun.act	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	ZOLINZA NNP B-noun.group	and CC 0	other JJ B-adj.all	HDAC_inhibitors NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	valproic_acid NNP B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d681.s0	May MD 0	interact VB B-verb.change	with IN 0	cimetidine NN B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	medicines NNS B-noun.person	to TO 0	control VB B-verb.stative	heart NN 0	rhythm NN B-noun.act	, , 0	sevelamer NN B-noun.person	, , 0	and CC 0	theophylline PRP 0	. . 0	. . 0
DDI-DrugBank.d597.s5	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	low JJ B-adj.all	- : 0	dose NN 0	aspirin NN 0	with IN 0	MOBIC NNP B-noun.group	may MD 0	result VB B-verb.stative	in IN 0	an DT 0	increased VBN B-adj.all	rate NN B-noun.time	of IN 0	GI NNP 0	ulceration NN B-noun.communication	or CC 0	other JJ B-adj.all	complications NNS B-noun.person	, , 0	compared VBN B-verb.cognition	to TO 0	use VB B-verb.consumption	of IN 0	MOBIC NNP 0	alone RB 0	. . 0	. . 0
DDI-DrugBank.d698.s1	Probenecid NNP B-noun.person	; : 0	concurrent JJ B-adj.all	use NN B-noun.communication	decreases VBZ B-verb.change	gastrointestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	riboflavin NN B-noun.body	, , 0	. . 0
DDI-DrugBank.d622.s2	2 CD B-adj.all	; : 0	4 LS 0	The DT 0	following JJ B-adj.all	precautions NNS B-noun.communication	should MD 0	be VB 0	kept VBN B-verb.stative	in IN 0	mind NN 0	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	anticholinesterase NN B-noun.event	poisoning NN I-noun.event	, , 0	although IN 0	they PRP 0	do VBP 0	not RB B-adv.all	bear VB B-verb.competition	directly RB I-verb.competition	on IN 0	the DT 0	use NN 0	of IN 0	pralidoxime NN B-noun.time	, , 0	since IN 0	barbiturates NNS B-noun.person	are VBP 0	potentiated VBN B-verb.communication	by IN 0	the DT 0	anticholinesterases NNS B-noun.attribute	, , 0	they PRP 0	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	convulsions NNS B-noun.food	, , 0	. . 0
DDI-DrugBank.d726.s2	Dose DT 0	adjustment NN B-noun.communication	of IN 0	Zemplar NNP B-noun.other	Capsules NNPS I-noun.other	may MD 0	be VB 0	required VBN B-verb.stative	, , 0	and CC 0	iPTH NN B-noun.attribute	and CC 0	serum NN B-noun.body	calcium NN I-noun.body	concentrations NNS B-noun.attribute	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	if IN 0	a DT 0	patient JJ B-noun.person	initiates NNS I-noun.person	or CC 0	discontinues VBZ B-verb.creation	therapy NN I-verb.creation	with IN 0	a DT 0	strong JJ B-noun.person	CYP3A4 JJ I-noun.person	inhibitor NN I-noun.person	such JJ 0	as IN 0	ketoconazole NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d714.s0	Not RB B-adv.all	compatible JJ B-adj.all	with IN 0	CNS_depressants NNS B-noun.artifact	or CC 0	trycyclic_antidepressants NNS B-noun.plant	. . 0
DDI-MedLine.d180.s12	In IN 0	addition NN 0	, , 0	DZNep NNP B-noun.person	insensitivity NN I-noun.person	might MD 0	be VB 0	associated VBN B-verb.cognition	with IN 0	overexpression NN B-noun.act	of IN 0	Bcl-2 NN B-noun.food	, , 0	and CC 0	the DT 0	combination NN B-noun.event	of IN 0	ABT-737 NNP B-noun.other	and CC 0	DZNep NNP B-noun.person	could MD 0	synergistically RB B-adv.all	induced VBN B-verb.creation	apoptosis NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d590.s0	Coadministration NN B-noun.person	of IN 0	TRITEC NNP B-noun.group	with IN 0	clarithromycin NN B-noun.person	resulted VBD B-verb.contact	in IN 0	increased VBN B-verb.change	plasma NN B-noun.substance	ranitidine NN B-noun.phenomenon	concentrations NNS B-noun.attribute	( ( 0	57 CD 0	% NN 0	) ) 0	, , 0	increased VBN B-verb.change	plasma NN B-noun.substance	bismuth NN B-noun.food	trough NN B-noun.act	concentrations NNS B-noun.attribute	( ( 0	48 CD 0	% NN 0	) ) 0	, , 0	and CC 0	increased VBD B-verb.change	14-_hydroxy-_clarithromycin JJ 0	plasma NN B-noun.substance	concentrations NNS B-noun.relation	( ( 0	31 CD 0	% NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d736.s1	Hypokalemia NNP B-noun.person	may MD 0	develop VB B-verb.communication	during IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	steroids NNS B-noun.communication	or CC 0	ACTH NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d587.s0	Since IN 0	Celontin NNP B-noun.person	( ( 0	methsuximide NN B-noun.attribute	) ) 0	may MD 0	interact VB B-verb.change	with IN 0	concurrently RB B-adv.all	administered VBN B-verb.emotion	antiepileptic_drugs NNS I-verb.emotion	, , 0	periodic JJ B-adj.all	serum NN B-noun.body	level NN B-noun.attribute	determinations NNS B-noun.process	of IN 0	these DT 0	drugs NNS B-noun.artifact	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	( ( 0	eg IN 0	methsuximide NN 0	may MD 0	increase VB B-verb.change	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	phenytoin NN B-noun.food	and CC 0	phenobarbital NN B-noun.body	) ) 0	. . 0	. . 0
DDI-MedLine.d215.s12	Standard JJ B-adj.all	antibiotic JJ B-adj.all	such JJ 0	as IN 0	Gentamicin NNP B-noun.person	( ( 0	10 CD B-adj.all	microg NN B-noun.quantity	) ) 0	, , 0	Cephalothin NNP 0	( ( 0	30 CD B-adj.all	microg NN B-noun.quantity	) ) 0	, , 0	Ceftriaxone NNP B-noun.person	( ( 0	10 CD B-adj.all	microg NN B-noun.quantity	) ) 0	, , 0	Nystatin NNP B-noun.person	( ( 0	10 CD B-adj.all	U NNP 0	) ) 0	discs NNS B-noun.person	were VBD 0	used VBN B-verb.consumption	for IN 0	comparison NN B-noun.person	with IN 0	the DT 0	antimicrobial JJ B-adj.all	activities NNS B-noun.act	of IN 0	essential JJ B-adj.all	oils NNS B-noun.attribute	of IN 0	these DT 0	plants NNS B-noun.plant	. . 0	. . 0
DDI-DrugBank.d775.s12	While IN 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	chronic JJ B-adj.pert	phenytoin NN B-noun.substance	or CC 0	carbamazepine NN B-noun.substance	therapy NN B-noun.artifact	on IN 0	the DT 0	action NN B-noun.process	of IN 0	MIVACRON NNP B-noun.group	are VBP B-verb.stative	unknown JJ B-adj.all	, , 0	slightly RB B-adv.all	shorter JJR B-adj.all	durations NNS B-noun.attribute	of IN 0	neuromuscular JJ B-adj.all	block NN B-noun.location	may MD 0	be VB 0	anticipated VBN B-verb.cognition	and CC 0	infusion NN B-adj.all	rate NN B-noun.time	requirements NNS B-noun.object	may MD 0	be VB B-verb.stative	higher JJR B-adj.all	. . 0	. . 0
DDI-MedLine.d184.s0	Amphetamine JJ B-adj.all	locomotor NN B-noun.artifact	sensitization NN B-noun.act	and CC 0	conditioned VBN B-noun.act	place NN I-noun.act	preference NN B-noun.person	in IN 0	adolescent JJ B-adj.all	male NN B-noun.person	and CC 0	female JJ B-adj.all	rats NNS B-noun.animal	neonatally RB B-adv.all	treated VBN B-verb.change	with IN 0	quinpirole NN B-noun.communication	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d783.s0	Posicor NNP B-noun.person	inhibits VBZ B-verb.social	some DT 0	of IN 0	the DT 0	liver NN B-noun.person	's POS 0	ability NN B-noun.cognition	to TO 0	metabolize VB B-verb.cognition	some DT 0	other JJ B-adj.all	drugs NNS B-noun.artifact	; : 0	terfenadine NN B-noun.artifact	, , 0	astemizole NN B-noun.location	, , 0	cisapride NN 0	, , 0	cyclosporine NN B-noun.person	, , 0	and CC 0	tricyclic_antidepressants NNS B-noun.plant	. . 0	. . 0
DDI-MedLine.d178.s2	In IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	the DT 0	antiplatelet_agent NNP B-noun.person	reduced VBD B-verb.change	significantly RB B-adv.all	vascular JJ B-adj.all	mortality NN B-noun.motive	and CC 0	death NN B-noun.person	from IN 0	any DT 0	cause NN B-noun.communication	when WRB 0	compared VBN B-verb.cognition	to TO 0	clopidogrel VB B-verb.contact	in IN 0	patients NNS B-noun.person	with IN 0	acute JJ B-adj.all	coronary JJ B-adj.all	syndrome NN B-noun.person	. . 0	. . 0
DDI-MedLine.d184.s2	The DT 0	objective NN B-noun.cognition	was VBD B-verb.stative	to TO 0	analyze VB B-verb.cognition	the DT 0	effects NNS B-noun.phenomenon	of IN 0	neonatal JJ B-adj.all	quinpirole JJ B-adj.all	treatment NN B-noun.plant	on IN 0	effects NNS B-noun.phenomenon	of IN 0	amphetamine NN B-noun.person	in IN 0	adolescent JJ B-adj.all	rats NNS B-noun.animal	using VBG B-verb.consumption	locomotor NN 0	sensitization NN B-noun.act	and CC 0	conditioned VBN B-noun.act	place NN I-noun.act	preference NN I-noun.act	procedures NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d595.s2	The DT 0	addition NN 0	of IN 0	sodium_bicarbonate JJ 0	to TO 0	parenteral JJ B-adj.all	solutions NNS B-noun.cognition	containing VBG B-verb.stative	calcium NN B-noun.substance	should MD 0	be VB 0	avoided VBN B-verb.social	, , 0	except IN 0	where WRB 0	compatibility NN B-noun.person	has VBZ 0	been VBN 0	previously RB B-adv.all	established VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d654.s2	Based VBN B-verb.cognition	on IN 0	in IN 0	vitro RB B-adv.all	P450 JJ 0	inhibition NN B-noun.attribute	studies NNS B-noun.artifact	and CC 0	the DT 0	low JJ B-adj.all	systemic JJ B-adj.all	exposure NN B-noun.person	observed VBD B-verb.perception	following VBG B-verb.stative	topical JJ B-adj.all	application NN B-noun.act	of IN 0	ALTABAX NNP B-noun.group	, , 0	retapamulin NN B-noun.person	is VBZ B-verb.stative	unlikely JJ B-adj.all	to TO 0	affect VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	other JJ B-adj.all	P450 JJ B-noun.body	substrates NNS I-noun.body	. . 0	. . 0
DDI-MedLine.d193.s2	It PRP 0	will MD 0	compete VB B-verb.stative	with IN 0	clopidogrel NN B-noun.artifact	( ( 0	Plavix NNP B-noun.person	) ) 0	and CC 0	prasugrel NN B-noun.person	( ( 0	Effient NNP B-noun.person	) ) 0	for IN 0	such JJ B-adj.all	use NN B-noun.person	. . 0	. . 0
DDI-MedLine.d222.s3	Varenicline NNP B-noun.person	reduces VBZ B-verb.change	nicotine JJ B-adj.all	withdrawal NN B-noun.artifact	symptoms NNS I-noun.artifact	, , 0	cigarette NN B-noun.person	craving NN B-verb.motion	and CC 0	nicotine JJ B-adj.all	satisfaction NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d694.s0	Digoxin NNP B-noun.person	, , 0	There EX 0	was VBD B-verb.stative	a DT 0	slight JJ B-adj.all	increase NN B-noun.event	in IN 0	the DT 0	area NN B-noun.body	under IN 0	the DT 0	curve NN B-noun.communication	( ( 0	AUC NNP 0	, , 0	11 CD B-adj.all	% NN 0	) ) 0	and CC 0	mean VB B-verb.stative	peak JJ B-adj.all	drug NN B-noun.artifact	concentration NN 0	( ( 0	Cmax NNP B-noun.person	, , 0	18 CD B-adj.all	% NN 0	) ) 0	of IN 0	digoxin NN B-noun.person	with IN 0	the DT 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	100 CD 0	mg NN B-noun.quantity	sitagliptin NN B-noun.state	for IN 0	10 CD B-adj.all	days NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d613.s0	A DT 0	study NN B-noun.artifact	published VBN B-verb.creation	in IN 0	2002 CD 0	found VBD B-verb.communication	that IN 0	vigabatrin NN B-noun.person	causes VBZ B-verb.communication	a DT 0	statistically RB B-adv.all	significant JJ B-adj.all	increase NN B-noun.event	in IN 0	plasma NN 0	clearance NN 0	of IN 0	carbamazepine NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d784.s0	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	oxybutynin NN B-noun.substance	with IN 0	other JJ B-adj.all	anticholinergic_drugs NNS B-noun.object	or CC 0	with IN 0	other JJ 0	agents NNS B-noun.person	which WDT 0	produce VBP B-verb.cognition	dry JJ I-verb.cognition	mouth NN B-noun.object	, , 0	constipation NN B-noun.person	, , 0	somnolence NN 0	( ( 0	drowsiness NN B-noun.attribute	) ) 0	, , 0	and/or CC 0	other JJ B-adj.all	anticholinergic JJ B-adj.pert	- : 0	like IN 0	effects NNS B-noun.phenomenon	may MD 0	increase VB B-verb.change	the DT 0	frequency NN B-noun.person	and/or CC 0	severity NN B-noun.attribute	of IN 0	such JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d672.s4	Cimetidine NNP B-noun.person	, , 0	Cimetidine NNP B-noun.person	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	sparfloxacin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d743.s5	Itraconazole NNP B-noun.person	, , 0	Torsades NNP B-noun.person	de IN 0	pointes NNS B-noun.location	and CC 0	elevated VBD B-verb.motion	parent NN B-noun.artifact	terfenadine NN B-noun.artifact	levels NNS B-noun.artifact	have VBP 0	been VBN 0	reported VBN B-verb.communication	during IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	terfenadine NN B-noun.artifact	and CC 0	itraconazole NN B-noun.person	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.cognition	of IN 0	itraconazole NN B-noun.artifact	and CC 0	from IN 0	foreign JJ B-adj.all	post NN B-noun.person	- : 0	marketing NN B-verb.communication	sources NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d572.s2	Fibrates NNS B-noun.person	, , 0	The DT 0	safety NN B-noun.artifact	and CC 0	effectiveness NN B-noun.cognition	of IN 0	ezetimibe NN B-noun.person	administered VBN B-verb.possession	with IN 0	fibrates NNS B-noun.substance	have VBP 0	not RB 0	been VBN 0	established VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d776.s34	Patients NNS B-noun.person	receiving VBG B-verb.communication	tacrolimus NN B-noun.person	and CC 0	fluconazole NN B-noun.person	concomitantly RB B-adv.all	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d632.s4	In IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	sulfonylureas NNS B-noun.cognition	or CC 0	biguanides NNS B-noun.group	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	adverse JJ B-adj.all	event NN 0	profile NN B-noun.quantity	of IN 0	SYMLIN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d713.s2	Drugs NNS B-noun.person	Eliminated VBN I-noun.person	by IN 0	Active NNP B-noun.other	Tubular NNP I-noun.other	Secretion NNP I-noun.other	, , 0	Although IN 0	studies NNS B-noun.person	to TO 0	assess VB B-verb.cognition	drug NN B-noun.person	- : 0	drug NN B-noun.act	interactions NNS I-noun.act	with IN 0	Sanctura NNP B-noun.person	have VBP 0	not RB 0	been VBN 0	conducted VBN B-verb.communication	, , 0	Sanctura NNP B-noun.person	has VBZ B-verb.possession	the DT 0	potential NN B-noun.person	for IN 0	pharmacokinetic JJ B-adj.all	interactions NNS B-noun.person	with IN 0	other JJ 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	eliminated VBN B-verb.cognition	by IN 0	active JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	( ( 0	e.g. JJ B-adv.all	digoxin NN I-adv.all	, , 0	procainamide NN B-noun.person	, , 0	pancuronium NN B-noun.person	, , 0	morphine NN B-noun.person	, , 0	vancomycin NN B-noun.person	, , 0	metformin NN B-noun.person	and CC 0	tenofovir NN B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d640.s10	UNIVASC NNP B-noun.group	___ NNP I-noun.group	has VBZ 0	been VBN 0	used VBN B-verb.consumption	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.person	concomitantly RB B-adv.all	with IN 0	calcium NN B-noun.person	- : 0	channel NN B-noun.act	- : 0	blocking_agents NNS B-noun.person	, , 0	diuretics NNS B-noun.person	, , 0	H2_blockers NNS B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	oral JJ B-adj.all	hypoglycemic_agents NNS B-noun.person	, , 0	and CC 0	cholesterol NN B-noun.act	- : 0	lowering VBG B-verb.communication	agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d668.s2	John NNP B-noun.person	__ NNP I-noun.person	s VBZ I-noun.person	Wort NNP I-noun.person	, , 0	and CC 0	certain JJ B-adj.all	anticonvulsants NNS B-noun.attribute	( ( 0	phenytoin NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	carbamazepine NN 0	) ) 0	may MD 0	induce VB B-verb.cognition	mifepristone JJ 0	metabolism NN B-noun.attribute	( ( 0	lowering VBG B-verb.motion	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	mifepristone NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d665.s6	Penicillin NNP B-noun.person	blood NN I-noun.person	levels NNS B-noun.state	may MD 0	be VB 0	prolonged VBN B-verb.creation	by IN 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	probenecid NN B-noun.shape	which WDT 0	blocks VBZ B-verb.change	the DT 0	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	penicillins NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d164.s1	Although IN 0	it PRP 0	was VBD 0	previously RB B-adv.all	reported VBD B-verb.communication	that DT 0	lapatinib NN B-noun.person	combined VBN B-verb.change	with IN 0	Herceptin NNP B-noun.person	improved VBD B-verb.change	the DT 0	progression NN B-noun.act	- : 0	free JJ B-adj.all	survival NN B-noun.state	rate NN I-noun.state	compared VBN B-verb.change	with IN 0	lapatinib NN 0	alone RB 0	for IN 0	patients NNS B-noun.person	with IN 0	Herceptin NNP B-noun.person	- : 0	refractory JJ B-adj.all	HER2-positive JJ 0	metastatic JJ B-adj.all	breast NN B-noun.person	cancer NN B-noun.person	, , 0	the DT 0	mechanism NN B-noun.object	is VBZ 0	purported VBN B-verb.communication	to TO 0	be VB B-verb.stative	an DT 0	antiproliferative JJ B-adj.all	effect NN 0	relating VBG B-verb.stative	to TO 0	the DT 0	synergism NN B-noun.artifact	of IN 0	these DT 0	two CD 0	agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d690.s3	Such JJ B-adj.all	occurrences NNS B-noun.event	have VBP 0	been VBN 0	reported VBN B-verb.communication	when WRB 0	propoxyphene NN B-noun.person	was VBD 0	administered VBN B-verb.perception	to TO 0	patients NNS B-noun.person	on IN 0	antidepressants NNS B-noun.person	, , 0	anticonvulsants NNS B-noun.person	, , 0	or CC 0	warfarin NN B-noun.act	- : 0	like IN 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d577.s0	In IN 0	elderly JJ B-adj.all	patients NNS B-noun.person	concurrently RB B-adv.all	receiving VBG B-verb.perception	certain JJ B-adj.all	diuretics NNS B-noun.person	, , 0	primarily RB B-adv.all	thiazides VBZ 0	, , 0	an DT 0	increased VBN B-adj.all	incidence NN B-noun.attribute	of IN 0	thrombopenia NN 0	with IN 0	purpura NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d610.s2	Abacavir NNP B-noun.person	has VBZ B-verb.possession	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetic JJ B-adj.all	properties NNS B-noun.attribute	of IN 0	ethanol NN 0	. . 0	. . 0
DDI-MedLine.d195.s6	The DT 0	synergistic JJ B-adj.all	antinociception NN B-noun.event	activity NN B-noun.process	of IN 0	ibuprofen NN B-noun.animal	when WRB 0	administered VBN B-verb.possession	with IN 0	piperine NN B-noun.person	can MD 0	be VB 0	attributed VBN B-verb.social	to TO 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentration NN B-noun.event	of IN 0	ibuprofen NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d572.s17	In IN 0	oral JJ B-adj.all	( ( 0	gavage NN B-noun.attribute	) ) 0	fertility NN B-noun.phenomenon	studies NNS B-noun.act	of IN 0	ezetimibe NN B-noun.person	conducted VBN B-verb.communication	in IN 0	rats NNS B-noun.animal	, , 0	there EX 0	was VBD B-verb.stative	no DT 0	evidence NN B-noun.attribute	of IN 0	reproductive JJ B-noun.phenomenon	toxicity NN I-noun.phenomenon	at IN 0	doses NNS B-noun.artifact	up IN 0	to TO 0	1000 CD 0	mg NN B-noun.quantity	/ ) 0	kg RB 0	/ JJ 0	day NN 0	in IN 0	male NN B-noun.animal	or CC 0	female JJ B-adj.all	rats NNS B-noun.animal	( ( 0	~7 PRP$ 0	times NNS B-noun.event	the DT 0	human JJ B-adj.all	exposure NN B-noun.person	at IN 0	10 CD B-adj.all	mg NN B-noun.quantity	daily RB B-adv.all	based VBN B-verb.cognition	on IN 0	AUC0 NN B-noun.act	- : 0	24hr JJ 0	for IN 0	total JJ B-adj.all	ezetimibe NN B-noun.act	) ) 0	. . 0	. . 0
DDI-DrugBank.d652.s6	Because IN 0	the DT 0	action NN B-noun.process	of IN 0	metoclopramide NN B-noun.attribute	will MD 0	influence VB B-verb.emotion	the DT 0	delivery NN B-noun.group	of IN 0	food NN B-noun.food	to TO 0	the DT 0	intestines NNS B-noun.artifact	and CC 0	thus RB 0	the DT 0	rate NN B-noun.time	of IN 0	absorption NN B-noun.artifact	, , 0	insulin NN B-noun.person	dosage NN B-noun.state	or CC 0	timing NN B-noun.event	of IN 0	dosage NN B-noun.act	may MD 0	require VB B-verb.consumption	adjustment NN I-verb.consumption	. . 0	. . 0
DDI-MedLine.d164.s0	Lapatinib NNP B-noun.person	enhances VBZ B-verb.communication	herceptin NN B-noun.person	- : 0	mediated VBD B-verb.stative	antibody NN 0	- : 0	dependent JJ B-adj.all	cellular JJ B-noun.body	cytotoxicity NN I-noun.body	by IN 0	up SYM 0	- : 0	regulation NN B-noun.act	of IN 0	cell NN B-noun.body	surface VB B-verb.body	HER2 JJ 0	expression NN B-noun.communication	. . 0	_ PRP 0	. . 0
DDI-MedLine.d196.s3	A DT 0	new JJ B-adj.all	orally RB B-adv.all	administered VBN B-verb.possession	agent NN B-noun.person	, , 0	fenofibric_acid NNP B-noun.person	, , 0	was VBD 0	developed VBN B-verb.creation	as IN 0	an DT 0	alternative NN B-noun.person	to TO 0	fenofibrate VB B-verb.emotion	. . 0	. . 0
DDI-MedLine.d213.s0	In IN 0	vivo RB B-adv.all	CYP3A JJ B-adj.all	activity NN B-noun.process	is VBZ B-verb.stative	significantly RB B-adv.all	lower JJR B-adj.all	in IN 0	cyclosporine NN 0	- : 0	treated VBN B-verb.communication	as IN 0	compared VBN B-verb.creation	with IN 0	tacrolimus NN B-noun.person	- : 0	treated VBD B-verb.communication	renal JJ B-adj.all	allograft NN B-noun.artifact	recipients NNS B-noun.artifact	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d653.s6	Aspirin NNP B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	in IN 0	conjunction NN 0	with IN 0	corticosteroids NNS B-noun.food	in IN 0	patients NNS B-noun.person	suffering VBG B-verb.body	from IN 0	hypoprothrombinemia NN B-noun.location	. . 0	. . 0
DDI-MedLine.d191.s7	The DT 0	present JJ B-adj.all	findings NNS B-noun.act	suggest VBP B-verb.communication	that IN 0	MWCHCP NNP B-noun.group	increases VBZ B-verb.change	the DT 0	inhibition NN B-noun.event	rate NN B-noun.time	of IN 0	tumor NN B-noun.feeling	growth NN 0	of IN 0	cisplatin NN B-noun.food	and CC 0	has VBZ B-verb.possession	a DT 0	beneficial JJ B-adj.all	influence NN B-noun.cognition	on IN 0	gastrointestinal JJ B-adj.all	lesion NN B-noun.communication	induced VBN B-verb.creation	by IN 0	cisplatin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d575.s0	In IN 0	a DT 0	study NN B-noun.artifact	in IN 0	which WDT 0	34 CD 0	different JJ B-adj.all	drugs NNS B-noun.artifact	were VBD 0	tested VBN B-verb.social	, , 0	therapeutically RB B-adv.all	relevant JJ B-adj.all	concentrations NNS B-noun.attribute	of IN 0	tolbutamide NN 0	, , 0	sodium_salicylate JJ B-adj.all	and CC 0	sulfamethizole NN B-noun.person	displaced VBD B-verb.perception	protein NN B-noun.person	- : 0	bound NN 0	teniposide NN 0	in IN 0	fresh JJ B-adj.all	human NN B-noun.person	serum NN B-noun.person	to TO 0	a DT 0	small JJ B-noun.person	but CC 0	significant JJ B-adj.all	extent NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d608.s4	Caution NN B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	if IN 0	TOLECTIN NNP 0	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	methotrexate NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d200.s7	Rate NN B-noun.time	of IN 0	achievement NN B-noun.act	of IN 0	target NN B-noun.cognition	BP NNP 0	with IN 0	fixed VBN B-verb.consumption	combination NN 0	amlodipine NN 0	/ : 0	valsartan NN B-noun.attribute	( ( 0	93 CD 0	% NN 0	) ) 0	was VBD B-verb.stative	comparable JJ B-adj.all	with IN 0	that DT 0	on IN 0	traditional JJ B-adj.all	therapy NN B-noun.cognition	( ( 0	90 CD B-adj.all	% NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d680.s9	Laboratory NNP B-noun.person	Tests NNPS I-noun.person	There EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	false JJ B-adj.all	- : 0	positive JJ B-adj.all	urine NN B-noun.person	screening VBG B-verb.communication	tests NNS B-noun.person	for IN 0	tetrahydrocannabinol NN 0	( ( 0	THC NNP 0	) ) 0	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	most JJS B-adj.all	proton_pump_inhibitors NNS B-noun.person	, , 0	including VBG B-verb.change	pantoprazole NN I-verb.change	. . 0	. . 0
DDI-MedLine.d169.s5	We PRP 0	evaluated VBD B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	calcium NN B-noun.artifact	doses NNS B-noun.artifact	between IN 0	200 CD 0	and CC 0	1500 CD 0	mg NN B-noun.quantity	on IN 0	absorption NN B-noun.act	of IN 0	5 CD 0	mg DT 0	nonheme_iron NNP B-noun.person	( ( 0	as IN 0	ferrous_sulfate NNP B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d597.s11	Cimetidine NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	200 CD 0	mg NN B-noun.quantity	cimetidine NN 0	QID NNP 0	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	single JJ B-noun.act	- : 0	dose NN B-noun.person	pharmacokinetics NNS B-noun.person	of IN 0	30 CD B-adj.all	mg NN B-noun.quantity	meloxicam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d588.s11	Sympathomimetics NNS B-noun.person	, , 0	Metolazone NNP B-noun.person	may MD 0	decrease VB B-verb.change	arterial JJ B-adj.all	responsiveness NN B-noun.cognition	to TO 0	norepinephrine VB B-verb.communication	, , 0	but CC 0	this DT 0	diminution NN B-noun.cognition	is VBZ B-verb.stative	not RB B-adv.all	sufficient JJ B-adj.all	to TO 0	preclude VB B-verb.possession	effectiveness NN B-noun.cognition	of IN 0	the DT 0	pressor NN B-noun.person	agent NN B-noun.person	for IN 0	therapeutic JJ 0	use NN 0	. . 0	. . 0
DDI-DrugBank.d672.s6	Zinc NNP B-noun.person	/ , 0	iron NN B-noun.person	salts NNS B-noun.substance	, , 0	Absorption NNP B-noun.person	of IN 0	quinolones NNS B-noun.animal	is VBZ 0	reduced VBN B-verb.change	significantly RB B-adv.all	by IN 0	these DT 0	preparations NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d710.s5	Coadministration NN B-noun.person	with IN 0	acetaminophen NN B-noun.person	reduced VBD B-verb.change	the DT 0	peak JJ B-adj.all	concentration NN B-noun.event	and CC 0	AUC NNP B-noun.group	values NNS B-noun.attribute	for IN 0	rimantadine NN B-noun.act	by IN 0	approximately RB B-noun.time	11 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-MedLine.d183.s0	Neuropharmacological JJ B-adj.all	approach NN B-noun.act	against IN 0	MPTP NNP B-noun.group	( ( 0	1-methyl-4-phenyl-1,2,3,6-_tetrahydropyridine)-induced JJ 0	mouse NN 0	model NN 0	of IN 0	Parkinson NNP B-noun.person	's POS 0	disease NN B-noun.communication	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d605.s0	SKELAXIN NN 0	may MD 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	alcohol NN B-noun.food	, , 0	barbiturates NNS B-noun.artifact	and CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d212.s3	The DT 0	effect NN B-noun.cognition	of IN 0	eugenol NN B-noun.act	on IN 0	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	colchicine NN B-noun.person	in IN 0	an DT 0	oral JJ B-adj.all	administrative JJ B-adj.all	nanoemulsion NN B-noun.act	formulation NN B-noun.act	was VBD B-verb.stative	also RB B-adv.all	demonstrated VBD B-verb.perception	in IN 0	vivo NN B-noun.animal	. . 0	. . 0
DDI-DrugBank.d603.s0	When WRB 0	administered VBN B-verb.communication	concomitantly RB B-adv.all	with IN 0	ProAmatine NNP B-noun.person	__ # 0	, , 0	cardiac_glycosides NNS B-noun.group	may MD 0	enhance VB B-verb.emotion	or CC 0	precipitate VB B-verb.emotion	bradycardia NNS I-verb.emotion	, , 0	A.V. NNP B-noun.person	. . 0
DDI-DrugBank.d645.s6	There EX 0	have VBP 0	been VBN B-verb.stative	spontaneous JJ B-adj.all	reports NNS B-noun.communication	of IN 0	increase NN B-noun.act	or CC 0	decrease VB B-verb.cognition	in IN 0	prothrombin NN B-adj.all	times NNS B-noun.event	in IN 0	patients NNS B-noun.person	concomitantly RB B-adv.all	taking VBG B-verb.change	oral JJ B-adj.all	terbinafine NN B-noun.artifact	and CC 0	warfarin NN B-noun.act	, , 0	however RB 0	, , 0	a DT 0	causal NN B-adj.all	relationship NN B-noun.state	between IN 0	LAMISIL NNP B-noun.group	___ NNP I-noun.group	Tablets NNPS I-noun.group	and CC 0	these DT 0	changes NNS B-noun.phenomenon	has VBZ 0	not RB 0	been VBN 0	established VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d710.s2	Acetaminophen NNP B-noun.person	, , 0	Rimantadine_HCl NNP B-noun.person	, , 0	100 CD 0	mg NN B-noun.quantity	, , 0	was VBD 0	given VBN B-verb.possession	twice RB B-adv.all	daily RB B-adv.all	for IN 0	13 CD B-adj.all	days NNS B-noun.person	to TO 0	12 CD B-adj.all	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d769.s1	Physicians NNS B-noun.person	should MD 0	carefully RB B-adv.all	monitor VB 0	PT NNP 0	and CC 0	INR NNP B-noun.group	in IN 0	patients NNS B-noun.person	concurrently RB B-adv.all	administered VBN B-verb.change	ZOLINZA NNP B-noun.group	and CC 0	coumarin_derivatives NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d702.s1	These DT 0	include VBP B-verb.stative	sympathomimetic_bronchodilators NNS I-verb.stative	, , 0	methylxanthines NNS B-noun.object	, , 0	and CC 0	oral JJ B-adj.all	and CC 0	inhaled JJ B-adj.all	steroids NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d159.s0	Protective JJ B-adj.all	effect NN B-noun.cognition	of IN 0	acetyl NN B-noun.person	- : 0	l SYM 0	- : 0	carnitine NN B-noun.person	and CC 0	_ $ 0	alpha_lipoic_acid JJ 0	against IN 0	the DT 0	acute JJ B-adj.all	toxicity NN B-noun.attribute	of IN 0	diepoxybutane NN 0	to TO 0	human JJ B-adj.all	lymphocytes NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d585.s2	Anticholinergic_drugs NNS B-noun.artifact	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	increased VBN B-verb.change	intraocular JJ B-adj.all	pressure NN B-noun.act	may MD 0	be VB B-verb.stative	hazardous JJ B-adj.all	when WRB 0	taken VBN 0	concurrently RB B-adv.all	with IN 0	agents NNS B-noun.person	such JJ 0	as IN 0	corticosteroids NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d709.s4	- : 0	Cisapride NN B-noun.other	, , 0	pimozide NN 0	, , 0	Other JJ 0	drugs NNS 0	such JJ 0	as IN 0	cisapride NN 0	or CC 0	pimozide NN 0	, , 0	which WDT 0	are VBP 0	metabolised VBN B-verb.cognition	by IN 0	hepatic JJ B-noun.person	CYP3A NNP I-noun.person	isozymes NNS I-noun.person	have VBP 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	QT NNP 0	interval JJ B-adj.all	prolongation NN B-noun.possession	and/or CC 0	cardiac JJ B-adj.all	arrythmias NN B-noun.person	( ( 0	typically RB B-adv.all	torsades VBZ B-verb.communication	de IN 0	pointe NN B-noun.location	) ) 0	as IN 0	a DT 0	result NN B-noun.act	of IN 0	increase NN B-noun.act	in IN 0	their PRP$ 0	serum NN B-noun.attribute	level NN I-noun.attribute	subsequent NN B-noun.artifact	to TO 0	interaction NN B-noun.act	with IN 0	significant JJ B-adj.all	inhibitors NNS B-noun.attribute	of IN 0	the DT 0	isozyme NN B-noun.location	, , 0	including VBG B-verb.social	some DT 0	macrolide_antibacterials NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d578.s11	There EX 0	are VBP 0	reports NNS B-noun.artifact	of IN 0	enhanced VBN B-verb.change	as RB 0	well RB 0	as IN 0	diminished JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	anticoagulant NN B-noun.attribute	when WRB 0	given VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	corticosteroids NNS B-noun.food	. . 0	. . 0
DDI-DrugBank.d640.s8	If IN 0	a DT 0	diuretic JJ B-noun.person	is VBZ B-verb.stative	also RB B-adv.all	used VBN B-verb.consumption	, , 0	the DT 0	risk NN 0	of IN 0	lithium NN B-noun.substance	toxicity NN B-noun.phenomenon	may MD 0	be VB 0	increased VBN B-verb.change	. . 0	. . 0
DDI-MedLine.d218.s8	Warfarin NN B-noun.person	users NNS B-noun.person	had VBD 0	an DT 0	increased VBN B-adj.all	odds NNS B-noun.artifact	ratio NN B-noun.person	of IN 0	gastrointestinal JJ B-adj.pert	bleeding NN B-verb.body	upon IN 0	initiation NN B-noun.act	of IN 0	citalopram NN B-noun.person	( ( 0	OR CC 0	__ : 0	= SYM 0	__ $ 0	1.73 CD 0	[ CD 0	95 CD 0	% NN 0	CI NNP 0	, , 0	1.25 CD 0	- : 0	2.38 CD 0	] CD 0	) ) 0	, , 0	fluoxetine NN B-noun.person	( ( 0	OR CC 0	__ : 0	= SYM 0	__ $ 0	1.63 CD 0	[ CD 0	95 CD 0	% NN 0	CI NNP 0	, , 0	1.11 CD 0	- : 0	2.38 CD 0	] CD 0	) ) 0	, , 0	paroxetine NN B-noun.person	( ( 0	OR CC 0	__ : 0	= SYM 0	__ $ 0	1.64 CD 0	[ CD 0	95 CD 0	% NN 0	CI NNP 0	, , 0	1.27 CD 0	- : 0	2.12 CD 0	] CD 0	) ) 0	, , 0	amitriptyline NN B-noun.person	( ( 0	OR CC 0	__ : 0	= SYM 0	__ $ 0	1.47 CD 0	[ CD 0	95 CD 0	% NN 0	CI NNP 0	, , 0	1.02 CD 0	- : 0	2.11 CD 0	] CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d672.s2	Since IN 0	there EX 0	is VBZ B-verb.stative	no DT 0	interaction NN B-noun.act	with IN 0	theophylline PRP 0	, , 0	interaction NN B-noun.act	with IN 0	other JJ 0	methylxanthines NNS B-noun.object	such JJ 0	as IN 0	caffeine NN B-noun.person	is VBZ B-verb.stative	unlikely JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d194.s9	HEY NNP 0	cells NNS B-noun.body	treated VBN B-verb.change	with IN 0	dasatinib NN B-noun.person	plus CC 0	paclitaxel NN B-noun.artifact	formed VBD B-verb.stative	fewer JJR B-adj.all	colonies NNS B-noun.person	than IN 0	did VBD 0	cells NNS B-noun.body	treated VBN B-verb.change	with IN 0	either DT 0	agent NN B-noun.person	alone RB 0	. . 0	. . 0
DDI-DrugBank.d572.s11	Carcinogenesis NNP B-noun.person	, , 0	Mutagenesis NNP B-noun.person	, , 0	Impairment NNP B-noun.other	of IN I-noun.other	Fertility NNP I-noun.other	A DT I-noun.other	104-week JJ I-noun.other	dietary JJ B-adj.all	carcinogenicity NN B-noun.phenomenon	study NN B-noun.artifact	with IN 0	ezetimibe NN B-noun.person	was VBD 0	conducted VBN B-verb.creation	in IN 0	rats NNS B-noun.animal	at IN 0	doses NNS B-noun.artifact	up IN 0	to TO 0	1500 CD 0	mg NN B-noun.quantity	/ ) 0	kg RB 0	/ JJ 0	day NN 0	( ( 0	males NNS B-noun.animal	) ) 0	and CC 0	500 CD 0	mg PRP 0	/ ( 0	kg RB 0	/ JJ 0	day NN 0	( ( 0	females NNS B-noun.person	) ) 0	( ( 0	~20 JJ 0	times NNS B-noun.event	the DT 0	human JJ B-adj.all	exposure NN B-noun.person	at IN 0	10 CD B-adj.all	mg NN B-noun.quantity	daily RB B-adv.all	based VBN B-verb.cognition	on IN 0	AUC0 NN B-noun.act	- : 0	24hr JJ 0	for IN 0	total JJ B-adj.all	ezetimibe NN B-noun.act	) ) 0	. . 0	. . 0
DDI-MedLine.d203.s6	Selective_serotonin_reuptake_inhibitors NNS B-noun.person	were VBD B-verb.stative	the DT 0	most RBS 0	commonly RB B-adv.all	prescribed VBN B-verb.communication	antidepressant NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d648.s1	Warfarin NNP B-noun.person	, , 0	The DT 0	coadministration NN B-noun.person	of IN 0	EVISTA NNP B-noun.other	and CC 0	warfarin NN B-noun.act	has VBZ 0	not RB 0	been VBN 0	assessed VBN B-verb.cognition	under IN 0	chronic JJ B-adj.pert	conditions NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d597.s27	The DT 0	effect NN B-noun.cognition	of IN 0	meloxicam NN B-noun.person	on IN 0	the DT 0	anticoagulant JJ B-adj.all	effect NN B-noun.cognition	of IN 0	warfarin NN B-noun.location	was VBD 0	studied VBN B-verb.cognition	in IN 0	a DT 0	group NN 0	of IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	receiving VBG B-verb.communication	daily JJ B-adj.pert	doses NNS B-noun.event	of IN 0	warfarin NN B-noun.act	that WDT 0	produced VBD B-verb.creation	an DT 0	INR NNP B-noun.group	( ( 0	International NNP B-noun.other	Normalized NNP I-noun.other	Ratio NNP I-noun.other	) ) 0	between IN 0	1.2 CD 0	and CC 0	1.8 CD 0	. . 0	. . 0
DDI-DrugBank.d781.s1	The DT 0	possibility NN B-noun.state	of IN 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	can MD 0	be VB 0	minimized VBN B-verb.change	by IN 0	either DT 0	discontinuing VBG B-verb.communication	the DT 0	diuretic JJ B-adj.all	or CC 0	increasing VBG B-verb.change	the DT 0	salt NN 0	intake NN 0	prior RB 0	to TO 0	initiation NN B-noun.act	of IN 0	treatment NN B-noun.plant	with IN 0	perindopril NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d584.s7	Furthermore RB B-adv.all	, , 0	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	both DT 0	drugs NNS B-noun.artifact	, , 0	careful JJ B-adj.all	monitoring NN B-noun.person	of IN 0	the DT 0	INR NNP B-noun.group	or CC 0	PT NNP 0	, , 0	and CC 0	adjustment NN B-noun.person	of IN 0	the DT 0	warfarin NN B-noun.artifact	dosage NN B-noun.artifact	if IN 0	indicated VBN B-verb.cognition	are VBP 0	recommended VBN B-verb.communication	when WRB 0	the DT 0	oxandrolone NN 0	dose NN 0	is VBZ 0	changed VBN B-verb.change	or CC 0	discontinued VBN B-verb.stative	. . 0	. . 0
DDI-DrugBank.d734.s1	Antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	guanethidine NN B-noun.location	and CC 0	related JJ B-adj.all	compounds NNS B-noun.person	may MD 0	be VB 0	counteracted VBN B-verb.cognition	when WRB 0	phenothiazines NNS B-noun.animal	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d725.s1	MAO_Inhibitors NNS B-noun.person	, , 0	The DT 0	pressor NN 0	effect NN 0	of IN 0	sympathomimetic_pressor_amines NNS B-noun.communication	is VBZ B-verb.stative	markedly RB B-adv.all	potentiated VBN B-verb.communication	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	monoamine_oxidase_inhibitors NNS B-noun.person	( ( 0	MAOI NNP B-noun.group	) ) 0	. . 0	. . 0
DDI-DrugBank.d726.s1	A DT 0	multiple JJ B-adj.all	dose NN B-noun.artifact	drug NN I-noun.artifact	- : 0	drug NN B-noun.group	interaction NN B-noun.act	study NN B-noun.artifact	demonstrated VBD B-verb.perception	that DT 0	ketoconazole NN B-noun.person	approximately RB B-adv.all	doubled VBD B-verb.contact	paricalcitol NN B-noun.person	AUC0- NN I-noun.person	__ '' 0	. . 0	Since IN 0	paricalcitol NN B-noun.act	is VBZ B-verb.stative	partially RB B-adv.all	metabolized VBN B-verb.cognition	by IN 0	CYP3A NNP B-noun.person	and CC 0	ketoconazole NN B-noun.artifact	le NN 0	is VBZ 0	known VBN B-verb.cognition	to TO 0	be VB B-verb.stative	a DT 0	strong JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	cytochrome NN B-noun.person	P450 NN I-noun.person	3A '' 0	enzyme NN B-noun.person	, , 0	care NN B-noun.group	should MD 0	be VB 0	taken VBN B-verb.cognition	while IN 0	dosing VBG B-verb.competition	paricalcitol NN I-verb.competition	with IN 0	ketoconazole NN B-noun.person	and CC 0	other JJ 0	strong JJ B-noun.person	P450 JJ I-noun.person	3A NN I-noun.person	inhibitors NNS B-noun.person	including VBG B-verb.social	atazanavir NN B-noun.person	, , 0	clarithromycin NN B-noun.person	, , 0	indinavir NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	nefazodone NN 0	, , 0	nelfinavir NN B-noun.person	, , 0	ritonavir NN B-noun.person	, , 0	saquinavir NN B-noun.person	, , 0	telithromycin NN B-noun.communication	or CC 0	voriconazole NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d753.s3	It PRP 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	that IN 0	the DT 0	incidence NN B-noun.event	of IN 0	bradycardia NN B-noun.person	was VBD 0	increased VBN B-verb.change	when WRB 0	oxymorphone NN B-noun.person	was VBD 0	combined VBN B-verb.change	with IN 0	propofol NN B-noun.person	for IN 0	induction NN B-noun.act	of IN 0	anesthesia NN B-noun.object	. . 0	. . 0
DDI-MedLine.d199.s2	We PRP 0	retrospectively RB B-adv.all	reviewed VBN B-verb.change	the DT 0	records NNS B-noun.communication	of IN 0	7 CD B-adj.all	pediatric JJ B-adj.pert	oncology NN B-noun.group	patients NNS B-noun.person	who WP 0	received VBD B-verb.possession	low JJ I-verb.possession	- : 0	dose NN B-noun.person	ketamine NN B-noun.person	in IN 0	conjunction NN 0	with IN 0	propofol NN B-noun.person	for IN 0	total JJ B-adj.all	intravenous JJ B-adj.all	anesthesia NN B-noun.location	( ( 0	TIVA NNP 0	) ) 0	repeatedly RB B-adv.all	for IN 0	radiation NN B-noun.act	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d717.s1	Therefore RB 0	, , 0	physicians NNS B-noun.person	should MD 0	closely RB 0	monitor VB 0	patients NNS B-noun.person	for IN 0	a DT 0	change NN B-noun.act	in IN 0	anticoagulant JJ B-adj.all	dosage NN B-noun.artifact	requirements NNS B-noun.artifact	when WRB 0	administering VBG B-verb.communication	Mitotane NNP B-noun.person	to TO 0	patients NNS B-noun.person	on IN 0	coumarin NN B-noun.person	- : 0	type_anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d224.s1	The DT 0	aim NN 0	of IN 0	this DT 0	study NN B-noun.artifact	was VBD 0	to TO 0	assess VB B-verb.cognition	the DT 0	influence NN B-noun.cognition	of IN 0	manganese_gluconate NNP B-noun.location	, , 0	a DT 0	chemical NN B-noun.group	activator NN B-noun.person	of IN 0	bleaching VBG B-verb.body	agents NNS B-noun.person	, , 0	at IN 0	a DT 0	concentration NN B-noun.event	of IN 0	0.01 CD 0	% NN 0	on IN 0	the DT 0	efficiency NN B-noun.cognition	of IN 0	a DT 0	10 CD B-adj.all	% NN 0	carbamide_peroxide NN B-noun.group	- : 0	based VBN B-verb.cognition	bleaching VBG B-verb.contact	agent NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d599.s6	Limited JJ B-adj.all	published VBN B-verb.creation	data NNS B-noun.cognition	indicate VBP B-verb.communication	that IN 0	GH NNP 0	treatment NN B-noun.communication	increases VBZ B-verb.stative	cytochrome NN 0	P450 NN 0	( ( 0	CP450 NN 0	) ) 0	mediated VBD B-verb.stative	antipyrine JJ B-adj.all	clearance NN B-noun.attribute	in IN 0	man NN 0	. . 0	. . 0
DDI-DrugBank.d633.s1	In IN 0	a DT 0	formal JJ B-adj.all	, , 0	single JJ B-adj.all	- : 0	dose NN 0	interaction NN 0	study NN B-noun.artifact	( ( 0	n UH 0	= $ 0	6 CD B-adj.all	males NNS B-noun.animal	) ) 0	the DT 0	clearance NN B-noun.act	of IN 0	mexiletine NN B-noun.person	was VBD 0	decreased VBN B-verb.change	by IN 0	38 CD 0	% NN 0	following VBG B-verb.stative	the DT 0	coadministration NN B-noun.person	of IN 0	fluvoxamine NN B-noun.substance	, , 0	an DT 0	inhibitor NN B-noun.person	of IN 0	CYP1A2 NNP B-noun.person	. . 0	. . 0
DDI-MedLine.d197.s7	Beside IN 0	this DT 0	, , 0	the DT 0	medication NN B-noun.communication	oriented VBN B-verb.stative	supplementation NN 0	of IN 0	vitamin_D NNP B-noun.person	can MD 0	also RB B-adv.all	ameliorate VBP B-verb.communication	the DT 0	pharmacologic JJ B-adj.pert	action NN B-noun.state	of IN 0	many JJ 0	drugs NNS B-noun.person	, , 0	such JJ 0	as IN 0	bisphosphonates NNS B-noun.food	, , 0	statins NNS B-noun.person	and CC 0	cytostatic_drugs NNS B-noun.plant	. . 0	. . 0
DDI-DrugBank.d700.s0	Antacids NNP B-noun.person	, , 0	Absorption NNP B-noun.person	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	Myfortic NNP B-noun.person	was VBD 0	decreased VBN B-verb.change	when WRB 0	administered VBN B-verb.communication	to TO 0	12 CD B-adj.all	stable JJ B-adj.all	renal JJ B-adj.all	transplant NN B-noun.person	patients NNS B-noun.person	also RB B-adv.all	taking VBG B-verb.social	magnesium NN B-noun.person	- : 0	aluminum NN B-noun.person	containing VBG B-verb.stative	antacids NNS B-noun.substance	( ( 0	30 CD B-adj.all	mL CD B-noun.quantity	) ) 0	, , 0	the DT 0	mean JJ B-adj.all	Cmax NNP B-noun.person	and CC 0	AUC(0-t NNP B-noun.location	) ) 0	values NNS B-noun.attribute	for IN 0	MPA NNP 0	were VBD B-verb.stative	25 CD B-adj.all	% NN 0	and CC 0	37 CD 0	% NN 0	lower JJR B-adj.all	, , 0	respectively RB B-adv.all	, , 0	than IN 0	when WRB 0	Myfortic NNP B-noun.person	was VBD 0	administered VBN B-verb.perception	alone RB B-adv.all	under IN 0	fasting NN B-verb.creation	conditions NNS I-verb.creation	. . 0	. . 0
DDI-DrugBank.d762.s3	There EX 0	is VBZ B-verb.stative	evidence NN B-noun.attribute	that IN 0	meropenem NN B-noun.act	may MD 0	reduce VB B-verb.change	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	valproic_acid NNP B-noun.location	to TO 0	subtherapeutic JJ B-adj.all	levels NNS B-noun.state	( ( 0	therapeutic JJ 0	range NN 0	considered VBN B-verb.cognition	to TO 0	be VB B-verb.stative	50 CD B-adj.all	to TO 0	100 CD 0	___ CD 0	g IN 0	/ : 0	mL CC 0	total JJ B-adj.all	valproate NN B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d721.s4	In IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	show VBP B-verb.communication	that DT 0	tiludronate NN B-noun.communication	does VBZ 0	not RB B-adv.all	displace VB B-verb.perception	warfarin NN B-noun.act	from IN 0	its PRP$ 0	binding JJ B-adj.pert	site NN B-noun.state	on IN 0	protein NN B-noun.person	. . 0	. . 0
DDI-MedLine.d209.s10	Depression NN B-noun.person	does VBZ 0	not RB 0	always RB B-adv.all	require VB B-verb.stative	antidepressant_drug JJ B-adj.all	therapy NN B-noun.act	, , 0	and CC 0	antidepressants NNS B-noun.person	have VBP B-verb.social	no DT 0	proven JJ B-adj.all	preventive JJ B-adj.all	impact NN B-noun.state	on IN 0	hot JJ B-adj.all	flushes NNS B-noun.substance	linked VBN B-verb.cognition	to TO 0	the DT 0	menopause NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d675.s0	CYP NNP B-noun.group	3A4 NNP I-noun.group	Inhibitors NNP I-noun.group	( ( 0	e.g. JJ B-noun.person	Macrolide_Antibiotics NNS I-noun.person	and CC 0	Protease_Inhibitors NNS B-noun.person	) ) 0	There EX 0	have VBP 0	been VBN B-verb.stative	rare JJ B-adj.all	reports NNS B-noun.artifact	of IN 0	serious JJ B-adj.all	adverse JJ B-noun.possession	events NNS I-noun.possession	in IN 0	connection NN 0	with IN 0	the DT 0	coadministration NN B-noun.person	of IN 0	certain JJ B-adj.all	ergot_alkaloid_drugs NNS B-noun.location	( ( 0	e.g. JJ B-adj.all	dihydroergotamine NN B-noun.person	and CC 0	ergotamine NN B-noun.location	) ) 0	and CC 0	potent JJ B-noun.person	CYP NNP I-noun.person	3A4 CD I-noun.person	inhibitors NNS I-noun.person	, , 0	resulting VBG B-verb.stative	in IN 0	vasospasm NN 0	leading VBG B-verb.stative	to TO 0	cerebral JJ B-adj.all	ischemia NN B-noun.feeling	and/or CC 0	ischemia NN B-noun.attribute	of IN 0	the DT 0	extremities NNS B-noun.group	. . 0	. . 0
DDI-MedLine.d175.s7	An DT 0	expert JJ B-adj.all	panel NN B-noun.person	reviewed VBD B-verb.perception	each DT 0	case NN B-noun.state	and CC 0	classified VBD B-verb.cognition	the DT 0	likelihood NN B-noun.location	of IN 0	colchicine NN B-noun.phenomenon	toxicity NN B-noun.attribute	, , 0	the DT 0	likelihood NN B-noun.location	of IN 0	a DT 0	causal JJ B-adj.all	role NN B-noun.attribute	of IN 0	colchicine NN B-noun.person	in IN 0	the DT 0	death NN 0	using VBG B-verb.consumption	the DT 0	WHO NNP 0	classification NN 0	system NN 0	, , 0	and CC 0	the DT 0	appropriateness NN B-noun.person	of IN 0	colchicine NN B-noun.phenomenon	dosing NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d671.s0	The DT 0	interaction NN B-noun.act	of IN 0	CYLERT NNP B-noun.group	( ( 0	pemoline NN 0	) ) 0	with IN 0	other JJ 0	drugs NNS B-noun.person	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	in IN 0	humans NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d682.s1	It PRP 0	may MD 0	also RB 0	interact VB B-verb.contact	with IN 0	thiazides NNS B-noun.cognition	( ( 0	increased VBN B-verb.change	thrombocytopenia NN B-noun.artifact	) ) 0	, , 0	cyclosporine NN B-noun.person	( ( 0	increased VBN B-verb.change	nephrotoxicity NN B-noun.attribute	) ) 0	, , 0	sulfonylurea_agents NNS B-noun.person	( ( 0	increased VBN B-verb.change	hypoglycemic JJ B-adj.all	response NN B-noun.event	) ) 0	, , 0	warfarin NN 0	( ( 0	increased VBN B-verb.change	anticoagulant JJ B-adj.all	effect NN B-noun.cognition	) ) 0	, , 0	methotrexate NN B-noun.person	( ( 0	decreased VBN B-verb.change	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	methotrexate NN B-noun.attribute	) ) 0	, , 0	phenytoin NN B-noun.person	( ( 0	decreased VBN B-verb.change	hepatic JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	phenytoin NN B-noun.body	) ) 0	. . 0	. . 0
DDI-DrugBank.d776.s37	If IN 0	short JJ B-noun.body	- : 0	acting_benzodiazepines NNS B-noun.person	, , 0	which WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	the DT 0	cytochrome NN 0	P450 NN 0	system NN B-noun.body	, , 0	are VBP 0	concomitantly RB B-adv.all	administered VBN B-verb.possession	with IN 0	fluconazole NN B-noun.attribute	, , 0	consideration NN B-noun.group	should MD 0	be VB 0	given VBN B-verb.possession	to TO 0	decreasing VBG B-verb.change	the DT 0	benzodiazepine NN B-noun.artifact	dosage NN B-noun.artifact	, , 0	and CC 0	the DT 0	patients NNS B-noun.person	should MD 0	be VB B-verb.stative	appropriately RB B-adv.all	monitored VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d776.s18	Theophylline PRP 0	, , 0	DIFLUCAN NNP B-noun.group	increases VBZ B-verb.change	the DT 0	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	theophylline NN 0	. . 0	. . 0
DDI-MedLine.d231.s8	Moxifloxacin NNP B-noun.person	and CC 0	Lomefloxacin NNP B-noun.person	reacts VBZ B-verb.cognition	faster RBR B-adj.all	with IN 0	sucralfate JJ B-adj.all	and CC 0	gelusil NN B-noun.artifact	in IN 0	acidic JJ B-adj.all	media NNS B-noun.location	whereas IN 0	with IN 0	erythromycin NN B-noun.food	in IN 0	basic JJ B-adj.all	media NNS B-noun.person	and CC 0	multi NNS B-noun.person	- : 0	minerals NNS B-noun.food	in IN 0	neutral JJ B-adj.all	media NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d716.s0	You PRP 0	can MD 0	not RB 0	take VB 0	mazindol NN B-noun.person	if IN 0	you PRP 0	have VBP 0	taken VBN B-verb.possession	a DT 0	monoamine_oxidase_inhibitor NN B-noun.person	( ( 0	MAOI NNP B-noun.group	) ) 0	such JJ 0	as IN 0	isocarboxazid NN 0	( ( 0	Marplan NNP B-noun.person	) ) 0	, , 0	tranylcypromine NN B-noun.person	( ( 0	Parnate NNP B-noun.person	) ) 0	, , 0	or CC 0	phenelzine NN B-noun.substance	( ( 0	Nardil NNP B-noun.person	) ) 0	in IN 0	the DT 0	last JJ B-adj.all	14 CD B-adj.all	days NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d622.s0	When WRB 0	atropine NN B-noun.person	and CC 0	pralidoxime NN B-noun.person	are VBP 0	used VBN B-verb.consumption	together RB B-adv.all	, , 0	the DT 0	signs NNS B-noun.communication	of IN 0	atropinization NN B-noun.act	( ( 0	flushing NN B-noun.substance	, , 0	mydriasis NN B-noun.person	, , 0	tachycardia NN B-noun.person	, , 0	dryness NN 0	of IN 0	the DT 0	mouth NN B-noun.object	and CC 0	nose NN 0	) ) 0	may MD 0	occur VB B-verb.stative	earlier JJR B-adj.all	than IN 0	might MD 0	be VB 0	expected VBN B-verb.cognition	when WRB 0	atropine NN B-noun.person	is VBZ 0	used VBN B-verb.consumption	alone RB 0	. . 0	. . 0
DDI-DrugBank.d597.s0	ACE_inhibitors NNS B-noun.person	Reports NNS I-noun.person	suggest VBP B-verb.communication	that IN 0	NSAIDs NNP B-noun.person	may MD 0	diminish VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	angiotensin NN B-noun.person	- : 0	converting_enzyme_(ACE)_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d638.s5	The DT 0	safety NN B-noun.artifact	of IN 0	using VBG B-verb.consumption	methylphenidate NN B-noun.food	in IN 0	combination NN 0	with IN 0	clonidine NN B-noun.attribute	or CC 0	other JJ 0	centrally RB 0	acting VBG B-verb.stative	alpha-2_agonists NNS B-noun.person	has VBZ 0	not RB 0	been VBN 0	systemically RB B-adv.all	evaluated VBN B-verb.communication	. . 0	___ NNP B-noun.person	. . 0
DDI-DrugBank.d633.s18	This DT 0	increase NN B-noun.event	was VBD 0	observed VBN B-verb.perception	at IN 0	the DT 0	first JJ B-adj.all	test NN B-noun.communication	point NN B-noun.cognition	which WDT 0	was VBD B-verb.stative	the DT 0	second JJ B-adj.all	day NN 0	after IN 0	starting VBG B-verb.change	Mexitil NNP B-noun.person	__ NNP I-noun.person	. . 0	Theophylline NNP B-noun.person	plasma NN I-noun.person	levels NNS B-noun.state	returned VBD B-verb.change	to TO 0	pre VB B-verb.social	- : 0	Mexitil RB 0	___ JJ 0	values NNS B-noun.attribute	within IN 0	48 CD 0	hours NNS 0	after IN 0	discontinuing VBG B-verb.social	Mexitil NNP B-noun.person	__ NNP I-noun.person	. . 0	If IN 0	Mexitil NNP B-noun.person	and CC 0	theophylline PRP 0	are VBP 0	to TO 0	be VB 0	used VBN B-verb.consumption	concurrently RB B-adv.all	, , 0	theophylline PRP 0	blood NN B-noun.body	levels NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.perception	, , 0	particularly RB B-adv.all	when WRB 0	the DT 0	Mexitil NNP B-noun.person	___ NNP I-noun.person	dose NN I-noun.person	is VBZ 0	changed VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d742.s9	Accordingly RB B-adv.all	, , 0	patients NNS B-noun.person	should MD 0	be VB 0	advised VBN B-verb.communication	to TO 0	avoid VB B-verb.social	alcohol NN B-noun.person	while IN 0	taking VBG B-verb.social	REMERON_SolTab JJ I-verb.social	. . 0	Diazepam NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	diazepam NN B-noun.person	( ( 0	15 CD B-adj.all	mg NN B-noun.quantity	) ) 0	had VBD B-verb.stative	a DT 0	minimal JJ B-adj.all	effect NN B-noun.cognition	on IN 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	mirtazapine NN B-noun.person	( ( 0	15 CD B-adj.all	mg NN B-noun.quantity	) ) 0	in IN 0	12 CD B-adj.all	healthy JJ B-adj.all	subjects NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d208.s3	We PRP 0	present VBP B-verb.communication	an DT 0	interesting JJ B-adj.all	case NN B-noun.state	of IN 0	an DT 0	HIV NNP B-noun.group	- : 0	positive JJ B-adj.all	woman NN B-noun.person	on IN 0	antiretroviral JJ B-adj.all	therapy NN 0	having VBG B-verb.stative	tubal JJ B-adj.pert	pregnancies NNS B-noun.person	on IN 0	two CD 0	separate JJ B-adj.all	occasions NNS B-noun.event	with IN 0	Implanon NNP B-noun.person	in IN 0	place NN 0	. . 0	. . 0
DDI-DrugBank.d680.s8	Because IN 0	of IN 0	profound NN B-noun.person	and CC 0	long RB 0	lasting JJ B-adj.all	inhibition NN B-noun.attribute	of IN 0	gastric JJ B-adj.all	acid NN B-noun.act	secretion NN B-noun.act	, , 0	pantoprazole NN B-noun.group	may MD 0	interfere VB B-verb.stative	with IN 0	absorption NN B-noun.act	of IN 0	drugs NNS B-noun.artifact	where WRB 0	gastric JJ B-adj.all	pH NN B-noun.attribute	is VBZ B-verb.stative	an DT 0	important JJ B-adj.all	determinant NN B-noun.cognition	of IN 0	their PRP$ 0	bioavailability NN B-noun.cognition	( ( 0	eg UH 0	, , 0	ketoconazole NN B-noun.person	, , 0	ampicillin JJ B-adj.all	esters NNS B-noun.substance	, , 0	and CC 0	iron NN B-noun.person	salts NNS B-noun.substance	) ) 0	. . 0	. . 0
DDI-DrugBank.d670.s9	Potential NNP B-noun.person	for IN 0	Other NNP B-noun.person	Drugs NNP I-noun.person	to TO 0	Affect VB B-verb.change	INVEGA NNP B-noun.group	___ NNP I-noun.group	Paliperidone NNP B-noun.person	is VBZ B-verb.stative	not RB I-verb.stative	a DT 0	substrate NN B-noun.person	of IN 0	CYP1A2 NNP B-noun.person	, , 0	CYP2A6 NNP B-noun.person	, , 0	CYP2C9 NNP B-noun.person	, , 0	and CC 0	CYP2C19 NNP B-noun.person	, , 0	so RB B-adv.all	that IN 0	an DT 0	interaction NN B-noun.act	with IN 0	inhibitors NNS B-noun.person	or CC 0	inducers NNS B-noun.person	of IN 0	these DT 0	isozymes NNS B-noun.act	is VBZ B-verb.stative	unlikely JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d640.s3	Use NNP B-noun.person	of IN 0	potassium NN B-noun.person	- : 0	sparing_diuretics NNS B-noun.person	( ( 0	spironolactone NN 0	, , 0	triamterene NN B-noun.person	, , 0	amiloride IN 0	) ) 0	or CC 0	potassium NN B-noun.artifact	supplements NNS B-noun.artifact	concomitantly RB B-adv.all	with IN 0	ACE_inhibitors NNS B-noun.person	can MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	hyperkalemia NN B-noun.person	. . 0	. . 0
DDI-MedLine.d143.s2	Contradictory JJ B-adj.all	results NNS B-noun.communication	regarding VBG B-verb.stative	the DT 0	effect NN B-noun.cognition	of IN 0	proton_pump_inhibitors NNS B-noun.person	on IN 0	platelet NN B-verb.creation	reactivity NN B-noun.state	and CC 0	on IN 0	clinical JJ B-adj.all	outcome NN B-noun.communication	in IN 0	clopidogrel NN B-noun.artifact	- : 0	treated VBN B-verb.communication	patients NNS B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	literature NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d704.s0	Drug NN B-noun.person	- : 0	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	The DT 0	pharmacokinetic JJ B-adj.all	and CC 0	pharmacodynamic JJ B-adj.all	interactions NNS B-noun.relation	between IN 0	FLOMAX NNP B-noun.group	capsules NNS B-noun.artifact	and CC 0	other JJ B-adj.all	alpha NN B-noun.person	- : 0	adrenergic_blocking_agents NNS B-noun.group	have VBP 0	not RB 0	been VBN 0	determined VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d655.s0	Methscopolamine NN B-noun.person	may MD 0	interact VB B-verb.change	with IN 0	antidepressants NNS B-noun.person	( ( 0	tricyclic JJ B-adj.all	type NN B-noun.cognition	) ) 0	, , 0	MAO_inhibitors NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	phenelzine NN B-noun.person	, , 0	linezolid JJ B-adj.all	, , 0	tranylcypromine NN B-noun.person	, , 0	isocarboxazid NN B-noun.person	, , 0	selegiline NN B-noun.person	, , 0	furazolidone NN 0	) ) 0	, , 0	quinidine NN B-noun.location	, , 0	amantadine NN B-noun.person	, , 0	antihistamines NNS B-noun.attribute	( ( 0	e.g. UH 0	, , 0	diphenhydramine NN 0	) ) 0	, , 0	other JJ 0	anticholinergics NNS B-noun.person	, , 0	potassium_chloride JJ B-adj.all	supplements NNS B-noun.artifact	, , 0	antacids NNS B-noun.person	, , 0	absorbent JJ B-noun.person	- : 0	type_anti SYM 0	- : 0	diarrhea_medicines NNS B-noun.substance	( ( 0	e.g. UH 0	, , 0	kaolin FW 0	- : 0	pectin NN B-noun.attribute	) ) 0	, , 0	phenothiazines NNS 0	( ( 0	e.g. UH 0	, , 0	chlorpromazine NN 0	, , 0	promethazine NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d572.s1	The DT 0	incremental JJ B-adj.all	LDL NNP B-noun.group	- : 0	C SYM 0	reduction NN 0	due JJ 0	to TO 0	adding VBG B-verb.communication	ezetimibe NN B-noun.person	to TO 0	cholestyramine NN B-noun.act	may MD 0	be VB 0	reduced VBN B-verb.change	by IN 0	this DT 0	interaction NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d725.s3	The DT 0	pressor NN 0	response NN B-noun.communication	of IN 0	adrenergic_agents NNS B-noun.group	may MD 0	also RB 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	tricyclic_antidepressants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d761.s8	Oral NNP B-noun.group	Contraceptives NNPS I-noun.group	, , 0	In IN 0	20 CD B-adj.all	normal JJ B-adj.pert	- : 0	weight NN B-noun.attribute	female JJ B-adj.all	subjects NNS B-noun.person	, , 0	the DT 0	treatment NN B-noun.communication	of IN 0	XENICAL NNP B-noun.group	120 CD 0	mg IN 0	three CD 0	times NNS B-noun.event	a DT 0	day NN B-noun.person	for IN 0	23 CD B-adj.all	days NNS B-noun.person	resulted VBD B-verb.communication	in IN 0	no DT 0	changes NNS B-noun.relation	in IN 0	the DT 0	ovulation NN B-noun.act	- : 0	suppressing VBG B-verb.social	action NN B-noun.process	of IN 0	oral JJ B-noun.body	contraceptives NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d633.s11	In IN 0	a DT 0	formal JJ B-adj.all	study NN B-noun.artifact	, , 0	benzodiazepines NNS B-noun.person	were VBD 0	shown VBN B-verb.perception	not RB B-adv.all	to TO 0	affect VB B-verb.change	Mexitil NNP B-noun.person	___ NNP I-noun.person	plasma NN I-noun.person	concentrations NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d648.s5	In IN 0	vitro NN B-noun.animal	, , 0	raloxifene NN B-noun.person	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	binding NN B-noun.act	of IN 0	warfarin NN B-noun.location	, , 0	phenytoin NN B-noun.person	, , 0	or CC 0	tamoxifen VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d617.s9	Therefore RB 0	, , 0	furosemide NN B-noun.attribute	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	in IN 0	intravenous JJ B-adj.all	lines NNS B-noun.communication	containing VBG B-verb.stative	PRIMACOR NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d645.s9	There EX 0	is VBZ B-verb.stative	no DT 0	information NN B-noun.cognition	available JJ 0	from IN 0	adequate JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.group	interaction NN B-noun.act	studies NNS B-noun.artifact	with IN 0	the DT 0	following JJ B-adj.all	classes NNS B-noun.attribute	of IN 0	drugs NNS B-noun.artifact	, , 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	hormone NN B-noun.person	replacement NN B-noun.person	therapies NNS B-noun.person	, , 0	hypoglycemics NNS B-noun.person	, , 0	theophyllines NNS 0	, , 0	phenytoins NNS B-noun.person	, , 0	thiazide_diuretics NNS B-noun.person	, , 0	beta_blockers NNS B-noun.person	, , 0	and CC 0	calcium_channel_blockers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d663.s3	in IN 0	10 CD B-adj.all	of IN 0	the DT 0	12 CD B-adj.all	patients NNS B-noun.person	, , 0	this DT 0	occurred VBD B-verb.stative	when WRB 0	LUCENTIS NNP 0	was VBD 0	administered VBN B-verb.possession	7 CD B-adj.all	days NNS B-noun.phenomenon	( ( 0	__ $ 0	2 CD B-adj.all	days NNS B-noun.act	) ) 0	after IN 0	verteporfin RB B-adj.all	PDT NNP 0	. . 0	. . 0
DDI-DrugBank.d676.s0	To TO 0	minimize VB B-verb.change	CNS NNP B-noun.group	depression NN B-noun.feeling	and CC 0	possible JJ B-adj.all	potentiation NN B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	antihistamines NNS B-noun.attribute	, , 0	narcotics NNS B-noun.person	, , 0	hypotensive_agents NNS B-noun.person	or CC 0	phenothiazines NNS B-noun.animal	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d617.s1	lidocaine NN B-noun.person	, , 0	quinidine NN B-noun.location	, , 0	. . 0
DDI-MedLine.d216.s2	In IN 0	this DT 0	randomized JJ B-noun.group	, , 0	blinded VBD B-verb.body	, , 0	crossover NN 0	study NN B-noun.artifact	, , 0	11 CD B-adj.all	healthy JJ B-adj.all	volunteers NNS B-noun.person	ingested VBD B-verb.consumption	0.2 CD 0	mg PRP 0	/ ( 0	kg IN 0	S NNP 0	- : 0	ketamine NN B-noun.communication	after IN 0	pretreatments NNS B-noun.person	with IN 0	oral JJ B-adj.all	ticlopidine NN B-noun.location	( ( 0	250 CD 0	mg NN B-noun.quantity	twice RB 0	daily JJ 0	) ) 0	, , 0	itraconazole NN B-noun.person	( ( 0	200 CD 0	mg NN B-noun.quantity	once RB B-adv.all	daily JJ I-adv.all	) ) 0	, , 0	or CC 0	placebo NN B-noun.substance	in IN 0	6-day JJ B-adj.all	treatment NN B-noun.plant	periods NNS B-noun.person	at IN 0	intervals NNS B-noun.cognition	of IN 0	4 CD B-adj.all	weeks NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d775.s0	Although IN 0	MIVACRON NNP 0	( ( 0	a DT 0	mixture NN B-noun.person	of IN 0	three CD 0	stereoisomers NNS 0	) ) 0	has VBZ 0	been VBN 0	administered VBN B-verb.possession	safely RB B-adv.all	following VBG B-verb.stative	succinylcholine JJ B-adj.all	- : 0	facilitated VBN B-verb.communication	tracheal NN B-noun.person	intubation NN B-noun.person	, , 0	the DT 0	interaction NN B-noun.act	between IN 0	MIVACRON NNP B-noun.person	and CC 0	succinylcholine NN B-noun.person	has VBZ 0	not RB 0	been VBN 0	systematically RB B-adv.all	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d603.s2	The DT 0	use NN 0	of IN 0	drugs NNS B-noun.artifact	that WDT 0	stimulate VBP B-verb.emotion	alpha NN I-verb.emotion	- : 0	adrenergic JJ B-adj.all	receptors NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	phenylephrine NN B-noun.person	, , 0	pseudoephedrine NN B-noun.person	, , 0	ephedrine NN B-noun.person	, , 0	phenylpropanolamine NN B-noun.person	or CC 0	dihydroergotamine NN B-noun.location	) ) 0	may MD 0	enhance VB B-verb.emotion	or CC 0	potentiate VB B-verb.communication	the DT 0	pressor NN B-noun.substance	effects NNS B-noun.phenomenon	of IN 0	ProAmatine NNP B-noun.person	__ : 0	. . 0	Therefore RB B-adv.all	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	used VBN B-verb.consumption	when WRB 0	ProAmatine NNP B-noun.person	___ NNP I-noun.person	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	agents NNS B-noun.person	that WDT 0	cause VBP B-verb.emotion	vasoconstriction NN I-verb.emotion	. . 0	. . 0
DDI-DrugBank.d628.s1	and CC 0	combinations NNS B-noun.person	of IN 0	opioids NNS B-noun.person	and CC 0	sedatives NNS B-noun.person	( ( 0	eg UH 0	, , 0	benzodiazepines NNS B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	chloral_hydrate NNP B-noun.person	, , 0	droperidol NN B-noun.person	, , 0	etc FW 0	. . 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d730.s0	The DT 0	pharmacokinetic JJ B-adj.all	profile NN B-noun.attribute	of IN 0	temazepam NN B-noun.attribute	does VBZ 0	not RB B-adv.all	appear VB B-verb.change	to TO 0	be VB 0	altered VBN B-verb.change	by IN 0	orally RB B-adv.all	administered VBN B-verb.possession	cimetidine NN B-noun.person	dosed VBD 0	according VBG 0	to TO 0	labeling VBG B-verb.communication	. . 0	. . 0
DDI-DrugBank.d592.s2	Heparin NNP B-noun.person	should MD 0	not RB 0	be VB 0	included VBN B-verb.stative	in IN 0	the DT 0	same JJ B-adj.all	syringe NN B-noun.communication	as IN 0	Sodium_Tetradecyl_Sulfate JJ 0	, , 0	since IN 0	the DT 0	two CD 0	are VBP B-verb.stative	incompatible JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d668.s1	Furthermore RB B-adv.all	, , 0	rifampin NN B-noun.person	, , 0	dexamethasone NN B-noun.person	, , 0	St. NNP B-noun.location	. . 0
DDI-DrugBank.d576.s4	Salicylates NNS B-noun.person	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	anticoagulant_drugs NNS B-noun.object	may MD 0	predispose VB B-verb.cognition	to TO 0	systemic JJ B-adj.all	bleeding NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d711.s2	Absorption NNP B-noun.person	of IN 0	tetracyclines NNS B-noun.phenomenon	is VBZ 0	impaired VBN B-verb.change	by IN 0	antacids NNS B-noun.substance	containing VBG B-verb.stative	aluminum NN I-verb.stative	, , 0	calcium NN B-noun.artifact	or CC 0	magnesium NN B-noun.person	, , 0	and CC 0	iron NN B-noun.person	- : 0	containing VBG B-verb.stative	preparations NNS B-noun.substance	. . 0	. . 0
DDI-DrugBank.d602.s0	Caution NN B-noun.person	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	administering VBG B-verb.creation	NEXAVAR NNP I-verb.creation	with IN 0	compounds NNS B-noun.person	that WDT 0	are VBP 0	metabolized VBN B-verb.change	/ : 0	eliminated VBN B-verb.cognition	predominantly RB B-adv.all	by IN 0	the DT 0	UGT1A1 JJ B-adj.all	pathway NN B-noun.location	( ( 0	e.g. JJ B-adv.all	irinotecan JJ I-adv.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d649.s1	It PRP 0	may MD 0	also RB 0	interact VB B-verb.contact	with IN 0	thiazides NNS B-noun.cognition	( ( 0	increased VBN B-verb.change	thrombocytopenia NN B-noun.artifact	) ) 0	, , 0	cyclosporine NN B-noun.person	( ( 0	increased VBN B-verb.change	nephrotoxicity NN B-noun.attribute	) ) 0	, , 0	sulfonylurea_agents NNS B-noun.person	( ( 0	increased VBN B-verb.change	hypoglycemic JJ B-adj.all	response NN B-noun.event	) ) 0	, , 0	warfarin NN 0	( ( 0	increased VBN B-verb.change	anticoagulant JJ B-adj.all	effect NN B-noun.cognition	) ) 0	, , 0	methotrexate NN B-noun.person	( ( 0	decreased VBN B-verb.change	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	methotrexate NN B-noun.attribute	) ) 0	, , 0	phenytoin NN B-noun.person	( ( 0	decreased VBN B-verb.change	hepatic JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	phenytoin NN B-noun.body	) ) 0	. . 0	. . 0
DDI-DrugBank.d704.s2	The DT 0	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	between IN 0	cimetidine NN B-noun.location	and CC 0	FLOMAX NNP B-noun.group	capsules NNS B-noun.artifact	was VBD 0	investigated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d624.s0	In IN 0	clinical JJ B-adj.all	studies NNS B-noun.group	of IN 0	TOBI NNP B-noun.group	, , 0	patients NNS B-noun.person	taking VBG B-verb.social	TOBI NNP I-verb.social	concomitantly RB B-adv.all	with IN 0	dornase_alfa NNP B-noun.person	( ( 0	PULMOZYME NNP B-noun.group	__ CC 0	, , 0	Genentech NNP B-noun.location	) ) 0	, , 0	( ( 0	beta)-agonists NNS B-noun.person	, , 0	inhaled JJ B-adj.all	corticosteroids NNS B-noun.person	, , 0	other JJ 0	anti NNS B-noun.person	- : 0	pseudomonal_antibiotics NNS B-noun.person	, , 0	or CC 0	parenteral JJ B-adj.all	aminoglycosides NNS B-noun.person	demonstrated VBD B-verb.perception	adverse JJ B-adj.all	experience NN B-noun.cognition	profiles NNS I-noun.cognition	similar JJ B-adj.all	to TO 0	the DT 0	study NN B-noun.artifact	population NN I-noun.artifact	as IN 0	a DT 0	whole NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d645.s0	In IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	with IN 0	human JJ B-adj.all	liver NN B-noun.person	microsomes NNS B-noun.person	showed VBD B-verb.communication	that IN 0	terbinafine NN B-noun.communication	does VBZ 0	not RB B-adv.all	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	tolbutamide NN 0	, , 0	ethinylestradiol NN B-noun.person	, , 0	ethoxycoumarin NN B-noun.person	, , 0	and CC 0	cyclosporine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d643.s0	Melatonin NNP B-noun.person	may MD 0	interact VB B-verb.change	with IN 0	the DT 0	following VBG 0	drugs NNS B-noun.person	, , 0	aspirin NN B-noun.person	and CC 0	other JJ 0	NSAIDs NNP B-noun.person	( ( 0	may MD 0	lower VB B-verb.change	melatonin NN B-noun.food	levels NNS B-noun.attribute	) ) 0	, , 0	fluvoxamine NN B-noun.person	( ( 0	bioavailability NN B-noun.cognition	of IN 0	oral JJ B-adj.all	melatonin NN B-noun.person	is VBZ 0	increased VBN B-verb.change	with IN 0	coadministration NN B-noun.feeling	) ) 0	, , 0	beta_blockers NNS B-noun.person	( ( 0	may MD 0	decrease VB B-verb.change	melatonin NN B-noun.food	levels NNS B-noun.attribute	) ) 0	, , 0	fluoxetine NN B-noun.person	( ( 0	reports NNS B-noun.communication	of IN 0	psychotic JJ B-adj.all	episodes NNS B-noun.time	when WRB 0	coadministered VBN B-verb.contact	) ) 0	, , 0	progestin NN B-noun.person	( ( 0	coadministration NN B-noun.person	of IN 0	melatonin NN B-noun.food	with IN 0	progestin NN B-noun.person	can MD 0	inhibit VB B-verb.change	ovarian JJ B-adj.all	function NN B-noun.act	in IN 0	women NNS B-noun.person	) ) 0	, , 0	benzodiazepenes NNS B-noun.person	and CC 0	other JJ 0	sedating VBG B-verb.communication	drugs NNS B-noun.person	( ( 0	may MD 0	result VB B-verb.stative	in IN 0	additive JJ B-adj.all	sedation NN B-noun.act	and CC 0	an DT 0	increased VBN B-adj.all	incidence NN B-noun.attribute	of IN 0	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	) ) 0	, , 0	and CC 0	corticosteroids NNS B-noun.person	( ( 0	coadministration NN B-noun.person	of IN 0	melatonin NN B-noun.food	and CC 0	corticosteroids NNS B-noun.object	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	efficacy NN B-noun.phenomenon	of IN 0	the DT 0	corticosteroids NNS B-noun.artifact	) ) 0	. . 0	. . 0
DDI-DrugBank.d622.s1	This DT 0	is VBZ B-verb.stative	especially RB B-adv.all	true JJ B-adj.all	if IN 0	the DT 0	total JJ B-adj.all	dose NN B-noun.act	of IN 0	atropine NN B-noun.act	has VBZ 0	been VBN B-verb.stative	large JJ B-adj.all	and CC 0	the DT 0	administration NN B-noun.time	of IN 0	pralidoxime NN B-noun.person	has VBZ 0	been VBN 0	delayed VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d647.s3	The DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	streptozocin NN B-noun.communication	and CC 0	phenytoin NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	one CD 0	case NN 0	to TO 0	result VB B-verb.stative	in IN 0	reduced JJ B-adj.all	streptozocin NN B-noun.substance	cytotoxicity NN B-noun.state	. . 0	___ NNP B-noun.person	. . 0
DDI-MedLine.d209.s1	Tamoxifen NNP B-noun.person	, , 0	an DT 0	estrogen_antagonist NN B-noun.communication	, , 0	is VBZ B-verb.stative	the DT 0	standard JJ B-adj.all	hormone NN B-noun.person	treatment NN B-noun.person	for IN 0	breast NN 0	cancer NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d761.s9	Phenytoin NN B-noun.person	, , 0	In IN 0	12 CD B-adj.all	normal JJ B-adj.pert	- : 0	weight NN B-noun.artifact	subjects NNS B-noun.artifact	receiving VBG B-verb.change	XENICAL NNP B-noun.group	120 CD 0	mg IN 0	three CD 0	times NNS B-noun.event	a DT 0	day NN B-noun.person	for IN 0	7 CD B-adj.all	days NNS B-noun.act	, , 0	XENICAL NNP B-noun.group	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	a DT 0	single JJ B-adj.all	300-mg JJ 0	dose NN B-noun.quantity	of IN 0	phenytoin NN B-noun.food	. . 0	. . 0
DDI-MedLine.d174.s1	Nonsteroidal_anti SYM 0	- : 0	inflammatory_drugs NNS B-noun.cognition	( ( 0	NSAIDs NNP B-noun.person	) ) 0	represent VBP B-verb.social	class NN B-noun.person	of IN 0	medicines NNS B-noun.shape	which WDT 0	is VBZ B-verb.stative	wide JJ B-adj.all	concerning VBG B-verb.communication	chemical NN B-noun.communication	structure NN B-noun.attribute	and CC 0	mechanism NN B-noun.act	of IN 0	action NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d598.s1	Trimethoprim NNP B-noun.person	, , 0	given VBN B-verb.possession	at IN 0	a DT 0	common JJ B-adj.all	clinical JJ B-noun.state	dosage NN I-noun.state	, , 0	increased VBD B-verb.change	the DT 0	phenytoin NN B-noun.person	half NN B-noun.person	- : 0	life NN B-noun.time	by IN 0	51 CD 0	% NN 0	and CC 0	decreased VBD B-verb.change	the DT 0	phenytoin NN B-noun.communication	metabolic JJ B-adj.all	clearance NN B-noun.event	rate NN B-noun.time	by IN 0	30 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d576.s6	Salicylate NNP B-noun.person	competes VBZ B-verb.change	with IN 0	a DT 0	number NN B-noun.quantity	of IN 0	drugs NNS B-noun.artifact	for IN 0	protein NN B-noun.substance	binding JJ B-verb.contact	sites NNS B-noun.location	, , 0	notably RB B-verb.perception	penicillin NN B-noun.person	, , 0	thiopental JJ 0	, , 0	thyroxine NN B-noun.body	, , 0	triiodothyronine NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	sulfinpyrazone NN 0	, , 0	naproxen NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	methotrexate NN B-noun.person	, , 0	and CC 0	possibly RB B-adj.all	corticosteroids NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d147.s0	Interaction NN B-noun.act	of IN 0	dacarbazine NN B-noun.person	and CC 0	imexon NN B-noun.person	, , 0	in IN 0	vitro NN B-noun.animal	and CC 0	in IN 0	vivo NN B-noun.animal	, , 0	in IN 0	human JJ B-adj.all	A375 NN B-noun.body	melanoma NN B-noun.body	cells NNS B-noun.body	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d739.s8	It PRP 0	is VBZ B-verb.stative	reasonable JJ B-adj.all	to TO 0	employ VB B-verb.consumption	appropriate JJ B-adj.all	clinical JJ B-adj.all	monitoring NN B-verb.perception	when WRB 0	potent JJ B-adj.all	cytochrome NN B-noun.person	P450 NN I-noun.person	enzyme NN I-noun.person	inducers NNS I-noun.person	, , 0	such JJ 0	as IN 0	phenobarbital JJ B-adj.all	or CC 0	rifampin NN B-noun.communication	, , 0	are VBP B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	montelukast NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d775.s5	Isoflurane NNP B-noun.person	and CC 0	enflurane NN B-noun.person	( ( 0	administered VBN B-verb.body	with IN 0	nitrous_oxide JJ 0	/ DT 0	oxygen NN B-noun.quantity	to TO 0	achieve VB B-verb.social	1.25 CD 0	M.C. NNP B-noun.time	. . 0
DDI-DrugBank.d627.s3	These DT 0	effects NNS B-noun.phenomenon	should MD 0	be VB 0	considered VBN B-verb.cognition	when WRB 0	anticholinergic JJ B-adj.all	properties NNS B-noun.group	may MD 0	be VB 0	contributing VBG B-verb.social	to TO 0	the DT 0	therapeutic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	concomitant JJ B-adj.all	medication NN B-noun.person	( ( 0	e.g. UH 0	, , 0	atropine NN B-noun.person	, , 0	inhaled VBD B-verb.contact	ipratropium NN B-noun.artifact	) ) 0	. . 0	. . 0
DDI-DrugBank.d739.s4	Montelukast NNP B-noun.person	at IN 0	Doses NNP B-noun.location	of IN 0	___ $ 0	100 CD 0	mg IN 0	Daily NNP B-noun.person	Dosed NNP I-noun.person	to TO 0	Pharmacokinetic NNP B-noun.person	Steady NNP I-noun.person	State NNP I-noun.person	, , 0	_ PRP 0	; : 0	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	alter VB B-verb.change	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	either DT 0	component NN B-noun.relation	of IN 0	an DT 0	oral JJ B-adj.all	contraceptive NN 0	containing VBG B-verb.stative	norethindrone NN 0	1 CD 0	mg RB 0	/ JJ 0	ethinyl NN 0	estradiol NN 0	35 CD 0	mcg NN 0	. . 0	. . 0
DDI-DrugBank.d645.s2	This DT 0	may MD 0	be VB B-verb.stative	of IN 0	clinical JJ B-adj.all	relevance NN B-noun.state	for IN 0	compounds NNS B-noun.person	predominantly RB B-adv.all	metabolized VBN B-verb.cognition	by IN 0	this DT 0	enzyme NN B-noun.cognition	, , 0	such JJ 0	as IN 0	tricyclic_antidepressants NNS B-noun.person	, , 0	___ PRP$ 0	-blockers NNS B-noun.person	, , 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	, , 0	and CC 0	monoamine_oxidase_inhibitors_(MAO NNP B-noun.person	- : 0	Is)_Type_B NN B-noun.other	, , 0	if IN 0	they PRP 0	have VBP B-verb.stative	a DT 0	narrow JJ B-adj.all	therapeutic JJ B-adj.all	window NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d230.s8	The DT 0	dosage NN B-noun.artifact	regimen NNS B-noun.person	of IN 0	amiodarone NN 0	does VBZ 0	not RB 0	need VB 0	to TO 0	be VB 0	taken VBN B-verb.social	into IN 0	consideration NN B-noun.time	when WRB 0	combined VBN B-verb.creation	with IN 0	neferine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d704.s5	Results NNS B-noun.person	from IN 0	limited VBN B-verb.social	in IN 0	vitro NN B-noun.animal	and CC 0	in IN 0	vivo JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.group	interaction NN B-noun.act	studies NNS B-noun.artifact	between IN 0	tamsulosin_HCI NNP B-noun.person	and CC 0	warfarin NN B-noun.act	are VBP B-verb.stative	inconclusive JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d143.s7	To TO 0	date NN B-noun.person	, , 0	there EX 0	is VBZ B-verb.stative	no DT 0	conclusive JJ B-adj.all	evidence NN B-noun.attribute	of IN 0	a DT 0	clinically RB B-adv.all	- : 0	relevant JJ B-adj.all	interaction NN B-noun.act	between IN 0	any DT 0	of IN 0	the DT 0	proton_pump_inhibitors NNS B-noun.person	and CC 0	clopidogrel NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d595.s1	norepinephrine NN B-noun.person	and CC 0	dobutamine NN B-noun.act	are VBP B-verb.stative	incompatible JJ B-adj.all	with IN 0	sodium_bicarbonate JJ B-adj.all	solution NN B-noun.cognition	. . 0	. . 0
DDI-MedLine.d212.s0	Improvement NN B-noun.state	of IN 0	colchicine NN B-noun.phenomenon	oral JJ B-adj.all	bioavailability NN B-noun.cognition	by IN 0	incorporating VBG B-verb.change	eugenol NN B-noun.food	in IN 0	the DT 0	nanoemulsion NN B-noun.communication	as IN 0	an DT 0	oil NN B-noun.artifact	excipient NN B-noun.act	and CC 0	enhancer NN B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d784.s4	Other JJ 0	inhibitors NNS B-noun.person	of IN 0	the DT 0	cytochrome NN 0	P450 RB 0	3A4 JJ 0	enzyme NN B-noun.cognition	system NN I-noun.cognition	, , 0	such JJ 0	as IN 0	antimycotic_agents NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	itraconazole NN B-noun.person	and CC 0	miconazole NN B-noun.location	) ) 0	or CC 0	macrolide_antibiotics NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	erythromycin NN B-noun.person	and CC 0	clarithromycin NN B-noun.attribute	) ) 0	, , 0	may MD 0	alter VB B-verb.change	oxybutynin NN B-noun.animal	mean JJ B-adj.all	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.person	( ( 0	i.e. FW B-adv.all	, , 0	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	) ) 0	. . 0	. . 0
DDI-DrugBank.d743.s2	Pharmacokinetic JJ B-adj.all	data NNS B-noun.cognition	indicate VBP B-verb.communication	that IN 0	ketoconazole NN B-noun.person	markedly RB B-adv.all	inhibits VBZ B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	terfenadine NN B-noun.artifact	, , 0	resulting VBG B-verb.stative	in IN 0	elevated JJ B-adj.all	plasma NN B-noun.plant	terfenadine NN B-noun.body	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d576.s1	ASPIRIN NN B-noun.group	AND CC 0	OTHER JJ 0	SALICYLATE_DRUGS NNS B-noun.group	WILL MD 0	BE VB B-verb.stative	ADDITIVE JJ 0	TO TO 0	DISALCID VB B-noun.group	AND CC 0	MAY MD 0	INCREASE VB B-verb.change	PLASMA NNP B-noun.group	CONCENTRATIONS NNPS I-noun.group	OF IN 0	SALICYLIC_ACID NN 0	TO TO 0	TOXIC JJ B-adj.all	LEVELS NNS B-noun.attribute	. . 0	. . 0
DDI-MedLine.d169.s1	Calcium NN B-noun.person	is VBZ B-verb.stative	the DT 0	only RB B-adj.all	known JJ I-adj.all	component NN B-noun.person	in IN 0	the DT 0	diet NN B-noun.communication	that WDT 0	may MD 0	affect VB B-verb.change	absorption NN B-noun.act	of IN 0	both DT 0	nonheme JJ B-adj.all	and CC 0	heme_iron NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d722.s0	There EX 0	is VBZ 0	usually RB B-adv.all	complete JJ B-adj.all	cross NN B-noun.person	- : 0	resistance NN B-noun.phenomenon	between IN 0	PURINETHOL NNP B-noun.group	( ( 0	mercaptopurine NN B-noun.act	) ) 0	and CC 0	TABLOID NNP B-noun.group	brand NN I-noun.group	Thioguanine NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d700.s6	Azathioprine NNP B-noun.location	/ POS I-noun.location	Mycophenolate_Mofetil NN I-noun.location	, , 0	Given VBN B-verb.possession	that IN 0	azathioprine NN B-noun.person	and CC 0	mycophenolate_mofetil NNP B-noun.person	inhibit VBP B-verb.stative	purine JJ B-adj.all	metabolism NN B-noun.attribute	, , 0	it PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	Myfortic NNP B-noun.person	not RB B-adv.all	be VB 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	azathioprine JJ B-adj.all	or CC 0	mycophenolate_mofetil NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d153.s1	A DT 0	rapid JJ B-adj.all	, , 0	sensitive JJ B-adj.all	and CC 0	reliable JJ B-adj.pert	high JJ B-adj.all	performance NN B-noun.attribute	liquid JJ B-adj.all	chromatography NN B-noun.communication	- : 0	tandem NN B-noun.artifact	mass NN I-noun.artifact	spectrometry NN B-noun.possession	( ( 0	HPLC NNP B-noun.group	- : 0	MS NN 0	/ '' 0	MS NNP 0	) ) 0	method NN B-noun.location	was VBD 0	developed VBN B-verb.creation	and CC 0	validated VBN B-verb.social	for IN 0	the DT 0	determination NN B-noun.cognition	of IN 0	propiverine_hydrochloride JJ 0	( ( 0	CAS NNP 0	54556 CD 0	- : 0	98 SYM 0	- : 0	8 LS 0	) ) 0	in IN 0	human JJ B-adj.all	plasma NN B-noun.substance	using VBG B-verb.consumption	cetirizine_di JJ I-verb.consumption	- : 0	hydrochloride NN 0	as IN 0	internal JJ B-adj.all	standard NN B-noun.state	( ( 0	IS VBZ 0	, , 0	CAS NNP 0	8388 CD 0	- : 0	51 SYM 0	- : 0	0 LS 0	) ) 0	. . 0	. . 0
DDI-MedLine.d169.s6	We PRP 0	also RB B-adv.all	evaluated VBD B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	calcium NN B-noun.artifact	doses NNS B-noun.artifact	between IN 0	200 CD 0	and CC 0	800 CD 0	mg NN B-noun.quantity	on IN 0	absorption NN B-noun.act	of IN 0	5 CD 0	mg DT 0	heme_iron NNP B-noun.person	[ CC 0	as IN 0	concentrated JJ B-adj.all	RBC NNP B-noun.group	( ( 0	CRBC NNP B-noun.group	) ) 0	] : 0	. . 0	. . 0
DDI-DrugBank.d710.s9	Peak NNP B-noun.person	plasma NN I-noun.person	concentrations NNS I-noun.person	and CC 0	AUC NNP B-noun.group	of IN 0	rimantadine NN B-noun.person	were VBD 0	reduced VBN B-verb.change	approximately RB B-adv.all	10 CD B-adj.all	% NN 0	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	aspirin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d196.s26	In IN 0	these DT 0	2 CD B-adj.all	single JJ B-noun.act	- : 0	dose NN B-noun.substance	studies NNS B-noun.artifact	, , 0	these DT 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	administered VBD B-verb.possession	a DT 0	single JJ B-adj.all	oral JJ B-adj.all	dose NN B-noun.quantity	of IN 0	105-mg JJ B-adj.all	fenofibric_acid NN B-noun.artifact	met VBD B-verb.stative	the DT 0	US NNP 0	Food NNP B-noun.location	and CC 0	Drug NNP B-noun.person	Administration NNP I-noun.person	regulatory JJ B-adj.all	criteria NNS B-noun.person	for IN 0	assuming VBG B-verb.cognition	bioequivalence NN B-noun.cognition	to TO 0	a DT 0	single JJ B-adj.all	oral JJ B-adj.all	dose NN B-noun.quantity	of IN 0	145-mg JJ B-adj.all	fenofibrate NN I-adj.all	tablets NNS B-noun.artifact	with IN 0	respect NN B-noun.act	to TO 0	the DT 0	rate NN B-noun.time	and CC 0	extent NN B-noun.act	of IN 0	fenofibric_acid JJ B-noun.phenomenon	absorption NN I-noun.phenomenon	in IN 0	both DT 0	fed NN B-noun.person	and CC 0	fasted VBD B-verb.creation	states NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d720.s4	If IN 0	concomitant JJ B-adj.all	treatment NN B-noun.communication	with IN 0	sumatriptan NN B-noun.food	and CC 0	an DT 0	SSRI NNP B-noun.group	is VBZ B-verb.stative	clinically RB B-adv.all	warranted VBN B-verb.communication	, , 0	appropriate JJ B-adj.all	observation NN B-noun.act	of IN 0	the DT 0	patient NN B-noun.person	is VBZ 0	advised VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d781.s2	If IN 0	diuretics NNS B-noun.person	can MD 0	not RB B-adv.all	be VB 0	interrupted VBN B-verb.communication	, , 0	close RB B-adj.all	medical JJ B-adj.all	supervision NN B-noun.feeling	should MD 0	be VB 0	provided VBN B-verb.communication	with IN 0	the DT 0	first JJ B-adj.all	dose NN B-noun.event	of IN 0	ACEON NNP B-noun.group	___ POS 0	Tablets NNS B-noun.location	, , 0	for IN 0	at IN 0	least JJS 0	two CD 0	hours NNS B-noun.person	and CC 0	until IN 0	blood NN B-noun.act	pressure NN B-noun.act	has VBZ 0	stabilized VBN B-verb.change	for IN 0	another DT 0	hour NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d629.s1	Drug NN B-noun.person	interactions NNS I-noun.person	should MD 0	be VB 0	kept VBN B-verb.stative	in IN 0	mind NN 0	when WRB 0	METROGEL NNP B-noun.group	( ( 0	metronidazole NN B-noun.attribute	gel NN I-noun.attribute	) ) 0	, , 0	1 CD B-adj.all	% NN 0	is VBZ 0	prescribed VBN B-verb.communication	for IN 0	patients NNS B-noun.person	who WP 0	are VBP 0	receiving VBG B-verb.change	anticoagulant JJ B-adj.all	treatment NN B-noun.communication	, , 0	although IN 0	they PRP 0	are VBP B-verb.stative	less RBR B-adv.all	likely JJ B-adj.all	to TO 0	occur VB B-verb.stative	with IN 0	topical JJ B-adj.all	metronidazole NN B-noun.attribute	administration NN B-noun.time	because IN 0	of IN 0	low JJ B-adj.all	absorption NN B-noun.artifact	. . 0	___ NNP B-noun.person	. . 0
DDI-DrugBank.d728.s2	Increases NNS B-noun.event	of IN 0	5-FU JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.phenomenon	by IN 0	approximately RB B-noun.time	20 CD B-adj.all	% NN 0	have VBP 0	been VBN 0	observed VBN B-verb.perception	with IN 0	doses NNS B-noun.person	of IN 0	130 CD 0	mg NN B-noun.quantity	/ '' 0	m2 IN 0	ELOXATIN NNP B-noun.group	dosed VBD B-verb.social	every DT 0	3 CD B-adj.all	weeks NNS B-noun.time	. . 0	. . 0
DDI-MedLine.d220.s7	The DT 0	effect NN B-noun.cognition	of IN 0	a DT 0	series NN B-noun.communication	of IN 0	flavonoids NNS B-noun.communication	, , 0	including VBG B-verb.change	flavonols NNS B-noun.artifact	, , 0	flavones NNS B-noun.communication	, , 0	isoflavone NN 0	, , 0	flavanone NN B-noun.person	, , 0	flavanonols NNS B-noun.artifact	and CC 0	catechins NNS B-noun.person	, , 0	on IN 0	the DT 0	elimination NN B-noun.act	of IN 0	luteolin NN B-noun.substance	and CC 0	apigenin NN B-noun.person	was VBD 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d639.s0	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	SUTENT NNP B-noun.group	with IN 0	strong JJ B-adj.all	inhibitors NNS B-noun.person	of IN 0	the DT 0	CYP3A4 NNP B-noun.person	family NN B-noun.group	( ( 0	e.g. UH 0	, , 0	ketoconazole NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	clarithromycin NN B-noun.person	, , 0	atazanavir NN B-noun.person	, , 0	indinavir NN B-noun.person	, , 0	nefazodone NN 0	, , 0	nelfinavir NN B-noun.person	, , 0	ritonavir NN B-noun.person	, , 0	saquinavir NN B-noun.person	, , 0	telithromycin NN B-noun.person	, , 0	voriconizole NN B-noun.attribute	) ) 0	may MD 0	increases VB B-verb.change	sunitinib NN B-noun.animal	concentrations NNS I-noun.animal	. . 0	. . 0
DDI-DrugBank.d665.s7	Displacement NN B-noun.person	of IN 0	penicillin NN B-noun.food	from IN 0	plasma NN B-noun.plant	protein NN B-noun.substance	binding JJ B-verb.contact	sites NNS B-noun.location	will MD 0	elevate VB B-verb.social	the DT 0	level NN B-noun.state	of IN 0	free JJ B-noun.person	penicillin NN I-noun.person	in IN 0	the DT 0	serum NN B-noun.body	. . 0	. . 0
DDI-DrugBank.d648.s0	Cholestyramine NN B-noun.person	, , 0	Cholestyramine NNP B-noun.person	causes VBZ B-verb.creation	a DT 0	60 CD B-adj.all	% NN 0	reduction NN B-noun.act	in IN 0	the DT 0	absorption NN B-noun.artifact	and CC 0	enterohepatic JJ B-adj.all	cycling NN B-noun.event	of IN 0	raloxifene NN B-noun.person	and CC 0	should MD 0	not RB 0	be VB 0	coadministered VBN B-verb.contact	with IN 0	EVISTA NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d739.s1	- : 0	did VBD 0	not RB B-adv.all	change VB B-verb.change	the DT 0	pharmacokinetic JJ B-adj.all	profile NN B-noun.attribute	of IN 0	warfarin NN B-noun.substance	( ( 0	a DT 0	substrate NN B-noun.person	of IN 0	cytochromes NNS B-noun.group	P450 POS 0	2A6 NN B-noun.artifact	and CC 0	2C9 NNP 0	) ) 0	or CC 0	influence VB B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	a DT 0	single JJ B-adj.all	30-mg JJ 0	oral JJ B-adj.all	dose NN B-noun.quantity	of IN 0	warfarin NN B-noun.act	on IN 0	prothrombin NN B-adj.all	time NN B-noun.time	or CC 0	the DT 0	INR NNP B-noun.other	( ( 0	International NNP B-noun.other	Normalized NNP I-noun.other	Ratio NNP I-noun.other	) ) 0	. . 0	. . 0
DDI-MedLine.d196.s10	The DT 0	criterion NN B-noun.act	for IN 0	a DT 0	lack NN B-noun.person	of IN 0	difference NN B-noun.cognition	between IN 0	products NNS B-noun.person	was VBD B-verb.stative	a DT 0	90 CD B-adj.all	% NN 0	CI NN 0	between IN 0	0.80 CD 0	and CC 0	1.25 CD 0	for IN 0	the DT 0	fenofibric_acid NNP B-noun.location	, , 0	fenofibrate JJ B-adj.all	ratios NNS B-noun.person	for IN 0	AUC(0-t NNP B-noun.location	) ) 0	, , 0	AUC(0- UH 0	__ : 0	) ) 0	, , 0	and CC 0	C(max NNP B-noun.person	. . 0	) ) 0	. . 0
DDI-DrugBank.d597.s14	Furosemide RB 0	, , 0	Clinical JJ B-noun.body	studies NNS I-noun.body	, , 0	as RB 0	well RB 0	as IN 0	post NN B-noun.person	- : 0	marketing NN B-noun.act	observations NNS B-noun.act	, , 0	have VBP 0	shown VBN B-verb.cognition	that IN 0	NSAIDs NNPS B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	natriuretic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	furosemide NN B-noun.artifact	and CC 0	thiazide_diuretics NNS B-noun.person	in IN 0	some DT 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d735.s4	Nifedipine NNP B-noun.person	AUC NNP I-noun.person	and CC 0	Cmax NNP B-noun.person	were VBD 0	increased VBN B-verb.change	by IN 0	18 CD B-adj.all	% NN 0	and CC 0	42 CD 0	% NN 0	, , 0	respectively RB B-adv.all	, , 0	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	steady JJ B-adj.all	- : 0	state NN B-adj.all	MYCAMINE NN 0	compared VBN B-verb.change	with IN 0	nifedipine NN B-noun.person	alone RB B-adv.all	. . 0	. . 0
DDI-MedLine.d217.s4	The DT 0	sensitivity NN B-noun.feeling	, , 0	cell NN B-noun.body	cycle NN I-noun.body	, , 0	apoptosis NN B-noun.person	and CC 0	DNA NNP 0	damage NN 0	of IN 0	five CD 0	different JJ B-adj.all	cancer NN B-noun.artifact	cell NN B-noun.artifact	lines NNS B-noun.communication	( ( 0	HeLa NNP B-noun.person	, , 0	HCT116 NNP B-noun.person	, , 0	HepG2 NNP B-noun.person	, , 0	MCF7 NNP B-noun.group	and CC I-noun.group	U251 NNP I-noun.group	) ) 0	to TO 0	5-FU VB 0	, , 0	cisplatin NN B-noun.person	, , 0	doxorubicin NN B-noun.person	and CC 0	etoposide VB B-verb.consumption	__ DT 0	celecoxib NN B-noun.body	following VBG B-verb.stative	different JJ B-adj.all	incubation NN B-noun.possession	schedules NNS B-noun.person	were VBD 0	analyzed VBN B-verb.cognition	. . 0	. . 0
DDI-MedLine.d206.s0	Evaluation NNP B-noun.person	of IN 0	antidepressant NN B-noun.location	like IN 0	activity NN B-noun.process	of IN 0	curcumin NN B-noun.communication	and CC 0	its PRP$ 0	combination NN B-noun.event	with IN 0	fluoxetine NN B-noun.person	and CC 0	imipramine NN B-noun.act	, , 0	an DT 0	acute NN B-noun.person	and CC 0	chronic JJ B-adj.all	study NN B-noun.artifact	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d775.s11	The DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	effect NN B-noun.cognition	of IN 0	MIVACRON NNP B-noun.group	may MD 0	be VB 0	enhanced VBN B-verb.change	by IN 0	drugs NNS B-noun.artifact	that WDT 0	reduce VBP B-verb.change	plasma NN B-noun.substance	cholinesterase NN B-noun.phenomenon	activity NN B-noun.process	( ( 0	e.g. UH 0	, , 0	chronically RB B-adv.all	administered VBN B-verb.possession	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	glucocorticoids NNS B-noun.person	, , 0	or CC 0	certain JJ B-adj.all	monoamine_oxidase_inhibitors NNS B-noun.location	) ) 0	or CC 0	by IN 0	drugs NNS B-noun.artifact	that WDT 0	irreversibly RB B-adv.all	inhibit JJ B-adj.all	plasma NN B-noun.substance	cholinesterase NN 0	. . 0	Resistance NNP B-noun.person	to TO 0	the DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	action NN B-noun.process	of IN 0	nondepolarizing VBG B-verb.communication	neuromuscular_blocking_agents NNS B-noun.person	has VBZ 0	been VBN 0	demonstrated VBN B-verb.perception	in IN 0	patients NNS B-noun.person	chronically RB B-adv.all	administered VBN B-verb.possession	phenytoin NN B-noun.possession	or CC 0	carbamazepine NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d572.s22	In IN 0	rabbits NNS 0	treated VBN B-verb.change	with IN 0	ezetimibe NN B-noun.person	, , 0	an DT 0	increased VBN B-adj.all	incidence NN B-noun.attribute	of IN 0	extra JJ B-adj.all	thoracic JJ 0	ribs NNS B-noun.body	was VBD 0	observed VBN B-verb.perception	at IN 0	1000 CD 0	mg NN B-noun.quantity	/ ) 0	kg RB 0	/ JJ 0	day NN 0	( ( 0	150 CD 0	times NNS B-noun.event	the DT 0	human JJ B-adj.all	exposure NN B-noun.person	at IN 0	10 CD B-adj.all	mg NN B-noun.quantity	daily RB B-adv.all	based VBN B-verb.cognition	on IN 0	AUC0 NN B-noun.act	- : 0	24hr JJ 0	for IN 0	total JJ B-adj.all	ezetimibe NN B-noun.act	) ) 0	. . 0	. . 0
DDI-MedLine.d154.s2	The DT 0	objective NN B-noun.cognition	of IN 0	this DT 0	study NN B-noun.artifact	was VBD 0	to TO 0	evaluate VB B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	oral JJ B-adj.all	administration NN B-noun.time	of IN 0	ginseng_stem NN B-noun.person	- : 0	and CC 0	- : 0	leaf_saponins NNS B-noun.person	( ( 0	GSLS NNP B-noun.group	) ) 0	on IN 0	the DT 0	humoral JJ B-adj.all	immune JJ B-adj.all	responses NNS B-noun.act	of IN 0	chickens NNS B-noun.animal	to TO 0	inactivated_ND JJ 0	and CC 0	AI NNP 0	vaccines NNS 0	. . 0	. . 0
DDI-DrugBank.d720.s3	Therefore RB 0	, , 0	the DT 0	use NN 0	of IN 0	sumatriptan_succinate JJ B-adj.all	tablets NNS B-noun.artifact	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	MAO NNP B-noun.group	- : 0	A_inhibitors NNS B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	Selective_serotonin_reuptake_inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	( ( 0	e.g. UH 0	, , 0	fluoxetine NN B-noun.person	, , 0	fluvoxamine NN B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	sertraline NN B-noun.body	) ) 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	, , 0	rarely RB B-adv.all	, , 0	to TO 0	cause VB B-verb.emotion	weakness NN I-verb.emotion	, , 0	hyperreflexia NN B-noun.person	, , 0	and CC 0	incoordination NN B-noun.time	when WRB 0	coadministered VBN B-verb.communication	with IN 0	sumatriptan NN B-noun.feeling	. . 0	. . 0
DDI-MedLine.d142.s2	The DT 0	rats NNS B-noun.person	received VBD B-verb.possession	intragastric JJ B-adj.all	administration NN B-noun.time	of IN 0	daphnetin NN B-noun.person	and CC 0	glycyrrhiza_extract NN B-noun.artifact	containing VBG B-verb.stative	the DT 0	same JJ B-adj.all	daphnetin NN B-noun.person	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d656.s1	Although IN 0	this DT 0	has VBZ 0	not RB B-adv.all	occurred VBN B-verb.cognition	in IN 0	in IN 0	vitro NN B-noun.animal	studies NNS I-noun.animal	with IN 0	coumarin NN B-noun.person	- : 0	type_anticoagulants NNS B-noun.person	, , 0	interactions NNS B-noun.person	with IN 0	coumarin NN B-noun.person	- : 0	type_anticoagulants NNS B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	FELDENE NNP B-noun.group	since IN 0	marketing NN B-noun.act	, , 0	therefore RB B-adv.all	, , 0	physicians NNS B-noun.person	should MD 0	closely RB 0	monitor VB 0	patients NNS B-noun.person	for IN 0	a DT 0	change NN B-noun.act	in IN 0	dosage NN B-noun.artifact	requirements NNS B-noun.artifact	when WRB 0	administering VBG B-verb.communication	FELDENE NNP B-noun.person	to TO 0	patients NNS B-noun.person	on IN 0	coumarin NN B-noun.person	- : 0	type_anticoagulants NNS B-noun.person	and CC 0	other JJ 0	highly RB B-adv.all	protein VBP B-verb.cognition	- : 0	bound NN B-noun.person	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d739.s3	- : 0	did VBD 0	not RB B-adv.all	change VB B-verb.change	the DT 0	plasma NN B-noun.substance	concentration NN 0	profile NN 0	of IN 0	terfenadine NN B-noun.phenomenon	( ( 0	a DT 0	substrate NN B-noun.person	of IN 0	cytochrome NN B-noun.person	P450 JJ I-noun.person	3A4 NN I-noun.person	) ) 0	or CC 0	fexofenadine NN B-noun.location	, , 0	its PRP$ 0	carboxylated JJ B-adj.all	metabolite NN B-noun.attribute	, , 0	and CC 0	did VBD 0	not RB B-adv.all	prolong VB B-verb.stative	the DT 0	QTc NNP 0	interval NN 0	following VBG 0	co SYM 0	- : 0	administration NN B-noun.time	with IN 0	terfenadine NN B-noun.communication	60 CD B-adj.all	mg NN B-noun.quantity	twice RB 0	daily RB 0	. . 0	. . 0
DDI-DrugBank.d602.s1	Concomitant JJ B-adj.all	treatment NN B-noun.communication	with IN 0	NEXAVAR NNP B-noun.group	resulted VBD B-verb.competition	in IN 0	a DT 0	21 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	the DT 0	AUC NNP B-noun.group	of IN 0	doxorubicin NN B-noun.food	. . 0	. . 0
DDI-MedLine.d217.s5	We PRP 0	found VBD B-verb.possession	antagonism NN B-noun.attribute	between IN 0	celecoxib NN B-noun.person	and CC 0	the DT 0	four CD B-adj.all	drugs NNS B-noun.artifact	in IN 0	the DT 0	breast NN 0	cancer NN B-noun.body	cells NNS B-noun.body	MCF7 VBP 0	following VBG B-verb.stative	all DT 0	incubation NN B-noun.possession	schedules NNS B-noun.person	and CC 0	between IN 0	celecoxib NN B-noun.person	and CC 0	doxorubicin NN B-noun.person	in IN 0	all DT 0	cell NN B-noun.communication	lines NNS B-noun.communication	except IN 0	for IN 0	two CD 0	combinations NNS B-noun.person	in IN 0	HCT116 JJ B-noun.body	cells NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d761.s0	Alcohol NNP B-noun.person	, , 0	In IN 0	a DT 0	multiple JJ B-noun.person	- : 0	dose NN B-noun.quantity	study NN B-noun.artifact	in IN 0	30 CD B-adj.all	normal JJ B-adj.all	weight NN B-noun.phenomenon	subjects NNS B-noun.artifact	, , 0	coadministration NN B-noun.person	of IN 0	XENICAL NNP B-noun.group	and CC 0	40 CD B-adj.all	grams NNS B-noun.quantity	of IN 0	alcohol NN B-noun.animal	( ( 0	e.g. UH 0	, , 0	approximately RB B-adv.all	3 CD B-adj.all	glasses NNS B-noun.quantity	of IN 0	wine NN B-noun.artifact	) ) 0	did VBD 0	not RB B-adv.all	result VB B-verb.stative	in IN 0	alteration NN 0	of IN 0	alcohol NN B-noun.person	pharmacokinetics NNS B-noun.person	, , 0	orlistat JJ B-adj.all	pharmacodynamics NNS B-noun.person	( ( 0	fecal JJ B-adj.all	fat JJ 0	excretion NN 0	) ) 0	, , 0	or CC 0	systemic JJ B-adj.all	exposure NN B-noun.cognition	to TO 0	orlistat VB B-verb.contact	. . 0	. . 0
DDI-DrugBank.d759.s0	Limited JJ B-adj.all	evidence NN B-noun.communication	suggests VBZ B-verb.communication	that IN 0	ascorbic_acid JJ 0	may MD 0	influence VB B-verb.emotion	the DT 0	intensity NN B-noun.attribute	and CC 0	duration NN B-noun.act	of IN 0	action NN B-noun.process	of IN 0	bishydroxycoumarin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d644.s4	Consult VB B-verb.cognition	your PRP$ 0	doctor NN B-noun.person	or CC 0	pharmacist NN B-noun.person	if IN 0	you PRP 0	are VBP 0	taking VBG B-verb.cognition	any DT 0	of IN 0	the DT 0	following NN 0	, , 0	seizure NN B-noun.act	medications NNS I-noun.act	antibiotics NNS I-noun.act	warfarin VBP B-verb.stative	medications NNS I-verb.stative	to TO 0	help VB 0	you PRP 0	sleep VBP B-verb.contact	. . 0
DDI-DrugBank.d743.s4	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	ketoconazole NN B-noun.shape	and CC 0	terfenadine NN B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d661.s0	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	The DT 0	use NN 0	of IN 0	ZEMURON NNP B-noun.group	___ NNP I-noun.group	( ( 0	rocuronium_bromide NN 0	) ) 0	Injection NN 0	before IN 0	succinylcholine NN B-noun.person	, , 0	for IN 0	the DT 0	purpose NN B-noun.attribute	of IN 0	attenuating VBG B-verb.social	some DT 0	of IN 0	the DT 0	side NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	succinylcholine NN B-noun.person	, , 0	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d579.s0	Patients NNS B-noun.person	receiving VBG B-verb.communication	antibiotics NNS B-noun.person	and CC 0	sulfonamides NNS B-noun.person	generally RB B-adv.all	should MD 0	not RB 0	be VB 0	treated VBN B-verb.change	with IN 0	ganglion_blockers NNS B-noun.person	. . 0	_ PRP 0	. . 0
DDI-MedLine.d218.s9	Also RB B-adv.all	mirtazapine VB B-verb.stative	, , 0	which WDT 0	is VBZ B-verb.stative	not RB B-adv.all	believed VBN B-verb.stative	to TO 0	interact VB B-verb.contact	with IN 0	warfarin NN B-noun.act	, , 0	increased VBD B-verb.change	the DT 0	risk NN 0	of IN 0	GI NNP 0	bleeding NN B-verb.body	( ( 0	OR CC 0	__ : 0	= SYM 0	__ $ 0	1.75 CD 0	[ CD 0	95 CD 0	% NN 0	CI NNP 0	, , 0	1.30 CD 0	- : 0	2.35 CD 0	] CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d700.s1	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	Myfortic NNP B-noun.person	and CC 0	antacids NNS 0	not RB 0	be VB 0	administered VBN B-verb.possession	simultaneously RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d602.s2	Caution NN B-noun.person	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	administering VBG B-verb.creation	doxorubicin NN I-verb.creation	with IN 0	NEXAVAR NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d644.s2	Drugs NNS B-noun.artifact	that WDT 0	may MD 0	decrease VB B-verb.cognition	the DT 0	effects NNS B-noun.phenomenon	of IN 0	this DT 0	medicine NN B-noun.person	include VBP B-verb.change	, , 0	Rifampin NNP B-noun.person	barbiturates VBZ B-verb.communication	phenytoin NN B-noun.animal	( ( 0	Dilantin NNP B-noun.person	) ) 0	carbamazepine NN 0	( ( 0	Tegretol NNP B-noun.person	) ) I-noun.person	Estrogens NNP I-noun.person	may MD 0	decrease VB B-verb.cognition	the DT 0	effects NNS B-noun.phenomenon	of IN 0	benzodiazepines NNS B-noun.animal	( ( 0	lorezepam NN 0	oxezepam NN 0	temezepam NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d652.s3	Absorption NNP B-noun.person	of IN 0	drugs NNS B-noun.artifact	from IN 0	the DT 0	stomach NN B-noun.act	may MD 0	be VB 0	diminished VBN B-verb.change	( ( 0	e.g. UH 0	, , 0	digoxin NN 0	) ) 0	by IN 0	metoclopramide NN B-noun.person	, , 0	whereas IN 0	the DT 0	rate NN B-noun.time	and/or CC 0	extent NN B-noun.attribute	of IN 0	absorption NN B-noun.process	of IN 0	drugs NNS B-noun.artifact	from IN 0	the DT 0	small JJ B-adj.all	bowel NN B-noun.artifact	may MD 0	be VB 0	increased VBN B-verb.change	( ( 0	e.g. UH 0	, , 0	acetaminophen NN B-noun.person	, , 0	tetracycline NN B-noun.person	, , 0	levodopa NN B-noun.person	, , 0	ethanol NN 0	, , 0	cyclosporine NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d631.s3	Mild JJ B-noun.person	hepatotoxicity NN I-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	some DT 0	patients NNS B-noun.person	when WRB 0	lorazepam NN B-noun.person	and CC 0	pyrimethamine NN B-noun.person	were VBD 0	administered VBN B-verb.perception	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d762.s0	Probenecid NNP B-noun.person	competes VBZ B-verb.communication	with IN 0	meropenem NN B-noun.food	for IN 0	active JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	and CC 0	thus RB 0	inhibits VBZ B-verb.stative	the DT 0	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	meropenem NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d721.s1	Aspirin NNP B-noun.person	may MD 0	decrease VB B-verb.cognition	bioavailability NN B-noun.cognition	of IN 0	SKELID NNP B-noun.group	by IN 0	up RB 0	to TO 0	50 CD B-adj.all	% NN 0	when WRB 0	taken VBN B-verb.possession	2 CD B-adj.all	hours NNS B-noun.person	after IN 0	SKELID NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d147.s6	There EX 0	was VBD B-verb.stative	a DT 0	> $ 0	75 CD 0	% NN 0	reduction NN B-noun.act	in IN 0	cellular JJ B-adj.all	glutathione NN B-noun.artifact	and CC 0	cysteine NN B-noun.person	with IN 0	imexon NN B-noun.person	but CC 0	not RB B-adv.all	DTIC JJ 0	. . 0	. . 0
DDI-DrugBank.d661.s2	The DT 0	median JJ B-adj.all	duration NN B-noun.act	of IN 0	action NN B-noun.process	of IN 0	ZEMURON NNP B-noun.group	___ VBD 0	0.6 CD 0	mg FW 0	/ FW 0	kg FW 0	administered VBN B-verb.possession	after IN 0	a DT 0	1 CD 0	mg FW 0	/ FW 0	kg FW 0	dose NN 0	of IN 0	succinylcholine NN 0	when WRB 0	T NNP 0	1 CD 0	returned VBD B-verb.communication	to TO 0	75 CD 0	% NN 0	of IN 0	control NN B-noun.act	was VBD B-verb.stative	36 CD 0	minutes NNS B-noun.time	( ( 0	range NN B-noun.communication	14 CD B-adj.all	- : 0	57 CD 0	, , 0	n=12 NNP B-noun.location	) ) 0	vs. FW 0	. . 0
DDI-DrugBank.d645.s3	In IN 0	vivo JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN 0	interaction NN 0	studies NNS B-noun.communication	conducted VBN B-verb.creation	in IN 0	normal JJ B-adj.all	volunteer NN B-noun.person	subjects NNS B-noun.person	showed VBD B-verb.communication	that IN 0	terbinafine NN B-noun.communication	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	antipyrine NN B-noun.attribute	or CC 0	digoxin NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d634.s5	Theophylline PRP 0	, , 0	Theophylline JJ 0	clearance NN B-noun.act	may MD 0	decrease VB B-verb.cognition	when WRB 0	hyperthyroid NN B-noun.person	patients NNS B-noun.person	on IN 0	a DT 0	stable JJ B-adj.all	theophylline NN B-noun.person	regimen NNS B-noun.person	become VBN B-verb.emotion	euthyroid NN I-verb.emotion	, , 0	. . 0
DDI-MedLine.d179.s5	Sunitinib NNP B-noun.person	exhibited VBD B-verb.social	dose RB I-verb.social	- : 0	dependent JJ B-adj.all	growth NN 0	inhibition NN 0	in IN 0	NSCLC NNP 0	cell NN B-noun.body	lines NNS B-noun.communication	and CC 0	arrested VBN B-verb.contact	cell NN 0	cycle NN 0	at IN 0	G1 JJ B-adv.all	phase NN I-adv.all	, , 0	whereas IN 0	docetaxel NN 0	arrested VBN B-verb.contact	at IN 0	S NNP 0	phase NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d777.s1	Use NNP B-noun.person	of IN 0	Anticoagulants NNPS B-noun.person	and CC 0	Antiplatelet_Agents NNS B-noun.person	-- : 0	Streptase NNP B-noun.person	, , 0	Streptokinase NNP B-noun.person	, , 0	alone RB 0	or CC 0	in IN 0	combination NN 0	with IN 0	antiplatelet_agents NNS B-noun.person	and CC 0	anticoagulants NNS B-noun.person	, , 0	may MD 0	cause VB 0	bleeding VBG B-verb.body	complications NNS I-verb.body	. . 0	. . 0
DDI-DrugBank.d756.s0	Dosages NNS B-noun.person	of IN 0	concomitantly RB B-adv.all	administered VBN B-verb.body	opioids NNS B-noun.person	should MD 0	be VB 0	reduced VBN B-verb.change	by IN 0	approximately RB B-adv.all	half JJ B-adj.all	, , 0	because IN 0	levomepromazine NN B-noun.attribute	amplifies VBZ B-verb.change	the DT 0	therapeutic JJ B-adj.all	actions NNS B-noun.act	and CC 0	side NN B-noun.body	- : 0	effects NNS B-noun.phenomenon	of IN 0	opioids NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d761.s4	XENICAL NNP B-noun.group	inhibited VBD B-verb.change	absorption NN B-noun.artifact	of IN 0	a DT B-adj.all	vitamin_E_acetate JJ I-adj.all	supplement NN B-noun.possession	by IN 0	approximately RB B-adv.all	60 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d770.s4	however RB 0	, , 0	in IN 0	patients NNS B-noun.person	with IN 0	Paget NNP B-noun.person	's POS 0	Disease NNP B-noun.other	prior RB B-adj.all	diphosphonate JJ B-adj.all	use NN B-noun.attribute	appears VBZ B-verb.stative	to TO 0	reduce VB B-verb.change	the DT 0	anti NNS B-noun.person	- : 0	resorptive JJ B-adj.all	response NN B-noun.communication	to TO 0	Calcitonin_(salmon VB B-verb.social	) ) 0	nasal NN B-noun.quantity	spray NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d169.s9	A DT 0	calcium NN B-noun.artifact	dose NN 0	of IN 0	800 CD 0	mg NN B-noun.quantity	diminished VBN B-verb.change	absorption NN B-noun.process	of IN 0	5 CD 0	mg DT 0	heme_iron NNP B-noun.person	by IN 0	37.7 CD 0	% NN 0	. . 0	. . 0
DDI-MedLine.d161.s5	After IN 0	21 CD B-adj.all	weeks NNS B-noun.time	of IN 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine CD 0	treatment NN B-noun.attribute	, , 0	all DT 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine CD 0	/ : 0	vehicle NN B-noun.communication	- : 0	treated JJ B-verb.communication	animals NNS B-noun.person	displayed VBD B-verb.consumption	parkinsonian JJ B-adj.all	symptoms NNS B-noun.location	, , 0	whereas IN 0	none NN 0	of IN 0	the DT 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine JJ B-noun.other	- : 0	treated VBD B-verb.communication	monkeys NNS B-noun.person	were VBD B-verb.stative	significantly RB B-adv.all	affected VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d738.s0	Do VB 0	not RB B-adv.all	exceed VB B-verb.stative	a DT 0	5 CD 0	mg PRP$ 0	daily JJ B-adj.pert	dose NN B-noun.act	of IN 0	VESIcare NNP B-noun.location	when WRB 0	administered VBN B-verb.possession	with IN 0	therapeutic JJ B-adj.all	doses NNS B-noun.event	of IN 0	ketoconazole NN B-noun.shape	or CC 0	other JJ B-adj.all	potent JJ B-noun.person	CYP3A4 JJ I-noun.person	inhibitors NNS I-noun.person	. . 0	. . 0
DDI-DrugBank.d713.s0	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	Sanctura NNP B-noun.person	with IN 0	other JJ B-adj.all	anticholinergic_agents NNS B-noun.plant	that WDT 0	produce VBP B-verb.creation	dry JJ B-noun.artifact	mouth NN I-noun.artifact	, , 0	constipation NN B-noun.person	, , 0	and CC 0	other JJ 0	anticholinergic JJ B-adj.all	pharmacological JJ B-adj.pert	effects NNS B-noun.phenomenon	may MD 0	increase VB B-verb.change	the DT 0	frequency NN B-noun.person	and/or CC 0	severity NN B-noun.attribute	of IN 0	such JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d781.s0	Diuretics NNS B-noun.person	, , 0	Patients NNPS B-noun.person	on IN 0	diuretics NNS B-noun.person	, , 0	and CC 0	especially RB B-adv.all	those DT 0	started VBN B-verb.creation	recently RB B-adv.all	, , 0	may MD 0	occasionally RB 0	experience VB B-verb.social	an DT 0	excessive JJ B-adj.all	reduction NN B-noun.process	of IN 0	blood NN B-noun.phenomenon	pressure NN I-noun.phenomenon	after IN 0	initiation NN B-noun.time	of IN 0	ACEON NNP B-noun.group	___ NNP I-noun.group	Tablets NNPS I-noun.group	therapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d766.s0	Since IN 0	trimetrexate NN B-noun.communication	is VBZ 0	metabolized VBN B-verb.change	by IN 0	a DT 0	P450 JJ 0	enzyme NN B-noun.cognition	system NN I-noun.cognition	, , 0	drugs NNS B-noun.artifact	that WDT 0	induce VBP B-verb.emotion	or CC 0	inhibit VB B-verb.cognition	this DT 0	drug NN B-noun.act	metabolizing NN I-noun.act	enzyme NN B-noun.cognition	system NN I-noun.cognition	may MD 0	elicit VB B-verb.cognition	important JJ B-adj.all	drug NN B-noun.group	- : 0	drug NN B-noun.act	interactions NNS I-noun.act	that WDT 0	may MD 0	alter VB B-verb.change	trimetrexate JJ B-adj.all	plasma NN B-noun.plant	concentrations NNS B-noun.food	. . 0	. . 0
DDI-MedLine.d212.s10	All PDT 0	the DT 0	results NNS B-noun.communication	suggested VBD B-verb.communication	that IN 0	eugenol NN B-noun.person	is VBZ B-verb.stative	an DT 0	efficient JJ B-adj.all	component NN B-noun.person	in IN 0	an DT 0	oral JJ B-adj.all	administrative JJ B-adj.all	formulation NN B-noun.act	for IN 0	improving VBG B-verb.change	the DT 0	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	colchicine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d734.s0	Thiazide_diuretics NNS B-noun.artifact	may MD 0	accentuate VB B-verb.cognition	the DT 0	orthostatic JJ B-adj.all	hypotension NN B-noun.event	that WDT 0	may MD 0	occur VB B-verb.stative	with IN 0	phenothiazines NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d618.s1	In IN 0	addition NN 0	to TO 0	bleeding VBG B-verb.body	associated VBN B-verb.cognition	with IN 0	heparin NN B-noun.person	and CC 0	vitamin_K_antagonists NNS B-noun.person	, , 0	drugs NNS B-noun.artifact	that WDT 0	alter VBP B-verb.change	platelet NN B-verb.creation	function NN B-noun.attribute	( ( 0	such JJ 0	as IN 0	aspirin NN B-noun.person	, , 0	dipyridamole NN B-noun.person	, , 0	and CC 0	abciximab NN B-noun.artifact	) ) 0	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	bleeding VBG B-verb.communication	if IN 0	administered VBN B-verb.possession	prior RB 0	to TO 0	or CC 0	after IN 0	Retavase NNP B-noun.person	___ NNP I-noun.person	therapy NN I-noun.person	. . 0	. . 0
DDI-DrugBank.d591.s3	Thus RB 0	strong JJ B-adj.all	inhibitors NNS B-noun.person	of IN 0	cytochrome DT 0	P4501A2 NNP B-noun.person	, , 0	such JJ 0	as IN 0	fluvoxamine NN B-noun.person	, , 0	given VBN B-verb.possession	concomitantly RB B-adv.all	during IN 0	administration NN B-noun.time	of IN 0	Ropivacaine NNP B-noun.location	, , 0	can MD 0	interact VB B-verb.change	with IN 0	Ropivacaine NNP B-noun.person	leading VBG B-verb.motion	to TO 0	increased VBN B-verb.change	ropivacaine NN 0	plasma NN B-noun.substance	levels NNS B-noun.state	. . 0	. . 0
